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Thesis Summary 
Rapid clearance of dying cells is a vital feature of apoptosis throughout development, 
tissue homeostasis and resolution of inflammation. The phagocytic removal of apoptotic 
cells is mediated by both professional and amateur phagocytes, armed with a series of 
pattern recognition receptors that participate in host defence and apoptotic cell clearance. 
CD14 is one such molecule. It is involved in apoptotic cell clearance (known to be 
immunosuppressive and anti-inflammatory) and binding of the pathogen-associated 
molecular pattern, lipopolysaccharides (a pro-inflammatory event). Thus CD14 is involved 
in the assembly of two distinct ligand-dependent macrophage responses. This project 
sought to characterise the involvement of the innate immune system, particularly CD14, in 
the removal of apoptotic cells. The role of non-myeloid CD14 was also considered and the 
data suggests that the expression of CD14 by phagocytes may define their professional 
status as phagocytes. 
 
To assess if differential CD14 ligation causes the ligand-dependent divergence in 
macrophage responses, a series of CD14 point mutants were used to map the binding of 
apoptotic cells and lipopolysaccharides. Monoclonal antibodies, 61D3 and MEM18, 
known to interfere with ligand-binding and responses, were also mapped.  Data suggests 
that residue 11 of CD14, is key for the binding of 61D3 (but not MEM18), LPS and 
apoptotic cells, indicating lipopolysaccharides and apoptotic cells bind to similar residues. 
Furthermore using an NF-kB reporter, results show lipopolysaccharides but not apoptotic 
cells stimulate NF-kB. Taken together these data suggests ligand-dependent CD14 
responses occur via a mechanism that occurs downstream of CD14 ligation but upstream 
of NF-κB activation. Alternatively apoptotic cell ligation of CD14 may not result in any 
signalling event, possibly by exclusion of TLR-4, suggesting that engulfment receptors, 
(e.g. TIM-4, BAI1 and Stablin-2) are required to mediate the uptake of apoptotic cells and 
the associated anti-inflammatory response.   
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Introduction 
The importance of cell loss in tissue homeostasis and embryonic development followed 
widespread acceptance in the early twentieth-century, that cells undergo programmed cell 
death (Lockshin and Williams, 1964 & Kerr et al., 1972). Lockshin and Williams (1964) 
proposed that cell loss during development was not purely accidental but followed a 
controlled sequence of events. Kerr et al. (1972) went on to describe the uniform and 
morphological feature of this programmed mode of cell death and coined the term 
apoptosis. Apoptosis is of Greek origin and means “falling or dropping of leaves”, with 
this analogy emphasizing the loss of cells as integral part of the cell life cycle.  Kerr et 
al.(1972) distinguished apoptosis from the other mode of cell death; necrosis. Necrosis has 
no morphological features and is the result of tissue damage, which causes the cell 
membrane to rupture and the intracellular contents is be released (Kerr et al., 1972). Kerr 
et al.(1972) was first to describe two stages of apoptosis that are physiological inseparable. 
The first stage starts with the initiation of cell death and ends with the fragmentation of the 
cell into membrane-bound vesicles termed apoptotic bodies. While the second stage 
culminates in the phagocytic clearance of the apoptotic bodies from the environment. The 
clearance of apoptotic cells is mediated by both neighbouring amateur phagocytes 
(epithelial cells and fibroblast) and professional phagocytes (macrophages and dendritic 
cells). Professional phagocytes are motile, highly phagocytic and uptake apoptotic cells 
upon contact. In contrast, amateur phagocytes are resident in tissues and are considered to 
delay phagocytosis upon contact with the apoptotic cell. The delay between contact and 
uptake of apoptotic cells by amateur phagocytes would suggest that further changes to the 
surface of the apoptotic cell are required to permit uptake (Parnaik et al., 2000). At normal 
rates of apoptosis, cellular corpses are rarely observed in vivo as they are rapidly cleared by 
neighbouring amateur phagocytes. However professional phagocytes are considered to 
‘step in’ when amateur phagocytes are overwhelmed to prevent secondary necrosis. 
1.1 The importance of dealing with death 
Today apoptosis is viewed as an active, protective mechanism that ensures the safe and 
rapid removal of cellular corpses. It is vital to maintain and regulate cell populations 
ensuring a balance between cell birth, from mitosis or differentiation and cell death. The 
importance of apoptosis in the developing embryo was recognised early, with the 
controlled removal of cells vital for tube formation, bone modelling along with separation 
of the digits and formation of the sex organs (reviewed in Vaux and Korsmeyer, 1999). 
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Apoptosis is also important for defence, as viral infected cells are rapidly removed limiting 
reproduction and spread of virus particles (Vaux and Korsmeyer, 1999).   
 
For many years the focus of apoptosis was on the mechanisms and processes involved in 
dismantling the cells and the production of apoptotic bodies. Unlike necrosis, the clearance 
of apoptotic cells was found to suppress inflammation therefore modulating immune 
responses. However failed clearance is considered to result in cells lysis and subsequently 
uptake of apoptotic cell debris by dendritic cells, which provides an opportunity for antigen 
presentation and the generation of autoimmunity (reviewed by Peng and Elkon, 2011). The 
importance of the final stage of apoptosis, the phagocytic removal of apoptotic cells, is 
really highlighted in the autoimmune disease systemic lupus erythematosus (SLE). 
Deficiency in molecules involved in the clearance of apoptotic cells such as C1q, and Mer 
tyrosine kinase receptor, results in SLE, characterised by secondary necrosis and the 
production of auto-antibodies to intracellular antigens (Savill and Fadok, 2000). This led to 
the assumption that failed clearance results in the re-exposure of auto-antigens that drives 
autoimmunity in SLE (Casciola-Rosen et al., 1994). A body of evidence has led to the 
generalisation that apoptotic cells are rich sources of auto-antigens. Cocca et al.(2002) 
suggests that the safe and efficient clearance of apoptotic cells by phagocytes is a 
tolerogenic process that prevents secondary necrosis and generation of autoantibodies, 
often associated with inflammation associated with SLE. The importance of removing 
apoptotic neutrophils in the resolution of inflammation is demonstrated in the pathogenesis 
of a group of vasculitides, characterised by the presence of anti-neutrophil cytoplasmic 
autoantibodies (Savill et al., 2002). These arise following the release of auto-antigens from 
secondary necrotic neutrophils including myeloperoxidase and proteinase 3 (Ciavatta et al., 
2010).  
 
Furthermore in some diseases, such as atherosclerosis, failed clearance is involved in the 
disease course following the initial onset. In atherosclerosis the capacity of macrophages to 
engulf apoptotic cells is decreased and the subsequent lack of clearance contributes to the 
formation of the necrotic core in vulnerable atherosclerotic plaques (Reviewed by Moore 
and Tabas, 2011). Defective clearance may also play a role in neurodegenerative diseases 
such as Parkinson’s and Alzheimer’s in which the accumulation of apoptotic cells is 
observed (reviewed by Elliott and Ravichandran, 2010). While this may be associated with 
increased cell death, the immunological consequences of failed clearance within the central 
nervous system is currently unknown. Inappropriate clearance can result in the loss of cells 
16 
 
that are required, for example loss of neurones observed in neurodegenerative diseases 
(Kao et al., 2011). Therefore, an understanding of the mechanisms involved in the 
clearance of apoptotic cells has provided an understanding of autoimmunity associated 
with defective clearance and highlights potential manipulation for emerging therapies. 
1.2 Programmed cell death 
Our current understanding of the recognition and phagocytic clearance of apoptotic cells 
comes largely from in vitro studies with inhibitors that block phagocytic recognition of 
apoptotic cells, or, in vivo studies with Caenorhabditis elegans and the genetic defects that 
prevent clearance. These studies identified the gene ced-3 as necessary for loss of 131 
somatic cells by apoptosis during nematode development  (Jacobson et al., 1997 & Lu et 
al., 2009). The mammalian ortholog was revealed to be IL-1β-converting enzyme 
otherwise known as caspase-1 (Jacobson et al., 1997). Caspases are a family of cysteine 
proteases which function as the executioners of the apoptosis programme (Hengartner, 
2000).  
 
The characteristic morphological changes accompanying apoptosis, described by Kerr et 
al.(1972) are mediated by activation of a caspase-cascade. There are two categories of 
caspases based on structural similarities, initiator caspases which have protein interaction 
sites allowing self-activation and effector caspases are responsible for the morphological 
features of apoptosis (reviewed by Hengartner, 2000). Caspases which are produced as 
inactive zymogens and following induction of apoptosis are activated, in a cascade with 
initiator caspases activating effector caspases.  
 
There are two apoptotic signalling pathways that result in caspase activation. The 
‘extrinsic’ pathway is activated following ligation of a death receptor with TNF-α family 
members, for example, the FAS-ligand, which results in the assembly of a death-inducing 
signalling complex that activates initiator caspases (Scoltock and Cidlowski, 2004). 
However ligation of FAS also leads to cytochome-c released from mitochondria which 
results in caspases activation (Scoltock and Cidlowski, 2004). The ‘intrinsic’ pathway is 
activated by cellular stress and results in the assembly of  the apoptosome which also 
activates initiator caspases (Scoltock and Cidlowski, 2004). 
 
Effector caspases such as 3 and 6 are responsible for the early nuclear events seen during 
apoptosis (Hengartner, 2000). Caspase-3 is responsible for DNAase activation and 
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cleavage of nuclear lamin that facilitates DNA fragmentation and permits packaging into 
membrane-bound bodies subsequently leading to nuclear shinkage (Rao et al., 1996 & 
Buendia et al., 1999). There are a number of factors cleaved by caspase-3 that are 
important for detachment and dismantling of the cell, for example gelsolin, actin and 
catenin (Kothakota et al., 1997& Lane et al., 2005). 
 
One of the major characteristic features of apoptosis is the breakup of the cell into 
apoptotic cell bodies a process known as blebbing.  Membrane blebbing is considered to be 
produced following contraction of the cell during cleavage of the cytoskeleton (Coleman et 
al., 2001). Coleman et al.(2001) suggested that caspase-mediated activation of ROCK I, a 
Rho effector kinase, is responsible for membrane blebbing, packaging and relocation of 
nuclear fragments into membrane-bound vesicles. It is these events of the apoptosis 
programme that advertise the status of the cell to surrounding phagocytes and facilitates 
the definitive stage, clearance by alteration of dying cell surface. 
1.2.1 Apoptotic cells are dressed to impress: ‘eat me’ signals 
It is well established that apoptotic cells display molecular markers known as ‘eat me’ 
signals that are required for phagocyte recognition and subsequent clearance. While 
relatively few ‘eat me’ signals have successfully been identified, it is accepted that these 
molecules can newly appear at the surface of the cell following induction of apoptosis. 
Known ‘eat me’ signals include, the externalization of phoshatidylserine (PS) and possibly 
the modification of already existing cell surface molecules such as ICAM 3, however such 
cell surface changes need to be accompanied by the loss of molecules known as ‘don’t eat 
me’ signals. 
1.2.1.1 Phoshatidylserine (PS) 
The best characterised ‘eat me’ signal is the translocation of PS from the inner leaflet of 
the plasma membrane (Fadok et al., 1998a & Krahling et al., 1999). During the activation 
of the apoptotic programme membrane asymmetry is disrupted, resulting in the 
translocation of PS to the outer-leaflet of the plasma membrane, a well-defined 
characteristic of apoptotic cells (Fadok et al., 1998a & Krahling et al., 1999).  In viable 
cells PS is restricted to the inner leaflet of the plasma membrane by an ATP-dependent 
aminophospholipid translocase (APLT) (Fadok et al., 1998a & Krahling et al., 1999). 
During execution of the apoptotic cell programme the APLT is inactivated and a non-
specific lipid flippase is activated causing translocation of PS down a concentration 
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gradient to the cell surfaces within a few hours of apoptosis (Fadok et al., 1998a & 
Krahling et al., 1999). However is PS exposure alone enough to induce the phagocytic 
clearance of apoptotic cells? Hoffmann et al.(2001) found that PS exposure alone was 
insufficient to mediate the phagocytic uptake of apoptotic cells, suggesting that additional 
phagocyte receptors were required to tether the apoptotic cell to the phagocyte prior to PS-
dependent uptake. This would suggest that other ‘eat me’ signals are required for apoptotic 
cell interaction with phagocytes. 
1.2.1.2 Modification of viable cell surface molecules 
Other ‘eat me’ signals may include ‘functional’ modification of already existing proteins 
such as intracellular adhesion molecule 3 (ICAM-3) present on viable cells. ICAM-3 is a 
member of the Ig-like superfamily expressed only on leukocytes (de Fougerolles et al., 
1993) and is required for T cell adhesion and activation on antigen presenting cells 
(Starling et al., 1995 & Bleijs et al., 2000). However Moffatt et al.(1999) suggested that 
following induction of apoptosis, ICAM-3 becomes modified and takes on a new role,  
functioning as an ‘eat me’ signal required for apoptotic cell adhesion in the clearance of 
apoptotic leukocytes. However the loss of ‘don’t eat me’ signals may underlie the role of 
ICAM-3 in the clearance of apoptotic cells. 
1.2.1.3 Redistribution events 
The redistribution of ligands found on viable cells, are also considered as potential ‘eat me’ 
signals that can stimulate engulfment following induction of apoptosis. Calreticulin is 
found on the surface of most viable mammalian cells, suggested to bind thombospondin 
forming a co-complex with lipoprotein receptor-related protein (LRP) and induce the 
disassembly of focal adhesion points (Orr et al., 2003, Gardai et al., 2005). However 
following the induction of apoptosis, calreticulin expression is upregulated and 
redistributed to localized regions with exposed PS. Calreticulin then binds directly to LRP 
receptor; a highly conserved engulfment receptor that mediates the clearance of apoptotic 
cells (Gardai et al., 2005). 
 
Another example of a molecule that is redistributed to the cell surface following induction 
of apoptosis is Annexin 1 found within the inner leaflet of the cellular membrane on viable 
cells (Parente and Solito, 2004). During apoptosis annexin 1 is externalized and recruited 
to patches on the cell membrane associated with PS (Arur et al., 2003) however the 
phagocyte receptor for annexin 1-mediated clearance is currently unknown. 
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1.2.1.4 Removal of Sialic acid 
The surface of cells is covered in sugars which are covalently linked to membrane proteins 
or lipids following golgi modification. Cell surface sugars include sialic acid, which is 
highly negatively charged and considered the principal source of membrane charge (Weiss 
and Mayhew, 1967). Lutz (2004) reported that a loss of sialic acid at the surface of 
senescent erythrocytes may cause a reduction in membrane charge which promoted 
clearance. Another more recent study by Meesmann et al.(2010) found that desialylation of 
apoptotic cells also enhanced phagocytic clearance.  However, no significant increase in 
the uptake of viable cells following removal of sialic acid was observed (Meesmann et al., 
2010). Therefore it seems more likely that a loss of the negative charge at the surface of 
apoptotic cells allows phagocyte interaction with other, discussed ‘eat-me’ signals. This is 
supported by Lutz (2004) hypothesised a reduction in membrane charge along with loss of 
CD47; a recognised ‘don’t eat me’ signal which is required for clearance of erythrocytes.  
1.2.2 ‘Don’t eat me’  
It is likely that the presence of ‘eat me’ signals are not completely absent from viable cells 
(Wu et al., 2006 & Ravichandran, 2010). However it is currently considered that viable 
cells present ‘don’t eat me’ signals at their surface which allows phagocytes to distinguish 
viable and apoptotic cells. These signals prevent uptake, often by mediating detachment 
from phagocytes but may also function by hiding ‘eat me’ signals present.  
1.2.2.1 CD31 
CD31 is a member of the immunoglobulin superfamily expressed by viable leukocytes and 
is involved in leukocyte migration (Muller et al., 1993). Brown et al.(2002) found that 
homophilic ligation of CD31, on macrophages mediated detachment.  During apoptosis the 
detachment signal induced by CD31 is lost and replaced with an attachment signal so the 
leukocyte remains tethered to the phagocyte awaiting uptake (Brown et al., 2002). This 
again could suggest that the loss of CD31 may physically uncover already existing ‘eat me’ 
signals present at the surface of the apoptotic cells.  
1.2.2.2 CD47 
CD47 is an integrin-associated membrane protein expressed by most cells (Oldenborg et 
al., 2000). CD47 was first considered as a marker of ‘self’ as erythrocytes taken from 
CD47 knockout mice are rapidly removed when placed in wild-type mice (Oldenborg et 
al., 2000). This supports the suggestion that ‘eat me’ signals are present on viable cells, but 
the presence of ‘don’t eat me’ signals, such as CD47 prevent uptake. CD47 on viable cells 
20 
 
interacts with macrophage surface protein, SIRPα and induces an inhibitory signal which 
prevents phagocytosis and the synthesis of proinflammatory cytokines (Oldenborg et al., 
2000, Brown and Frazier, 2001 & Gardai et al., 2005). However during apoptosis CD47 is 
redistributed away from ‘eat me’ signals such as PS and cells lose their ability to activate 
SIRPα and are therefore engulfed (Brown and Frazier, 2001 & Gardai et al., 2005). 
1.2.2.3 CD46 
Another potential ‘don’t eat me’ signal is a loss of complement protection factor, CD46, 
expressed by all nucleated cells. Elward et al.(2005) found that a loss of CD46 during 
apoptosis, from various cell types resulted in C3b deposition and there by enhanced 
clearance. Again this supports suggestions that ‘don’t eat me’ signals potentially mask eat 
me signals present on viable cells or sterically hinder phagocytes interacting with such 
markers. Furthermore apoptosis results in the caspase-dependent formation of membrane-
associated microparticles that were found to contain CD46 (Elward et al., 2005). This 
suggested that following apoptosis, CD46 was relocated from the surface of the apoptotic 
cell into apoptotic blebs. 
 1.2.3 To eat or not to eat? 
Taken together these findings suggest that the presence of ‘eat me’ signals alone on 
apoptotic cells is not sufficient to induce phagocyte internalization. The combined 
appearance of ‘eat me’ signals with the loss or redistribution of viable ‘don’t eat me’ 
signals permit the binding and engulfment of apoptotic cells by phagocytes. Findings here 
also suggest that viable cells have stipulated ‘eat me’ signals present and changes in 
membrane charge or loss of ‘don’t eat me’ signals that may also function as ‘self’ markers, 
induce phagocytic clearance. Therefore cells appear to be constantly under phagocyte 
surveillance and have to prove that they are worthy of not being engulfed. With respect to 
host defence, the importance of this mechanism may be fully appreciated when cells are 
damaged, diseased, or senescent, prior to becoming less functional or dysplastic. However 
during the early stages of apoptosis, soluble factors are redistributed into microparticles. 
The microparticles are released into the local area and selectively function to induce 
phagocyte migration towards sites of apoptosis and potentially prime phagocytes for the 
meal ahead. 
1.2.4 Flirting with phagocytes: ‘Find me’ signals 
At normal rates of cellular turnover in tissues, free apoptotic cells are rarely observed in 
situ suggesting that the number of apoptotic cells and the capacity of phagocytes for uptake 
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are balanced. This led to the conclusion that apoptotic cells could advertise their cellular 
status prior to any morphological feature of apoptosis. Furthermore disruption of this 
balance, for example, by an increase in the level of apoptosis which exceeds the capacity 
of amateur phagocytes results in the recruitment of professional phagocytes. Lauber et 
al.(2003) and Truman et al.(2004) provided evidence that apoptotic cells secrete caspase-
dependent soluble factors that selectively induce mononuclear phagocyte migration and are 
considered as ‘find me’ signals. Several lipid, protein and nucleotide based ‘find me’ 
signals have now been characterised of varying molecular sizes (reviewed by 
Ravichandran, 2010). ‘Find me’ signals are considered to be released and establish a 
chemoattractive gradient that guides phagocyte migration. However there is some debate 
over the range at which ‘find me’ signals can induce migration. Short range ‘find me’ 
signals are considered to act on local tissue residing phagocytes while long range ‘find me’ 
signals may recruit mononuclear phagocytes from the circulation (reviewed by Gregory 
and Pound, 2010). The range of ‘find me’ signals seems to be dependent on the tissue 
concentration and the rate of degradation. 
1.2.4.1 Phospholipids 
Phospholipids including lysophosphatidylcholine  and sphingosine-1-phosphate  have been 
shown to act as soluble mediators, able to induce migration of mononuclear phagocytes 
towards apoptotic cells (Lauber et al., 2003; Gude et al., 2008). In addition more complex 
lipid-based mediators play a role in inducing this chemotaxis. Microparticles are plasma 
membrane-derived vesicles, released early during apoptosis which express surface markers 
derived from the apoptotic cell (Segundo et al., 1999,Mause and Weber, 2010 & Torr et 
al., 2011). With a diameter ranging from 100nm to 1000nm (Mause and Weber, 2010 & 
Torr et al., 2011) these particles are capable of diffusing through the extracellular matrix 
and interacting with macrophages. These particles are considered to induce chemotaxis 
(Segundo et al., 1999) via their complement of adhesion factors and classical 
chemoattractants such as S1P. In addition microparticle-associated fractalkine has been 
shown to play a key role in recruiting phagocytes to sites of B-cell apoptosis in vivo 
(Truman et al., 2008). Fractalkine is a type I transmembrane protein that acts as a 
chemokine and intracellular adhesion molecule that is associated with inflammatory 
processes within the central nervous system (Truman et al., 2008). Truman et al.(2008) 
suggested that intracellular processing of fractalkine; most likely in a caspase-dependent 
manner resulted in its release associated with microparticles, produced during the blebbing 
phase of apoptosis. Inhibition of fractalkine or blockade of its macrophage receptor was 
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found to result in the inhibition of macrophage migration towards apoptotic cells (Truman 
et al., 2008). 
1.2.4.2 ATP/UTP 
Recently, Elliott et al.(2009) reported the caspase-dependent release of soluble heat-stable 
mediators that induced migration of primary monocytes. Further analysis led to the 
discovery that enzymatic removal of ATP and UTP from apoptotic supernatants inhibited 
monocyte migration in vivo (Elliott et al., 2009). ATP and UTP are released from the 
apoptotic cell via Pannexin-1 membrane channels (Chekeni et al., 2010) and signal via 
interaction with the P2Y receptor. Furthermore Elliott et al. (2009) found that 
concentrations similar to physiological concentrations of ATP and UTP mediated 
monocyte migration in vitro. Due to the relative instability of these nucleotides and their 
potential uptake by neighbouring cells it may be speculated that nucleotides function to 
fine-tune migration over short ranges close to their target. Nucleotides at high 
concentrations are considered to promote inflammation, by functioning as damage-
associated molecular patterns (DAMPs), however lower concentrations are thought to 
suppress inflammation (Elliott et al., 2009). This supports the suggestion that apoptotic 
cells regulated recruitment of mononuclear phagocytes to sites of cell death therefore 
preventing unnecessary neutrophil infiltration and inflammation that potentially results in 
autoimmunity. This was supported by Chen et al.(2006) that reported neutrophils release 
ATP to enhance neutrophil migration as a positive feedback mechanism therefore 
associating ATP release with inflammation. However apoptotic neutrophils are considered 
to maintain membrane integrity for longer than most cells, in an attempt to avoid the 
release of ATP (Reviewed by Bratton and Henson, 2011). This may reduce nucleotide 
concentration and consequently prevent neutrophil migration to sites of cell death. 
1.2.5 ‘Keep out’ signals 
The absence of neutrophils and the presence of mononuclear phagocytes is often 
considered to define normal sites of cell death from sites of necrotic cell death (Smith, 
1994, Bratton and Henson, 2011). Truman et al.(2004) found that apoptotic Burkitt 
lymphoma cells induce migration of monocytes and macrophages but not neutrophils. 
Considered as the first recruited line of cellular defence; neutrophils, are rapidly recruited 
following initiation of an innate immune response (Smith, 1994). Following phagocytosis 
neutrophils, use a combination of reactive oxygen species, proteolytic enzymes and anti-
microbial peptides to kill (Smith, 1994). However neutrophil also damage surrounding 
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tissue and secrete cytokines and chemokines that regulate the inflammatory response and 
the adaptive immune response. Therefore neutrophils have been implicated in the 
pathology of many chonic inflammatory conditions. Under normal conditions neutrophil 
migration is regulated by signals that induce and inhibit neutrophil migration (Smith, 
1994). Apoptotic cells are considered to negatively regulate neutrophil migration by 
secreting lactoferrin, a ‘keep out’ signal (Bournazou et al., 2009). Bournazou et al.(2009) 
found that lactoferrin selectively inhibited neutrophil migration towards apoptotic cells in a 
dose-dependent manner.  
 
Lactoferrin is an anti-microbial polypeptide released from neutrophils during inflammation 
(Elass-Rochard et al., 1998) and has many anti-inflammatory and regulatory roles (Ward et 
al., 2005). Elass-Rochard et al.(1998) found that lactoferrin competed with LBP for 
binding to LPS therefore inhibiting binding to CD14 and preventing proinflammatory 
cytokine release. Lactoferrin was found to bind to specific lactoferrin receptors present on 
neutrophils and inhibit cytoskeleton rearrangement that permits the contraction and 
retraction of neutrophils during migration (Bournazou et al., 2009). It seems logical to 
consider that a combination of ‘keep out’ and ‘find me’ signals induce monocyte migration 
while preventing migration of neutrophils. Thus ensuring at each level of apoptotic cell 
clearance process the immune response is orchestrated and regulated. However it is also 
reasonable to consider that ‘find me’ signals could also function to prime macrophages for 
apoptotic cell uptake. This is supported by Truman et al.(2004) that found monocyte 
migration towards apoptotic cells was associated with the upregulation of CD14, a known 
tethering receptor for apoptotic cell (Devitt et al., 1998 Devitt et al., 2004). Furthermore  
fractalkine released from apoptotic cells was found to induce the upregulation of milk fat 
globule epidermal growth factor (MFG-EGF)(Truman et al., 2008) which acts as an 
apoptotic cell bridging molecule that facilitates clearance (Hanayama et al., 2002).  
1.3 Apoptotic cell clearance: A four-course meal 
The interaction between an apoptotic cell and its phagocyte, culminating in clearance, is a 
complex and multistage process. Hoffmann et al.(2001) initially described the clearance 
process in two stages. An initial tethering phase that shows significant redundancy as 
demonstrated by the persistence of apoptotic cells in the absence of inflammation in mice 
deficient in MBL or CD14 (Devitt et al., 2004 & Stuart et al., 2005). Subsequently 
followed by as a PS-mediated phagocytosis stage (Hoffmann et al., 2001). Studies since 
have found that additional receptors are capable of inducing signalling for phagocytosis 
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1. Recognition 2. Tethering 3. Signalling 4. Phagocytosis 
including the receptor complexes calreticulin/CD91 and vitronectin/CD36 (Krieser and 
White, 2002 & Akakura et al., 2004). Since the discovery of ‘find me’ signals, ‘eat me’ 
signals and a subsequent requirement for the loss of ‘don’t eat me’ signals, an initial 
recognition event prior to tethering is accepted (Brown and Frazier 2001, 2002 & 
Grimsley, 2003). Lucas et al.(2006) found that TGF-β alone was insufficient to inhibit pro-
inflammatory cytokine release following apoptotic cell uptake. Lucas et al.(2006) proposed 
the “kiss & tell” model, suggesting that phagocytes require additional signals provided by 
contact with the apoptotic cells to respond to TGF-β. Therefore phagocytes must first bind 
apoptotic cells, not only to promote phagocytosis and the release of TGF-β, but also to 
respond to TGF-β released. Taken together with the two stage model proposed by 
Hoffman, these suggested cell-surface signalling events were required to induce uptake 
along with an anti-inflammatory response. Gregory and Devitt (2004) have described the 
clearance process from the perspective of the macrophage, as a four stage process (figure 
1): 1. Recognition, 2. Tethering, 3. Signalling events results in anti-inflammatory response 
and cytoskeletal rearrangements thus permitting 4. Subsequent phagocytosis of the cellular 
corpse. 
 
 
 
 
 
 
 
Figure 1: The four stages of apoptotic cell clearance 
The interaction between an apoptotic cell and its phagocyte culminating in clearance is a 
complex and multistage process. From the perspective of the macrophage, the clearance of 
apoptotic cells is considered to occur in four stages: 1. Recognition of ‘eat me’ signals at 
the surface of the apoptotic cell which results in, 2. Tethering of the apoptotic cell to the 
phagocyte. 3. Induction of signalling events which initiates a characteristic anti-
inflammatory response associated with apoptotic cell clearance along with cytoskeletal 
rearrangements which facilitates 4. phagocytosis of the cellular corpse. 
 
1.4 Involvement of the innate immune system in the clearance of 
apoptotic cells 
Phagocytes are considered to use a series of pattern recognition receptors (PRR) and 
soluble bridging molecules (figure 2), well characterised within host defence, to recognise 
and remove apoptotic cells (Savill et al., 2002 & Monks et al., 2005). Within their role in 
host defence, PRRs recognise evolutionarily conserved pathogen-associated molecular 
25 
 
patterns (PAMPs). However it is widely accepted that the innate immune system also has a 
role in apoptotic cells clearance suggesting that the molecular structures displayed by 
apoptotic cells and PAMPs share similarities. This poses the hypothetical questions: did 
pathogens evolve surface patterns that resemble apoptotic cells with the aim of avoiding 
immune surveillance or to infect other cells? Or did apoptotic cells evolve to expose 
ligands recognised by the innate immune system to facilitate clearance? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The super macrophage and the perfect apoptotic cell 
Apoptotic cells present ‘eat me’ signals that interact directly or indirectly with phagocytes. 
Soluble pattern recognition molecules may bind to apoptotic cells as bridging molecules 
which then interact with phagocyte receptors.  These include members of the collectins 
family, SPA and SPD, surfactant proteins A and D,  members of the complement cascade; 
C1q and C3b, members of the pentraxin, C-reactive protein (CRP) and serum amyloid 
protein (SAP), Gas-6, growth arrest-specific 6; MFG-E8, milk fat globule-epidermal 
growth factor-8 and thombospondin (TSP-1). Phagocyte-associated PRRs can interact 
directly or indirectly with the apoptotic cell include integrin receptors; the vitronectin 
receptor (αvβ3) and αvβ5, complement receptor 3 and 4(CR3 & CR4) scavenger receptors;  
scavenger receptor A (SR-A), oxidized low-density lipoprotein particle 1 (LOX-1), CD68, 
and class B scavenger receptor B, CD36;CD91, CD14, FC-gamma receptor (FcγR,); 
phoshatidylserine receptor (PSR); β2-glycoprotein receptor, (β2GPI-R); tyrosine-kinase 
receptor, Mer, T-cell immunoglobulin and mucin-containing molecule, TIM family, Brain-
specific angiogenesis inhibitor, BAI-1 and Stablin-2. Adapted from Lauber et al., 
2004.1.4.1 Soluble bridging molecules and their phagocyte receptors 
1.4.1.1 Complement-mediated clearance 
Complement components can form a biochemical cascade that provides defence against 
pathogens and serves to induce inflammation, opsonise pathogens for phagocytosis or 
directly kill following assembly of a membrane attack complex. C1q is a member of the 
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collectin family and forms part of the classical complement cascade implicated in apoptotic 
cell clearance (Korb and Ahearn, 1997). Furthermore apoptotic cell-associated C1q is 
known to interact with the phagocyte receptor complex calreticulin/CD91 (Ogden et al., 
2001). However the importance of C1q, in the clearance of apoptotic cells, is really 
highlighted in the development of the autoimmune disease SLE (Kirschfink et al., 1993). 
SLE is associated with failed clearance as a result of C1q deficiency and results in chronic 
inflammation and a loss of tolerance caused by the generation of autoantibodies.  
 
The alternative complement pathway is also involved in the clearance of apoptotic cells as 
C3b binds to PS exposed at the surface of apoptotic cells. Apoptotic cell-associated C3 is 
then rapidly cleaved to form C3bi which interacts with the integrin receptors CR3 and CR4 
(Mevorach et al., 1998).  
 
MBL, a member of collectin family is present in serum and binds pathogen-associated 
carbohydrates, activating the lectin-complement pathway and again associated with 
apoptotic cell clearance (Stuart et al., 2005).  Furthermore Stuart et al.(2005) reported that 
MBL-deficient mice showed reduced clearance of apoptotic cells in vivo without 
inflammation. This supported findings by Devitt et al. (2004) that suggest the binding of 
apoptotic cells to phagocytes could be uncoupled from the anti-inflammatory effects of 
clearance.  
 
Other collectin family members include lung surfactant proteins A (SP-A) and D (SP-D) 
that also bind apoptotic cells and facilitate clearance in the lungs. Furthermore SP-A, SP-D 
and MBL are known to bind CD14 and modulate LPS responses (Chiba et al., 2001). With 
respect to apoptotic cell clearance, SP-A, SP-D and MBL interact with the receptor 
complex calreticulin/CD91 to mediate uptake (Ogden et al., 2001).  
 
C-reactive protein (CRP) is a member of the pentraxin family known to bind 
polysaccharides and phosphocholine in pathogen-membranes and activate the classical 
complement pathway. Gershov et al.(2000) reported that CRP binds to apoptotic cells and 
enhances complement-mediated clearance while preventing assembly of membrane-attack 
complex protecting against lysis and proinflammatory consequences. Serum amyloid P 
(SAP) is another member of the pentraxin family associated with complement-mediated 
clearance of apoptotic cells.  
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1.4.1.2 Antibodies    
IgM antibodies have been shown previously to bind apoptotic cells and function as 
opsonins that promote complement-dependent clearance (Quartier et al., 2005).  
Antibodies have specific roles within the adaptive immune response tailored to foreign 
antigens. Antibodies function to neutralize and opsonise pathogens which facilitates 
activation of the classical complement pathway and enhances removal by effector cells. 
Quartier et al.(2005) found that natural IgM antibodies were required for C1q-dependent 
C3 deposition on apoptotic cells in vivo, while mice deficient in natural IgM, have been 
shown to develop lupus-like diseases due to failed clearance. IgG antibodies are considered 
to function in apoptotic cell clearance along with host defence. During erythocyte ageing a 
senescent erythocyte-specific antigen is displayed resulting in IgG binding which 
facilitates clearance (Bosman et al., 2005).  
1.4.1.3 Thombospondin (TSP-1) 
TSP-1 is a member of the extracellular matrix protein family widely distributed in human 
tissues (Sid et al., 2004). TSP-1 is secreted by various cells types including macrophages, 
fibroblasts and neutrophils (Poon et al., 2009 & Moodley et al., 2003). TSP-1 is implicated 
in various biological processes including chemotaxis, cell adhesion, proliferation and the 
clearance of apoptotic cells (Poon et al., 2009). Savill et al.(1992) found that addition of 
TSP-1 to apoptotic neutrophils co-cultured with HMDM enhanced uptake. TSP-1 is 
suggested to interact with a phagocyte-associated complex; vitronectin receptor/CD36 
(Savill et al., 1992). CD36 has a short cytosolic signalling domain and is considered to 
signal using the integrin, vitronectin receptor to induce engulfment (Savill et al., 1992). 
Furthermore Moodley et al.(2003) found that apoptotic fibroblasts released TSP-1 which 
functioned as a chemoattractant for macrophage migration suggesting that TSP-1 released 
from apoptotic cells also functions as a ‘find me’ signal. This is supported by findings that 
blockade of CD36 on macrophages inhibited their migration, suggesting TSP-1 may bind 
to CD36 and induce migration (Moodley et al., 2003). TSP-1 is currently considered to 
forms a bridge between the apoptotic fibroblasts and the macrophage receptor complex 
CD36/vitronectin. With respect to amateur phagocytes, Monks et al.(2005) reports that 
mammary epithelial cells also use CD36/vitronectin receptor which potentially suggests 
that TSP-1-dependent clearance could also be mediated by amateur phagocytes. Therefore 
if amateur phagocytes express and utilise receptors also used by professional phagocytes to 
clear apoptotic cells, can they too be considered as ‘resident professional’ like resident 
macrophages? This ultimately suggests that it may be the receptors expressed by the 
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phagocyte that is responsible for its ability to efficiently clear apoptotic cells and therefore 
its level of profession. 
1.4.2 PS-binding molecules 
PS is recognised as a fundamental surface marker of apoptotic cells and as such there has 
been a great deal of interest in identifying its cognate phagocyte receptor (reviewed by 
Bratton and Henson, 2008).  It was originally considered that phagocytes expressed just 
one universal receptor that recognised PS, termed PSR (Fadok et al., 2000). This was 
identified using mAb 217 found to blocks the PS-dependent uptake of apoptotic cells by 
macrophages (Fadok et al., 2000). The gene, psr was identified following binding of 
mAb217 to a phage display library of proteins from macrophages and considered to code 
for the PSR (Fadok et al., 2000). However several studies found that the protein encoded 
by psr was primarily located in the nucleus of cells and did not function as a surface 
receptor (reviewed by Schlegel and Williamson, 2007, Bratton and Henson, 2008). Further 
work demonstrated that mAb217 showed cross-reactivity with a small sequence of protein 
encoded by the psr and was responsible for its being identified as the original PSR 
(reviewed by Schlegel and Williamson, 2007, Bratton and Henson, 2008). However 
current thinking is that there are two PS recognition mechanisms; 1. Direct PS-binding 
receptors, for example, the TIM family (Kobayashi et al., 2007 & Miyanishi et al., 2007) 
and 2. Indirect PS binding molecules that bridge the apoptotic cells and phagocyte 
facilitating clearance, for example, GAS6(Hanayama et al., 2002 & Ravichandran, 2010).  
1.4.2.1 Indirect PS-binding molecules  
1.4.2.1.1 Growth arrest specific 6 (GAS6) and protein S 
GAS6 and protein S are members of plasma vitamin K-dependent proteins (Ishimoto et al., 
2000). Protein S functions as an anticoagulant that inhibits protease activation in the 
clotting cascade (Stitt et al., 1995) while GAS6 is secreted by fibroblasts during the 
growth-arrest state to prevent apoptosis and mediate proliferation (Ishimoto et al., 2000). 
Gas6 and protein S bind to PS on the surface of apoptotic cells and enhance phagocytic 
clearance using Tyro, Axl and Mer known as the TAM family of tyrosine kinases receptors 
(Ishimoto et al., 2000, Anderson et al., 2003 & Lemke and Burstyn-Cohen, 2010). TAM 
family member recruit the crk-DOCK180-ELMO complex to the membrane resulting in 
Rac1 activation and consequently actin-dependent engulfment (Wu et al., 2006). 
Activation of adhesion receptors including integrins such as the vitronectin receptor also 
results in crk-DOCK180 recruitment (Wu et al., 2006). 
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1.4.2.1.2 MFG-E8 
Hanayama et al.(2002) found a secreted glycoprotein known as MFG-E8 which is 
abundant in milk fat globules. This binds PS on apoptotic cells and bridges phagocyte 
interaction. MFG-E8 bound to PS, has been reported to bind to β2-integrins which includes 
the vitronectin receptor and mediates Rac1-dependent phagocytosis (Akakura et al., 2004 
& Wu et al., 2006). The importance of MFG-E8 in the clearance of apoptotic cells was 
demonstrated by Peng and Elkon (2011) that found mice with MFG-E8 deficiency develop 
lupus-like diseases. Therefore this suggests that the role of MFG-E8 in apoptotic cell 
clearance is non-redundant.  
1.4.3 Phagocyte-associated receptors that interact with apoptotic cells 
1.4.3.1 PS receptors 
Phagocyte interaction with PS can be direct or indirect and interaction with PS can result in 
signalling for corpse engulfment (Hoffmann et al., 2001). Here several potential 
membrane-associated PS receptors along with the signalling pathways that mediate 
engulfment are discussed.  
1.4.3.1.1 T-cell immunoglobulin and mucin-domain-containing molecules 4 
(TIM-4) 
TIM-4 is a member of a the type I transmembrane family of proteins which, following 
expression in fibroblasts were found to enhance uptake of apoptotic cells (Miyanishi et al., 
2007). Furthermore blockade of TIM-4 resulted in the production of autoantibodies 
suggesting that the TIM-4-dependent engulfment of apoptotic cells is a non-redundant 
clearance mechanism. TIM members 4 and 1 have been shown to bind to PS on the surface 
of apoptotic cells using their immunoglobulin-domain to induce uptake. Miyanishi et 
al.(2007) also suggest that TIM family members present in microparticles, secreted by 
apoptotic cells may induce intracellular signalling that enhance phagocytosis when the 
phagocyte meets the apoptotic cells. 
1.4.3.1.2 Brain-specific angiogenesis inhibitor1 (BAI1) 
 In vivo studies illustrated an inhibition of apoptotic cell clearance following reduced BAI1 
expression (Park et al., 2007a). BAI1 is a member of the adhesion-type G-protein coupled 
receptor family recognised to contain TSP-1-type repeats within the extracellular domain 
that binds PS (Park et al., 2007a). Following ligation BAI1 forms a trimeric complex with 
ELMO/DOCK180/Rac which promotes cytoskeleton rearrangement and consequently 
phagocytosis (Park et al., 2007a). 
30 
 
1.4.3.1.3 Stabilin-2 
Stabilin-2 is a multidomain receptor that binds hyaluronic acid (Politz et al., 2002), and 
bacteria (Adachi and Tsujimoto, 2002) and can function as an endocytic receptor for 
advanced-glycated end products (AGEs) (Tamura et al., 2003). A decrease in the uptake of 
senescent erythocytes was demonstrated following knock-down of stabilin-2 expression by 
siRNA and co-incubation with PS-containing liposomes suggesting a role for stabilin-2 as 
a receptor for PS (Park et al., 2008). Furthermore treatment of phagocytes with an agonist 
for stabilin-2, increased the production of anti-inflammatory cytokines to a level 
comparable to apoptotic cell or PS-containing liposomes (Park et al., 2008). Ligation of 
stabilin-2 results in the recruitment of GULP and is therefore likely to influence the 
MEGF10/ABCA1/GULP/Rac 1 pathway leading to engulfment. 
1.4.3.2 Scavenger receptors 
There are many different classes of scavenger receptors of which recognise and bind 
different targets on Gram positive and Gram negative cells. However scavenger receptors 
CD36, LOX-1, CD68, SRA1, SRB1 and CLA-1 recognise oxidised lipids generated at the 
surface of apoptotic cells. Murphy et al.(2006) found that LOX-1 a C-type lectin, 
scavenger receptor directly binds PS in a calcium dependent-manner and facilitates 
clearance.  Furthermore Imachi et al.(2000) found that the scavenger receptors SRB1 and 
CLA-1 were used by ‘amateur’ phagocytes to facilitate apoptotic cell clearance in the 
thymus. 
1.4.3.3 CD14 
The gene encoding CD14 is located on chromosome 5 and is composed of two exons that 
codes for a single 1.4kb transcript which once translated produces a 356 amino acid protein 
(Ziegler-Heitbrock and Ulevitch, 1993).  Post-translation modifications include 
glycosylation at O-and N-linked sites and the addition of a hydrophobic 
glycophosphatidylinositol (GPI) tail to the C-terminal that anchors the protein in the cell 
membrane (Zielgler-Heitbrock and Ulevitch, 1993). CD14 functions as a PRR expressed 
on monocytes, macrophages, granulocytes and B cells (Ziegler-Heitbrock and Ulevitch, 
1993). Pugin et al.(1998) used THP-1 stably transfected with a membrane CD14 
expressing plasmid and isolated CD14 within the Triton X-100 insoluble-fraction 
suggesting that CD14 is located in microdomains within the plasma membrane.  
 
CD14 expression is upregulated during monocyte maturation and was therefore originally 
considered a marker of macrophage differentiation (Ziegler-Heitbrock and Ulevitch, 1993). 
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Surface expression of CD14 is upregulated on both professional and amateur phagocytes, 
following LPS stimulation, with the exception being alveolar macrophages (Fearns et 
al.,1995). CD14 also exists as a soluble form found in serum and is upregulated following 
LPS stimulation (Fearns et al., 1995). Soluble CD14 (sCD14) is generated following 
proteolysis of membrane associated receptor (mCD14) or released prior to cleavage of the 
C-terminus and subsequent addition of GPI tail  (Bufler et al., 1995). While the exact role 
of sCD14 in innate immunity is unknown, sCD14 is reported to convey LPS 
responsiveness to cells that do not express mCD14, for example, endothelial cells (Frey et 
al., 1992). 
 
CD14 is known to bind an array of endogenous and exogenous ligands most notably, LPS 
and promotes inflammation (Wright et al., 1990). However other microbial ligands, 
include, peptidoglycan (Dziarski et al., 1998) and lipoteichoic acid (Cleveland et al., 
1996). CD14 also binds endogenous ligands including heat shock proteins (Kol et al., 
2000a), β amyloid (Liu et al., 2005), pulmonary surfactant proteins (Sano et al., 2000), rat 
mannose-binding lectin (Chiba et al., 2001), minimally-modified-LDL (Miller, 2002) and 
apoptotic cells (Devitt et al., 1998).  
1.4.3.3.1 Role of CD14 in LPS binding 
The binding of LPS to CD14 generates inflammatory  responses, characterised by the 
activation of NF- B-dependent genes causing the expression of proinflammatory 
cytokines; including TNF- and chemokines (Haziot et al., 1996). CD14-deficient mice 
were reported to be highly resistant to septic shock indicating that CD14 mediates 
inflammatory responses (Haziot et al., 1996).  However a decrease in the dissemination of 
bacteria was also observed, suggesting that CD14 facilitates the spread of infection 
too(Haziot et al., 1996). LPS are the major component of the outer membrane of the cell 
wall of Gram negative bacteria and is released during growth, lysis or on exposure to 
human serum (Aurell and Wistrom, 1998 & Zhang et al., 1994a). This amphiphilic 
molecule is composed of three subunits (figure 3); a highly conserved lipid A region that 
anchors the whole molecule to the bacterial cell membrane, covalently attached to a core 
oligosaccharide and the O-antigen which protrudes into the surrounding area (Rietschel et 
al., 1994). The core polysaccharide and O-antigen vary in composition depending on the 
serotype of bacteria (Rietschel et al., 1994). However lipid A is responsible for biological 
activity of LPS and while this region is highly conserved, slight variations between 
bacterial strains are responsible for the potency of LPS (Rietschel et al., 1994).   
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Due to the chemical nature of LPS, in aqueous solutions such as blood and tissue culture 
medium, aggregates known as micelles form, with LPS monomer transfer to CD14 being 
slow (Aurell and Wistrom, 1998 & Fenton and Golenbock, 1998). The binding of LPS to 
CD14 is enhanced by the serum glycoprotein LPS-binding protein (LBP) which is a lipid 
transferase that destabilises aggregates and transfers monomers of LPS from micelles to 
CD14, producing a CD14-LPS receptor complex (Tobias et al., 1986 & Hailman et al., 
1994).  In vitro data suggest that LBP is necessary for LPS responsiveness however in vivo 
data from LBP-deficient mice suggests LPS response is unaffected (Wurfel et al., 1997).  
Furthermore Youn et al.(2008) found that HMGB1 bound directly to LPS and facilitated 
transfer to CD14.  Formation of LPS:CD14 complex recruits TLR4 associated with MD-2 
to the membrane along with associated signalling molecules, for example, MyD88 (da 
Silva Correia et al., 2001 & Triantafilou et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Structure of LPS 
LPS is the major component of Gram 
negative bacterial cell wall and 
therefore a potent activator of the 
innate immune system. LPS is 
composed of three main subunits, a 
repeating sugar unit known as the O-
antigen, a core oligosaccharide and a 
highly conserved lipid A region. 
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1.4.3.3.2 Signalling partner 
Membrane CD14 does not contain a cytosolic signalling domain therefore CD14 interacts 
with different signalling partners to confer ligand-dependent responses (reviewed by 
Bosshart & Heinzelmann, 2002).  The CD14-LPS complexes activate TLR4 (figure 4) to 
propagate the signal causing the activation of NF- B-dependent proinflammatory genes 
(Hoshino et al., 1999 & Miyake, 2004). Studies conducted with TLR4-deficient mice or 
mutated TLR4 domains were hyporesponsive to LPS therefore confirming the requirement 
of TLR4 in LPS signalling (Hoshino et al., 1999). Shimazu et al.(1999) revealed the 
requirement of the accessory protein, MD-2, required for glycosylation and cell surface 
expression of TLR4 (Nagai et al., 2002). TLR4 propagates the signal by interaction with 
the adaptor molecules myeloid differentiation factor 88 (MyD88) or a MyD88-independent 
pathway which activates the adaptor molecule (TRAM) and TIR-domain containing 
adaptor including interferon-beta (TRIF) (Takeda and Akira, 2004). Activation of these 
pathways results in the activation of the transcription factor NF-kB which is responsible 
for the expression of proinflammatory genes (review by Miyake, 2004).   
 
Isolation of microdomains containing CD14 by Triantafilou et al.(2002) along with SDS-
PAGE and immunoblotting revealed the presence of other LPS binding molecules 
including Heat shock protein (Hsp) 70 and 90 (Byrd et al., 1999 & Wallin et al., 2002). 
Following LPS stimulation Triantafilou et al., 2002 found that along with TLR4, other 
LPS-binding proteins including chemokine receptor 4 (CXCR4) and growth differentiation 
factor 5 (GDF5) were recruited and formed a CD14-independent LPS receptor (da Silva 
Correia et al., 2001).  Previous studies have shown that incubation with CD14-blocking 
mAb only partially inhibit LPS-induced binding or responses (Troelstra et al., 1997 & 
Gessani et al., 1993). Monocytes and macrophages express scavenger receptors, β2 
integrins and L-selectins which are also bind LPS (reviewed by Fenton and Golenbock, 
1998& Peppelenbosch et al., 1999). However these receptors are reported to have a low 
affinity for LPS therefore a high concentration of LPS is required for activation 
(Peppelenbosch et al., 1999). 
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Figure 4: LPS binds to CD14 and activates TLR4 
LPS aggregates into micelles in aqueous solutions therefore LBP is required to destabilise 
aggregates and transfer monomers of LPS from micelles to CD14, producing a CD14-LPS 
receptor complex. CD14-LPS complexes activate signalling partner, TLR4 to propagate an 
proinflammatory signal resulting in the transcription NF- B-dependent genes (Hoshino et 
al., 1999 & Miyake, 2004).  
 
1.4.3.3.3 CD14 binds apoptotic cells 
The clearance of apoptotic cells is currently known to be more than simply waste disposal 
as originally considered. Voll et al.(1997) highlighted the immunomodulatory effects of 
apoptotic cell clearance by macrophages. Furthermore Fadok et al. (1998, 2002) found that 
apoptotic cell uptake by macrophages, actively inhibited production of  tumour necrosis 
factor- TNF-  and other proinflammatory cytokines following stimulation with 
zymosan or LPS. Fadok et al.(1998) established that the immunosuppressive effects 
produced by apoptotic cell uptake could be inhibited by anti-transforming growth factor-β 
(TGF-β) antibodies (Fadok et al., 1998b). The lead to the suggestion that interactions 
formed between the apoptotic cell and the interface of the macrophage; known as the 
phagocytic synapse, produced a dominant anti-inflammatory response. This anti-
inflammatory macrophages response is characterised by the expression and release of the 
TGF-  and immunomodulatory cytokines such as IL-10 (Fadok et al., 1998b). 
 
Flora and Gregory (1994) tested a range of mAbs, against monocyte and macrophage 
surface antigens, for their ability to inhibit the in vitro binding and phagocytosis of 
apoptotic cells. These studies identified mAb 61D3 which could block the binding of 
apoptotic cells to cultured macrophages. Analysis of the epitope recognised by 61D3 by 
Devitt et al.(1998) identified this epitope as the LPS receptor, CD14. The transient 
expression of CD14 by COS-1 then identified the role of CD14 in the binding and 
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phagocytosis of apoptotic cells.  Devitt et al. (1998) demonstrated that LPS interaction 
with macrophages induced the release of the pro-inflammatory mediator TNF-  whereas 
macrophages interacting with apoptotic cells did so without such consequences. 
Furthermore Devitt et al.(2004), investigated the importance and level of redundancy of 
CD14 in apoptotic cell clearance in vivo using CD14-knockout mice. In these mice 
persistent apoptotic cells were found in tissues, including the thymus, spleen and lung 
suggesting a defect in apoptotic cell clearance related to their CD14 deficiency (Devitt et 
al., 2004). The persistence of these apoptotic cells was for the first time, without 
inflammatory consequences (Devitt et al., 2004). This suggesting that the anti-
inflammatory response produced by macrophages following apoptotic cell uptake, could be 
uncoupled from the initial binding events (Devitt et al., 2004). Therefore CD14 is currently 
considered to function as a tethering receptor, required for the binding of apoptotic cells.  
 
CD14 was the first PRR identified with a role in the clearance of apoptotic cells and 
quickly led to the discovery that other PRRs were also involved in apoptotic cell clearance 
(e.g C1q and MBL). Furthermore this led to the suggestion that apoptotic cells display 
apoptotic cell-associated molecular patterns termed ACAMPs considered to resemble 
PAMPs (Gregory and Devitt, 2004). In the case of CD14, Gregory and Devitt (2004) 
suggested that the ACAMP recognised by CD14 are LPS-like. This was suggested 
following findings by Devitt et al. (1998) that 61D3 and another CD14-blocking mAb, 
MEM18, blocked both LPS responses and apoptotic cell binding. Therefore suggestion that 
the epitope for LPS and apoptotic cells within CD14,  are the same or closely associated 
(Devitt et al., 1998). This promoted interest into the mechanisms employed by CD14 to 
produce two contrasting ligand-dependent responses.  
1.4.3.4 Another PRR involved in the clearance of apoptotic cells? 
Recent findings have implicated another innate immune molecule, the receptor for non-
enzymatically glycated and oxidised proteins (RAGE) in the clearance of apoptotic cells by 
phagocytes (Liu et al., 2008, Banerjee et al., 2010). RAGE shares much similarity with 
CD14, both receptors bind exogenous and endogenous ligands and have been implicated in 
innate immunity (Lin, 2006, Foell et al., 2006 & Bianchi, 2009).  Furthermore RAGE, like 
CD14 also forms complexes with LPS and employs TLR4 to promote inflammation 
(Bianchi, 2009, Park et al., 2004, Youn et al., 2008, Hofmann et al., 1999 & Ziegler-
Heitbrock and Ulevitch, 1993). Ligation of RAGE also activates the transcription factor 
NF-κB, sequentially promoting the expression of proinflammatory cytokines and 
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chemokines (Chavakis et al., 2003,Schmidt et al., 2000). However with previous 
suggestions that ACAMPs share similarities with PAMPS, along with previous findings 
that CD14 also binds and facilitates the removal of apoptotic cells, the role of RAGE in the 
clearance of apoptotic cells is of interest. 
1.4.3.4.1 RAGE 
RAGE was first identified by Neeper et al.(1992), as a cell surface receptor for the 
products of non-enzymatically glycated and oxidised proteins (AGEs). Later RAGE was 
identified to recognise other families of ligands, including members of the 
S100/calgranulins, amyloid fibril and high mobility group box-1 (HMGB1) (Schmidt et al., 
2000 & Bucciarelli et al., 2002). The structures of these ligands are heterogeneous and 
crystallography revealed that the ligands of RAGE share common structural characteristics 
with all of the three dimensional structures having multiple -sheet conformations 
(Schmidt et al., 2000 & Bucciarelli et al., 2002).  Therefore RAGE functions as a PRR 
expressed at low levels by most cell types, including neurons, glioma, endothelial, smooth 
muscle cells, and professional phagocytes (Park et al., 2004 & Lutterloh et al., 2007).  The 
involvement of RAGE in innate immunity was first suggested by Liliensiek et al.(2004) 
who found RAGE-deficient mice displayed normal physiology but were protected against 
septic shock as seen in CD14-deficient mice. This protective effect could be reversed 
following the reconstitution suggesting a direct role for RAGE in innate immune responses 
(Liliensiek et al., 2004 & Lutterloh et al., 2007). The RAGE gene is located within the 
major histocompatibility class III locus, known to code for other members of the innate 
immune system (Xie et al., 2008).   
1.4.3.4.2 RAGE binds HMGB1 
The presence of HMGB1 outside the cell is reported to function as a damage-associated 
molecular pattern (DAMP), considered as an endogenous molecule that signifies tissue 
damage and activates the innate immune system. Necrotic cells passively release HMGB1 
due to loss of membrane integrity and HMGB1 binds with high affinity to RAGE which 
promotes inflammation (Scaffidi et al., 2002). During activation of the apoptosis 
programme, HMGB1 becomes bound to chromatin therefore sequestering this DAMP 
signal (Scaffidi et al., 2002). Macrophages have also been reported to secrete HMGB1 as a 
proinflammatory cytokine considered to function though RAGE ligation (Scaffidi et al., 
2002). A study by Liu et al.(2008) found that preincubating apoptotic neutrophils with 
HMGB1 prior to co-culturing with mouse peritoneal macrophages inhibited the phagocytic 
uptake of apoptotic cells. Furthermore HMGB1 was found to compete with MFG-E8 for 
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binding to the  vitronectin receptor expressed by phagocytes (Friggeri et al., 2010). 
However loss of C-terminus of HMGB1 diminished both the inhibitory effects on 
apoptotic cell clearance and ability to bind RAGE (Friggeri et al., 2010). Therefore 
suggesting that this innate immune receptor; RAGE, may also function in the clearance of 
apoptotic cells. 
1.5 Aims & objectives 
The established role for CD14 in both LPS response and apoptotic cell clearance implies 
that CD14 is capable of producing two distinct ligand-dependent macrophage responses. 
Therefore this project seeks to use a series of point-mutants to dissect the role of CD14 in 
the binding of LPS and apoptotic cells and seeks to establish an understanding of the 
molecular mechanisms underlying the involvement of CD14 in the non-inflammatory 
clearance of apoptotic cells. Previous findings suggest that CD14 employs the same or 
closely associated region of CD14 to interact with PAMPs and ACAMPs therefore there 
are several possible scenarios in which CD14 ligation with PAMPs and ACAMPs can 
induce divergent macrophage responses (figure 5). 
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Figure 5: Possible scenarios involved in CD14-dependent responses 
CD14-dependent response to LPS: 1. LPS binds CD14 (purple domains) and induces a pro-
inflammatory signal (red arrows) though association with TLR4, resulting in NF-κB 
translocation and an inflammatory response. Possible CD14-dependent responses to 
apoptotic cells: 2 ACAMP on apoptotic cells bind to CD14 in an identical manner to LPS 
(purple domains) and induce a pro-inflammatory signal as seen in scenario one. However 
pro-inflammatory signalling is suppressed following further phagocyte receptor ligation 
(e.g. PS-PS receptor) which produces a dominant anti-inflammatory signal (blue arrows). 3 
ACAMP binding to CD14 differs from LPS binding (grey domains), thereby dictating the 
recruitment of an alternative signalling partner to CD14 resulting in anti-inflmmatory 
signalling 4. CD14 here functions very simply just to tether the apoptotic cell to the 
phagocyte. The tethering effects of CD14 may be mediated thought ACAMP interaction 
with LPS binding regions of CD14 (purple domains) or another region of CD14 (grey 
domains), but interaction does not result in signalling. Therefore interaction of the 
apoptotic cell with another phagocyte receptor independently mediates corpse uptake and 
the anti-inflammatory response.Adapted from Gregory and Devitt, 2004 
 
 
The hypotheses underlying this project are: 1. Apoptotic cells present ACAMPs that 
share structural similarities with PAMPs, which in the case of CD14 are considered to 
be LPS-like structures. 2. ACAMP and PAMP binding to CD14 is indistinguishable, 
however apoptotic cells bind to CD14 in a manner that re-programmes the 
downstream responses to be non-inflammatory or even anti-inflammatory.  
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Therefore the specific aims and objectives of this project are: 
1) Given the knowledge of LPS binding, a series of mutants with single amino acid 
changes within key LPS binding regions of CD14 will be used to address apoptotic 
cell binding and will compare and contrast ligand binding.  
2) However if the same regions of CD14 are employed to bind LPS and apoptotic 
cells, this project will seek to identify the point at which CD14 signalling pathways 
diverge. 
3) Given findings that amateur phagocytes use receptors also expressed by 
macrophages to clear apoptotic cells, this project aims to characterise the function 
of CD14 in the clearance of apoptotic cells by a series of amateur phagocytes. 
4) Given CD14, an LPS binding molecule, binds to apoptotic cells this project seeks 
to address if another LPS binding molecule, RAGE can also bind. Therefore this 
project aims to produce soluble RAGE to function as a competitive decoy for 
membrane-bound RAGE in order to assess the role of RAGE in the clearance of 
apoptotic cells.  
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Materials & Methods 
2.1 Equipment 
Cryo-freezing container NALGENE (Fisher, Loughborough,UK  
Eppendorf Centrifuge 5810R (DJB Labcare Ltd, Buckinghamshire, UK) 
Flow cytometer Quanta SC (Beckman Coulter High Wycombe, UK) 
Flow cytometric analysis software VenturiOne (Dinnington, Sheffield, UK) 
Haemocytometer  Double cell standard (Camlab Ltd, Cambridge, UK) 
Inverted fluorescence microscope Zeiss Axiovert 200M  (Hertfordshire, UK) 
Luminometer (Berthold detection systems, Phorzhein, Germany)  
Nano drop 1000 spectrophotomer (Thermoscientific, Loughborough,UK) 
Plate reader EL800 (BioTek Potton, Bedfordshire, UK)  
RENA air 50 (Chalfont, PA, USA) 
Thermocycler Gene Amp (Applied Bio systems Paisley, UK) 
UVP transilluminator (Cambridge, UK) 
2.2 Reagents 
All general laboratory consumables were purchased from Sigma Aldrich (Dorset, UK) 
unless otherwise specified.   
2.2.1 Antibodies 
Goat anti-mouse IgG (whole molecule)-FITC (GAM-FITC), goat anti-human IgG (Fc 
specific)-FITC, mouse IgG1 (MOPC 21), goat anti-rabbit-PE and goat ant-mouse-PE 
Sigma Aldrich (Dorset, UK). Mouse IgG2a (MOPC 173), TLR4 (clone HTA 125)-PE, 
Mouse IgG2a-PE, Rabbit polyclonal antibody to RAGE Abcam (Cambridge, UK). Rabbit 
immunoglobulin fraction (normal) negative control Dako (20mg/ml) (Ely, Cambridgeshire, 
UK). ECL-anti-rabbit IgG horseradish peroxidise (anti-rabbit-HRP), ECL anti-mouse 
horseradish peroxidise (anti-mouse-HRP), Streptavidin horseradish peroxidise 
(Streptavidin-HRP), Amersham biosciences (Cambridge, UK). Rabbit anti-Escherichia 
coli LPS anti-serum AbD serotec (Oxford, UK). 
 
2.3 Tissue culture 
2.3.1 Tissue culture reagents 
All tissue culture reagents were purchased from PAA Laboratories Ltd (Yeovil, Somerset, 
UK) unless otherwise specified. 
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2.3.2 Tissue culture media and solutions 
Suspension cell growth medium (cRPMI): RPMI 1640, penicillin (final concentration of 
100U/ml) and streptomycin (to a final concentration of 100µg/ml) , 2 mM L-glutamine and 
10% (v/v) foetal calf serum (FCS). 
Adherent cell growth medium (cDMEM): DMEM, penicillin (final concentration of 
100U/ml) and streptomycin (to a final concentration of 100µg/ml), 2 mM L-glutamine and 
10% (v/v) FCS. 
Growth medium for oral epithelial (H400) cells: DMEM/F12 (gift kindly received from 
Professor Ian Chapel, Birmingham Dental School), penicillin (final concentration of 
100U/ml) and streptomycin (to a final concentration of 100µg/ml), 2 mM L-glutamine and 
10% (v/v) FCS.  
Human pulmonary fibroblast growth medium: Fibroblast growth medium (Promocell, 
Heidelberg, Germany), supplemented with the antibiotic Normocin (Promocell) (final 
concentration of 100µg/ml), 2 mM L-glutamine, 15% (v/v) FCS and the manufacturer’s 
supplement. 
Growth medium for Calu-3 cells: DMEM/F12 (Promocell), 15% (v/v) FCS, Normocin 
(final concentration of 100µg/ml) and 2 mM L-glutamine. 
Airway epithelial growth medium: Airway epithelial growth medium (Promocell), 5% 
(v/v) FCS, Normycin (final concentration 100µg/ml), 2 mM L-glutamine and the 
manufacture’s supplement. 
Cell freezing medium: 5% (v/v) Dimethyl sulphoxide (DMSO) in FCS. 
Wash buffer for flow cytometry: 0.1% (w/v) BSA in PBS. 
Fixative for flow cytometry staining: 0.1% (w/v) BSA, 1% (w/v) formaldehyde in PBS 
Apoptotic cell interaction assay medium: sfRPMI containing 0.2% (w/v) BSA 
Jenner-Giemsa buffer (50x): Solution A:100mM sodium dihydrogen orthophosphate 
dihydrate. Solution B:100mM disodium hydrogen phosphate. Solution B is added to 
solution A to pH 5.6 and diluted in dH2O to x1 solution. 
Cell lysis buffer: 5μl/ml protease inhibitor cocktail (Sigma Aldrich, Dorset UK) (broad 
spectrum of protease inhibitors including 4-(2-aminoethyl) benzenesulfonyl fluoride, 
pepstatin A, E-64, bestatin, leupeptin, and aprotinin) 0.5% (v/v) Triton X-100 (Sigma 
Aldrich, Dorset UK) in PBS. 
2 x HEPES buffered saline: (HBS) 8g sodium chloride, 0.2g 1.5mM disodium hydrogen 
phosphate, 6.5g HEPES diluted in dH2O to pH7.0 then made to 500ml solution. 
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2.3.3 Cell lines  
2.3.3.1 Suspension cell lines 
Mutu: EBV-positive Burkitt lymphoma cell line (Gregory et al., 1991). Supplied courtesy 
of Professor Christopher Gregory (MRC Centre for Inflammation Research, Edinburgh 
University). 
THP-1: Human monocytic leukaemic cell lines. 
U937: Human monocytic leukaemic lymphoma cell line. 
Jurkat:  human T cell leukaemia cell line. 
2.3.3.2 Adherent cell lines 
HEK293: An adherent adenovirus transformed human embryonic kidney cell line (Graham 
et al., 1977). 
COS-1: African green monkey kidney cell line; derived from CV-1 by transformation with 
origin defective SV-40 mutant (Jensen et al., 1964). 
H400: Human oral squamous carcinoma cell line cultured in complete DMEM/F12 (Prime 
et al., 1990). These cells were kindly received from Ian Chapel from School of dentistry, 
University of Birmingham. 
HeLa: Human cervical epithelial cells taken from a carcinoma transformed by human 
papillomavirus 18 sequences.  
MCF-7: Mammary epithelial cell line from human breast adenocarcinoma (Soule et al., 
1973). 
Beas-2B cells: Normal human bronchial epithelial cell line transformed by SV40 T-
antigen (Reddel et al., 1988). Received with thanks from Dr Lindsay J. Marshall (School 
of Life & Health Sciences, Aston University, UK). 
HPF: A primary human pulmonary fibroblast cell line received from Dr Lindsay J. 
Marshall (School of Life & Health Sciences, Aston University, UK). The cells were 
cultured in cHPFM 
Calu-3: Human sub-bronchial gland cell line from submucosal adenocarcinoma origin. 
Received from Dr Lindsay J. Marshall (School of Life & Health Sciences, Aston 
University, UK). This cell line was cultured in cDMEM/F12. 
2.3.4 Tissue culture  
All cell lines were routinely cultured every 2-3 days and maintained in a 37°C, 5% CO2 
humidified incubator. Suspension cells were cultured by gently resuspending the cells and 
replacing 70-80% of the culture medium with fresh, prewarmed cRPMI. Adherent cell 
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lines were cultured by rinsing the monolayer first with PBS (PAA) then with 
trypsin/EDTA (PAA). Following incubation at room temperature for 10-15min, the cells 
were resuspended and 90% of the culture medium replaced with prewarmed cDMEM 
unless specified in section 2.3.3.2. 
2.3.4.1 Freezing Cells 
Only healthy cultures of cells with high viability were frozen down.  Cells harvested as 
outlined in section 2.3.4 were centrifuged and resuspended in freezing medium. 1ml 
aliquots were transferred to labelled cryovials and placed in a cryo-freezing container at -
80
°
C to allow freezing to be controlled to -1
°
C/min. Cryovials were then transferred to 
nitrogen vapour for long-term storage.   
2.3.4.2 Thawing Cells 
Cryovials of cells were stored in nitrogen vapour.  Non-adherent cells were thawed rapidly 
at 37°C in a water bath. Once defrosted, cells were transferred to a 25ml tube and gently 
mixed (in a drop-wise manner) with 10ml prewarmed growth medium. Cells were 
centrifuged gently (300xg for 5 min) and the pellet resuspended in fresh growth medium to 
remove cryoprotectant.  Adherent cells lines were similarly thawed but cryoprotectant was 
removed by changing culture medium following cell adhesion.   
2.3.5 Differentiation of THP-1 into macrophage-like cells 
Differentiation of THP-1 into macrophage-like was induced with 100nM dihydroxyvitamin 
D3 (vitamin D3) (Biomol, Exeter, UK), 250nM phorbol 13-myristate12-acetate (PMA) 
(Sigma Aldrich, Dorset, UK) or both (vitamin D3/PMA) for 72h at 37°C in 5% CO2 
incubator.  
2.3.6 Immunofluorescence staining of cells  
2.3.6.1 Indirect Immunofluorescence staining  
2x10
5
 cells were washed in flow buffer and incubated with 100µl of primary antibody for 
30min on ice. All antibodies were used in excess or at saturating concentrations. Cell 
surface CD14 expression was detected with undiluted tissue culture supernatant 61D3, 
63D3 or the IgG1:  (10μg/ml) isotype-control MOPC 21. Cell surface expression of 
RAGE was detected with (1μg/ml) polyclonal anti-RAGE antibody or the isotype-control 
pre-immune rabbit serum (1μg/ml). Following incubation cells were washed twice with 
flow buffer before incubation with 100µl secondary-conjugated antibody (goat anti-mouse 
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FITC/PE (1:50) or goat anti-rabbit FITC (1:50) for at least 30min on ice.  Cells were 
washed and fixed in 1% (w/v) formaldehyde in PBS prior to analysis. 
2.3.6.2 Direct Immunofluorescence staining 
Cell surface TLR4 was determined using direct immunofluorescence staining with TLR4 
(HTA 125)-PE or IgG2a/  isotype-control. 2x10
5
 cells were washed with flow buffer and 
incubated with 2μL of HTA125 or the isotype-control at saturating concentrations for 
30min on ice. Following incubation cells are washed twice with flow buffer and fixed in 
1% (w/v) formaldehyde in PBS prior to analysis. 
2.3.6.3 Immunofluorescence staining of apoptotic cells 
Mutu were induced to apoptosis as outlined in section 2.3.9.1. Following incubation 2x10
5
 
cells were washed in flow buffer and incubated with 100μl of supernatant taken from cells 
transfected with sRAGE, PSA or with polyclonal anti-LPS polyclonal antibodies (1:1000) 
or negative control normal pre-immune rabbit serum (10µg/ml) in flow buffer for 30 min 
on ice. Following incubation, cells were washed and bound sRAGE detected with (1μg/ml) 
polyclonal anti-RAGE antibodies or isotype-control pre-immune rabbit serum (10μg/ml) in 
flow buffer for 30 min on ice. Cell were washed prior to incubation with (1:50) anti-
Rabbit-PE in flow buffer for 30 min on ice, washed then fixed in 1% (w/v) formaldehyde 
in PBS prior to analysis 
2.3.7 LPS responsiveness of THP-1-derived macrophages 
THP-1 were seeded to wells in 24 well plates and stimulated to differentiate as outlined in 
section 2.3.5.  To allow for the growth of THP-1 and VD3 cells, these cells were reseeded 
post differentiation at 6x10
5
 cells per well.  All THP-1-derived macrophages were 
challenge with lipopolysaccharide (LPS) (from Escherichia coli O111:B4 purchased from 
Sigma Aldrich, Dorset UK) in the presence of 10% (v/v) human serum (from male AB 
plasma, purchased from Sigma Aldrich, dorset UK) and mAbs (as appropriate) for 4h. 
TNF-α release in phagocyte-culture supernatants was quantified using an anti-human TNF-
α capture ELISA (R&D systems, Minneapolis, USA) 
2.3.7.1 LPS binding to THP-1-derived macrophages 
THP-1 were induced to differentiate with vitamin D3 for 72 hours. Following 
differentiation, cells were washed with 5mM EDTA in PBS to remove any adherent cells 
from culture flask. 2x10
5
 cells were incubated with LPS-FITC in PBS containing 10% 
(v/v) normal human serum in flow buffer for 15 min on ice. LPS binding was inhibited by 
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preincubating cells with CD14-blocking mAb MEM18 (10µg/ml) (Juan et al, 1995) prior 
to LPS-FITC incubation. Cells were washed and fixed in 1% formaldehyde in PBS prior to 
flow cytometric analysis. 
2.3.8 LPS responsiveness of HeLa 
Following LT-1-mediated transfection (2.3.10.3), mock-transfected HeLa or HeLa 
expressing mCD14 were seeded in triplicate at a density of 3.5x10
5
/well in 96-well plates 
and incubated overnight to allow for attachment. Cells were stimulated with 200µl of 
either medium alone or LPS in sfDMEM containing 10% NHS at 1µg/ml, 10µg/ml or 
100µg/ml for 24 hours. Following incubation, cell supernatants were collected and frozen 
at -20°C until analysis. Cells were washed and cytosolic IL-8 was collected following 
incubation with 200μl of lysis buffer for 30 min at 37°C. Cytosolic supernatants were 
collected and frozen at -20°C until analysis. 
2.3.9 Apoptotic cell phagocyte interaction assay 
2.3.9.1 Generating apoptotic cells 
For the preparation of apoptotic cells, Mutu were induced to undergo apoptosis by 
exposure to 100mJ/cm
2
 UV radiation and incubated for 18-24h at 37°C in 5% CO2 
atmosphere. Apoptotic cells were resuspended in assay medium prior to the assay and cell 
death estimated by flow cytometry where cells were gated based on side scatter into viable 
and apoptotic populations. 18-24 hours following the induction of apoptosis, Mutu 
resembled secondary necrotic cells in terms of propidium iodide and annexin IV staining. 
2.3.9.2 Phagocyte interaction assay 
THP-1 were seeded to four well glass slides and stimulated to differentiate as outline in 
section 2.3.5. Following differentiation medium was removed and phagocytes co-cultured 
with apoptotic cells for 1h at 37°C in the presence or absence of sRAGE or mAbs (e.g. 
61D3, 63D3 or an isotype-control MOPC 21). Slides were washed three times in cold PBS, 
prior to fixation with methanol (30 min) and staining with Jenner-Giemsa. Interaction of 
apoptotic Mutu was assessed by light microscopy and values scored as a percentage of 
phagocytes interacting with apoptotic cells (minimum number of phagocytes counted 200) 
2.3.9.3 Amateur phagocyte interaction assay 
Amateur phagocytes were seeded at 2x10
4
 cells on four well glass slides and left to adhere 
overnight. Apoptotic cells were incubated with epithelial cells for 1h at 37°C in the 
presence or absence of 61D3 or 63D3 in apoptotic cell interaction assay medium.  Slides 
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were washed three times in cold PBS, prior to fixation with methanol (30 min) and staining 
with Jenner-Giemsa. Interaction of apoptotic Mutu was assessed by light microscopy and 
values scored as a percentage of phagocytes interacting with apoptotic cells (minimum 
number of phagocytes counted 200) 
2.3.9.4 Mapping apoptotic cell binding to mCD14 
HeLa were transiently transfected, using LT-1 as outlined in section 2.3.10.3 with plasmids 
encoding mCD14 point mutants. 24h post-transfection, cells were re-seeded at 1x10
4
per 
well to four well glass slides and left to adhere overnight. Prior to the apoptotic cell 
interaction assay slides were placed at 4
°
C for 30 min then washed in cold assay medium to 
reduce the rate of interaction. Apoptotic cells were prepared as outlined in 2.3.9.1 and 
resuspended in cold assay medium.  1x10
6
 apoptotic cells were added to each well at room 
temperature for 5 min.  Slides were then washed in cold PBS, prior to fixation in methanol 
(30 min) and staining with Jenner-Giemsa stained. Interaction of HeLa with apoptotic 
Mutu was assessed using light microscopy from a sample size of at least 200 cells and the 
percentage of HeLa cells interacting with apoptotic cells estimated. 
2.3.9.5 Jenner-Giemsa staining of cells 
Jenner and Giemsa stains (both purchased from Oxoid, Basingstoke, UK) were diluted 
with 1x Jenner-Giemsa buffer. The slides were incubated in a 1:3 dilution of Jenner stain 
for 4.5min.  Slides were washed in Jenner-Giemsa buffer and incubated in 1:10 dilution of 
Giemsa stain for 9.5min.  Slides were dried by aspiration and mounted with D.P.X. (BDH 
reagents, Lutterworth, Leicestershire, UK).  Interaction with apoptotic Mutu was assessed 
by light microscopy and values scored as a percentage of phagocytes interacting with 
apoptotic cells. 
2.3.10 Transient transfection of cells 
The transient transfection of mammalian cells was conducted several ways depending on 
the cell line used, transfection efficiency required, use of protein expressed and cost. The 
transient transfection of HEK293 was performed using either calcium phosphate or LT-1 
transfection reagent and generally used to produce soluble protein for harvest. The 
transient transfection of HeLa and COS-1 was performed using LT-1 transfection and used 
to produce cells expressing surface-bound CD14 mutants. With every transfection, a mock-
transfection (no DNA) was conducted as a negative control and a reporter assay (GFP) was 
conducted to demonstrate transfection efficiency then cells were analysed by flow 
cytometry. 
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2.3.10.1 CaPO4–mediated transfection 
250mM CaCl2 (Fisher, Loughborough, UK) containing 2 µg plasmid DNA was added 
(drop-wise manner) to an equal volume of 2xHBS (see section 2.3.2 for details) with 
continuous agitation by aeration.  The precipitate was incubated at room temperature then 
added to 3x10
5
 HEK293 suspended in 2ml of cDMEM.  Cells were plated and cultured for 
72h at 37°C, 5% CO2 in a humidified atmosphere. When producing soluble proteins 24h 
after transfection the medium was replaced with sfDMEM to avoid contamination with 
serum. 
2.3.10.2 DEAE-Dextran-mediated transfection of COS-1 
COS-1 were seeded in 6 well plates at density of 3x10
5
cells/ well and incubated for a short 
period to allow cells to adhere.  Following adhesion cells were washed with sfDMEM then 
transfection mix added (5µg DNA, 500µl/ml DEAE-Dextran (Sigma), 100μM chloroquine 
diphosphate and volume was made up with sfDMEM) and incubated until vesicles formed. 
Cells were then washed in 10% (v/v)DMSO in PBS for 2min and resuspended in cDMEM. 
2.3.10.3 LT-1-mediated transfection  
24h prior to transfection HeLa or COS-1 were plated in 6 well plates at a density of 3x10
5
 
per well. Following preliminary experiments it was found the ratio 5µl:2μg (HeLa) or 3μl: 
2μg (COS-1) of LT1 reagent to DNA produced optimum transfection efficiency for 6 well 
plate HeLa or COS-1 transfection.   LT-1 was mixed with 250µl of sfRPMI and 2µg of 
plasmid DNA was added, transfection mixture was then incubated (15min at room 
temperature) to allow complexes with DNA to form. Following incubation the transfection 
mixture was added (drop-wise) to the 6 well plates and the cells were cultured for 24-72h 
at 37°C, 5% CO2 in a humidified atmosphere. 
2.3.10.3.1 Transfecting HeLa with NF-κB reporter 
HeLa were seeded at 1.5x10
4
/well in a 96 well plate 24 h prior to transfection.  In separate 
eppendorfs, 100ng of NF-κB reporter plasmid DNA (Promega) was mixed with 100ng of 
mCD14 plasmid DNA, 9µl of sfRPMI then 0.3µl of LT-1 added and the mixture was 
incubated for 30min (room temperature). Following incubation the transfection mixtures 
were added (drop-wise) to each of the 96 wells and cultured for 24h at 37°C, 5% CO2 in a 
humidified atmosphere prior to stimulation.  
2.3.11 NF-κB reporter assay 
An NF-κB reporter containing firefly luciferase upstream of NF-κB response element was 
used to map the LPS responsiveness of membrane CD14 within HeLa transfectants. 
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Following transfection of HeLa with NF-κB reporter (section 2.3.10.3.1) the medium was 
removed and cells were incubated with 100µl of sfDMEM containing 10µg/ml of LPS 
(supplemented with 10% (v/v) NHS), apoptotic cells or medium alone (control wells). 
Plates were incubated for 5h at 37°C and luciferase activity was detected by addition of 
100µl of One-Glo (Promega) to each well and incubated at room temperature for 3min. 
The luminescent signal generated was measured at room temperature using a luminometer. 
2.4 Enzyme Linked Immuno-sorbent Assay (ELISA) 
2.4.1 ELISA solutions 
TNF-  ELISA block solution: 1% (w/v) BSA, 5% (w/v) sucrose and 0.05% (w/v) sodium 
azide in PBS. 
IL-8 block buffer: 1% (w/v) BSA in PBS 
IL-8 diluents: 0.05% (v/v) Tween 20, 0.1% (w/v) BSA in PBS 
ELISA buffer: 0.05% (v/v) Tween 20 in PBS. 
ELISA wash buffer: 0.9% (w/v) saline supplemented with 0.05% (v/v) Tween 20 
LPS solution: 10µg/ml (w/v) of LPS with 10% (v/v) NHS in PBS. 
 
2.4.2 Indirect ELISA  
2.4.2.1 Detection of soluble RAGE 
In order to detect sRAGE within supernatants following transfection, 100µl of undiluted 
culture supernatants was added, in triplicate, directly to ELISA plates and incubated at 4°C 
overnight.  Plates were washed with ELISA wash buffer and 100µl of polyclonal anti-
RAGE antibody (1µg/ml, excess concentration) or pre-immune rabbit serum (1µg/ml) 
incubated for 1h at 37°C.  Plates were washed and 100µl anti-rabbit-HRP (1:1000 in PBS 
(T)) incubated for 1h at 37°C.  Bound HRP was detected by addition of OPD, the reaction 
was stopped by 50µl of 1M hydrochloric acid and the absorbance read at 490nm. 
2.4.2.2 Detection of soluble RAGE binding to LPS 
In order to detect soluble RAGE binding to LPS, 100µl of (10μg/ml excess concentration) 
LPS was added in quadruplet, directly to the ELISA plate and incubated at 4°C overnight.  
Plates were washed with ELISA wash buffers and blocked with 300μl of 0.05% (v/v) 
Tween in PBS for 2h at 37°C. Following incubation plates were washed and incubated 
with 100µl of supernatant taken from HEK293 transfected with a plasmid coding for 
sRAGE or control (prostate-specific antigen, PSA) for 2h at 37°C. Bound RAGE was 
detected with 100μl polyclonal anti-RAGE antibody (1µg/ml) or pre-immune rabbit serum 
(1µg/ml) incubated for 1h at 37°C. Plates were washed and 100µl anti-rabbit-HRP (1:1000 
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in PBS (T)) incubated for 1h at 37°C.  Bound HRP was detected by addition of OPD, the 
reaction was stopped by 50µl of 1M hydrochloric acid and the absorbance read at 490nm. 
 
2.4.3 Capture ELISA 
2.4.3.1 TNF-α ELISA 
In order to detect human TNF-α produced by THP-1-derived macrophages following LPS 
stimulation, ELISA plates were coated with (2µg/ml) TNF-α capture antibody diluted in 
PBS, overnight at 4°C.  The ELISA plate was blocked for 1h at 37°C by the addition of 
100µl of TNF ELISA block. After washing three times with ELISA wash buffer, 100µl of 
cell supernatant or known concentrations of recombinant TNF-α were added to each well 
and incubated for 2h at 37°C. Plates were washed and incubated with 100µl of TNF-α 
detection antibody (200ng/ml in PBS (T)) for 2h at 37°C.  Plates were washed and 100µl 
streptavidin-HRP (1:2000 in PBS (T)) was incubated for 1h at 37°C.  Bound HRP was 
detected by the addition of 100µl of OPD and the reaction was stopped by the addition of 
50µl of 1M hydrochloric acid. The plates were read at absorbance 490nm.  
2.4.3.2 IL-8 ELISA 
In order to detect IL-8 produced by HeLa following LPS stimulation, ELISA plates were 
coated with (5µg/ml) IL-8 capture antibody diluted in PBS overnight at room temperature.  
Plates were blocked for 1h at room temperature by the addition of 300µl of IL-8 ELISA 
block. After washing four times with ELISA wash buffer, 100µl of cell supernatant or 
known concentrations of recombinant human IL-8 were added to each well and incubated 
for 2h at room temperature. Plates were washed and incubated with 100µl of IL-8 detection 
antibody (250ng/ml in diluents) for 2h at room temperature.  Plates were washed and 100µl 
avidin-HRP (1:2000 in PBS (T)) was incubated for 30min at room temperature.  Bound 
HRP was detected with the addition of 100µl of OPD and the reaction was stopped 
following the addition of 50µl of 1M hydrochloric acid. The plates were read at absorbance 
490nm.  
2.4.3.3 Soluble CD14-Fc ELISA 
In order to map 61D3/MEM18 binding to sCD14 point mutants ELISA plates were coated 
with (5µg/ml) sheep anti-human-Fc in PBS at 4°C overnight. 100µl of sCD14 mutants 
were added to wells in triplicate and plates incubated for 1h at 37°C.  Plates were washing 
and mAbs added in excess: (1:100) 61D3, MEM18 (8µg/ml), 63D3(1:100) or MOPC 21 
(10µg/ml) for 1h at 37°C. Any binding was detected with anti-mouse-HRP (1:2000 in 
PBS-T) for 1h at 37°C. Bound HRP was detected with the addition of 100µl of OPD and 
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the reaction was stopped following the addition of 50µl of 1M hydrochloric acid. The 
plates were read on a plate reader at absorbance 490nm.   
2.4.3.4 LPS-binding ELISA 
In order to map the binding of LPS to sCD14 point mutants, ELISA plates were coated 
with 100µl of 5µg/ml of sheep anti-human-Fc in PBS at 4°C overnight.  100µl of sCD14-
Fc mutant was added to wells in triplicate and plates incubated at 37°C for 1h.  Plates were 
washed with ELISA wash buffer and non-specific binding of LPS blocked with 300µl of 
goat serum overnight at 20°C while control wells were incubated with ELISA buffer. 
100µl of LPS solution (10μg/ml excess concentration) was added to each mutant and 
incubated at 37°C for 1h, again control wells were incubated with ELISA buffer. Soluble 
CD14 mutants were detected with excess amount of 63D3 ((1:100) positive control) or 
MOPC 21(10µg/ml) negative isotype-control) while LPS binding was detected with anti-
LPS antibody (1:2000 in PBS-T) for 1h at 37°C. 63D3 and MOPC 21 binding was detected 
with anti-mouse HRP (1:2000) while anti-LPS binding was detected with anti-rabbit HRP 
(1:1000). Bound HRP was detected with the addition of 100µl of OPD and the reaction 
stopped following the addition of 50µl of 1M hydrochloric acid. The plates were read on a 
plate reader at absorbance 490nm. 
 
2.4.4 Competition ELISA 
2.4.4.1 MEM18 and biotinylated-61D3 
In order to establish the independent binding of MEM18 and 61D3 to CD14 a competition 
ELISA conducted. Prior to competition ELISA, both MEM18 and biotinylated-61D3 were 
titrated to establish required concentrations (figure 6). Following titration ELISA plates 
were coated with 100µl of 5µg/ml of anti-human-FC in PBS at 4°C overnight.  Plates were 
washed and 100µl of soluble wtCD14 (1:10 in PBS-T) was added to wells in triplicate and 
incubated at 37°C for 1 h. All concentrations of MEM18 were made to double-
concentration in PBS-T and 50µl added to appropriate wells followed immediately by 50µl 
of competing mAb (61D3-biotin final concentration of 100ng/ml) and incubated for 1h at 
37°C.  Plates were washed and incubated with streptavidin-HRP (1:2000) for 1 h at 37°C.  
Bound HRP was detected with the addition of 100µl of OPD and the reaction stopped by 
the addition of 50µl of 1M hydrochloric acid. The plates were read on a plate reader at 
absorbance 490nm. 
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Figure 6: Titrating MEM18 and biotinylated-61D3 for competition ELISA 
Soluble wtCD14-Fc was immobilised from supernatant by capture with 5μg/ml of sheep 
anti-human Fc for 1h at 37°C. Following incubation, the indicated concentrations of 61D3 
(biotin) or MEM18 was added and plates incubated for 1h at 37°C. Plates were washed and 
incubated with streptavidin-HRP (1:2000 for detection of biotin) or anti-mouse-HRP for 1h 
at 37°C.  Bound HRP was detected with the addition of 100µl of OPD and the reaction 
stopped by the addition of 50µl of 1M hydrochloric acid. The plates were read on a plate 
reader at absorbance 490nm. Results are mean ± SD. 
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2.5 Molecular Biology 
2.5.1 Molecular Biology reagents 
Receptor for Advanced Glycation End-products (RAGE) DNA was a gift from Dr Susan 
Staddon (Aston University). pSecTag expression plasmids, One Kilobase DNA ladder, 
Zeocin, and pSecTag expression plasmids were purchased from Invitrogen (Renfrew, UK) 
2.5.2 Molecular Biology solutions 
TE buffer: 10mM Tris pH 8.0 containing 1mM EDTA. 
LB broth: 1% (w/v) Bacto Tryptone (Oxoid, Basingstoke, UK), 0.5% (w/v) Bacto yeast 
extract (Oxoid), 0.5% (w/v) sodium chloride in dH2O.   
LB agar: 1.5% (w/v) Bactoagar (Oxoid) in LB broth. 
GTE: 50mM glucose (Fisher), 25mM Tris pH 8.0, 10mM EDTA solution and autoclaved. 
Bacterial cell lysis buffer: 10% (v/v) sodium dodecylsulphate solution (SDS) (Fisher), 2% 
(w/v) sodium hydroxide in dH2O. 
2.5.3 Bacterial cell lines 
Novablue single competent cells (Novagen, Nottingham, UK): were purchased as ready 
use competent cells for transforming plasmid DNA  
E. coli DH5  cells: Competent DH5  cells were a gift from Dr David Nagal (Aston 
University) and used for transforming plasmid DNA. 
2.5.4 Preparation of DNA 
2.5.4.1 Primers design 
All primers were purchased from Functional Genomics (Birmingham, UK) 
 
RAGE forwards primer: 5’ CAG GTA CCG CTC AAA ACA TCA CAG 3' 
 
RAGE untagged reverse primer:  5’ CAC TCG AGC AGA GCC TGC AGT TG -3' 
 
RAGE tagged reverse primer: 5’ CAC TCG AGA GCC TGC AGT TG 3' 
2.5.4.2 General PCR and colony PCR 
All PCR reactions were performed in 50µl reaction volumes, containing 50ng of DNA or a 
bacterial colony, 50pmol of reverse and forward primers (25pmol/µl) and 25µl of AcciSure 
(Bioline, London, UK). All PCR reactions were carried out in a PCR machine employing a 
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standard PCR cycle of 30 cycles at the following temperatures: 94°C for 30 secs, 58°C or 
30 secs and 72°C for 1min. 
2.5.4.3 Gel electrophoresis 
1% (w/v) agarose gels were prepared using electrophoresis grade agarose (Fisher) and 1X 
TAE buffer with the addition of eth idium bromide at a final concentration of 0.5µg/ml to 
stain DNA for visualisation (DNA samples were mixed with 6X gel loading buffer and 
loaded into wells; 5µl of 1 kb DNA ladder was also loaded into gel). Gels were 
electrophoresed 100 Volts, 150 Watts 250 mA and viewed using a UVP transilluminator.  
2.5.5 Isolation of DNA from gel (freeze/squeeze or purification kit) 
DNA to be purified was separated on a 1% agarose gel and bands excised using a sharp 
clean scalpel. The gel slices were frozen in liquid nitrogen then were wrapped in Parafilm, 
gently squeezed to thaw and the liquid collected (freeze/squeeze). One tenth the extraction 
volume of 3M sodium acetate and twice the extraction volume of 100% ethanol was added. 
The precipitated DNA was pelleted at 14,400xg for 5min, dried by aspiration and 
resuspended in 50µl of TE buffer then stored at -20
°
C until required. DNA was also 
isolated from gels using a purification kits (Qiagen,Crawley,UK) in accordance with the 
manufacturer’s instructions. 
2.5.6 DNA Quantitation 
DNA concentration was estimated by comparison to quantitative DNA molecular ladder 
using agarose gels prepared as outlined above or with the use of a nanodrop machine.  
2.5.7 Restriction enzyme digestion  
DNA for digestion was incubated with the desired restriction enzymes (Promega, 
Southampton, UK) diluted with the appropriate buffers in 20µl reaction volumes prior to 
incubation at 37°C for at least 2h. Following digestion restriction enzymes were either heat 
inactive or DNA isolated from a gel (as outlined in section 2.5.5) or using phenol-
chloroform extraction. Purification of plasmid DNA by phenol-extraction was carried out 
following DNA precipitation by the addition of an equal volume of phenol chloroform: 
isoamyl alcohol which was then vortexed to form an emulsion before being centrifuged 
(14,400xg 5min). The upper aqueous phase was removed and the process repeated to 
prevent DNA loss. DNA was recovered by ethanol precipitation.  
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2.5.7.1 Antarctic Phosphatase 
Following digestion, DNA was treated with Antarctic phosphates (Biolabs, London, UK) 
to remove 5’phosphate groups and prevent self-ligation. One tenth the volume of Antarctic 
phosphatase reaction buffer was added for 1-5µg of digested DNA.  5 units of Antarctic 
phosphatase were added and incubated for 15min at 37°C then heat-inactivated for 15min 
at 65°C prior to down-stream manipulations. 
2.5.8 Ligation reactions 
Ligations were performed in 20µl reaction volumes in (1X) T4 ligation buffer (Promega), 
at a 3 molar ratio of insert DNA to plasmid DNA and T4 DNA ligase (Promega). Ligation 
reactions were incubated for 16h at 14°C. 
2.5.9 Sequencing reactions 
Sequencing reactions were carried out in conjunction with Birmingham University 
Functional Genomics Laboratory and performed in accordance with supplier’s instructions. 
 
2.5.10 Transformation of competent bacteria 
2.5.10.1 DH5  cells 
Competent DH5  cells were thawed on ice, mixed with pcDNA3 plasmids (10ng)  and 
incubated on ice for 20-30min prior to heat shock  (1min and 20 secs  at 37°C) then 
returned to ice for 5min. Sterile LB broth (900µl) was added and the cells cultured (50min 
at 37°C) to allow for expression of antibiotic resistance conferred from transformed 
plasmid.  Aliquots of transformed bacterial cells containing pcDNA3 plasmid were spread 
on LB agar plates containing 50µg/ml of ampicillin and incubated at 37°C overnight. 
2.5.10.2 Novoblue cells 
Novoblue single competent bacterial cells were used for the growth of pSec Tag 2 plasmid 
and therefore selected by zeocin resistance (50µg/ml). Novoblue cells were transformed in 
accordance with the manufacturer’s instructions. 
2.5.11 Small scale Plasmid Preparation (‘Mini prep’) 
1.5ml of overnight liquid culture was pelleted (14,400xg for 5min) and the bacterial cells 
resuspended in 200µl of GTE.  Bacterial cells were then lysed with the addition of 400µl 
bacterial cell lysis buffer and incubation on ice.  Genomic DNA was removed with the 
addition of 300µl of 3M potassium acetate (Fisher), incubation (5min on ice) to allow 
precipitation and removed by centrifugation (14,400xg for 5min) leaving the plasmid DNA 
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in solution.  Plasmid DNA was precipitated from solution with the addition of 600µl of 
ice-cold isopropanol then centrifuged (14,400xg for 5min), the remaining pellet was 
washed with 70% (v/v) ethanol, dried by aspiration and resuspended in 20μl TE buffer.  
2.5.12 Large scale plasmid preparation (‘Maxi prep’) 
Plasmid DNA was recovered from bacterial cells grown in 50ml selective liquid cultures 
grown overnight using the pure yield plasmid midi prep system (Promega) in accordance 
with the manufacturer’s instructions.  
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2.6 Preparation of RAGE 
2.6.1 Preparing the expression plasmid pSec Tag2 
pSec Tag 2 A, B and C are 5.2kb expression plasmids (Invitrogen, Paisley.UK)  and vary 
by the reading frame that the insert is subcloned into. The plasmids contains an Ig κ-chain 
leader sequence upstream of the MCS, allowing secretion and a myc epitope and six 
histidine residues that allow detection and purification of the product downstream MCS 
(figure 7). All three plasmids were used to ensure that the RAGE insert would be inserted 
in the correct reading frame allowing the transient expression of sRAGE in HEK 293 cells, 
whilst also providing an out of frame control plasmid. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Map of expression plasmid pSec Tag 2 
The plasmid contains an Ig κ-chain leader sequence upstream of the multiple cloning sites 
(MCS) allowing secretion of cloned product.  Downstream of the MCS are myc-epitope 
and histidine tag for purification and detection. The plasmid confers both zeocin and 
ampicillin resistance for antibiotic selection.  
 
All expression plasmids were digested with the restriction enzymes Kpn I and Xho I and 
the enzymes removed using phenol-chloroform extraction to prevent further digestion. The 
plasmid extracted was run on a 1% agarose gel to ensure digestion (figure 8).  
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Figure 8: Agarose gel analysis of purified, digested pSec Tag2 plasmids  
Expression plasmids pSec Tag 2 A, B and C were digested with Kpn I and Xho I. 
Following digestion, the plasmid DNA was extracted and samples were run on a 1% 
agarose gel. The molecular ladder used was a 1kb ladder 
 
The expression plasmids prior to digestion are often supercoiled, which form thick, slightly 
smeared bands on agarose gel. However the results in figure 8 show clear single bands for 
the pSec Tag 2 expression plasmids that corresponds to the marker at 5090bp. The bands 
are linear and slightly less than 5.2kb therefore the agarose gel analysis suggests that all the 
plasmid has been digested and successfully isolated from restriction enzymes.  
2.6.2 Amplification of RAGE  
The cDNA encoding for human wildtype mRAGE (figure 9A) was kindly received from 
Dr Susan Staddon (Aston University). As shown in figure 9A human wildtype RAGE 
contains a signal sequence, an extracellular-ligand binding domain, a transmembrane 
domain and a short cytosolic tail. Forwards and reverse primers (section 2.5.4.1) were 
designed, directed against the extracellular ligand-binding domain of RAGE cDNA not 
including the leader sequence or the transmembrane domain thus allowing secretion of the 
protein following sub-cloning into expression plasmid. The predicted size of this fragment 
of RAGE cDNA was 930bp. 
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Molecular markers 
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Figure 9: Human wildtype mRAGE cDNA and generation of sRAGE 
A. Membrane-associated RAGE DNA contains a signal sequence (black), an extracellular 
ligand-binding domain (grey), one transmembrane domain (blue) and a short cytosolic tail 
(yellow). Primers (arrows) were designed, directed against the extracellular region of 
RAGE generating a PCR product estimated at 930bps in length. B. The PCR product was 
run on a 1% agarose gel to verify the size of the product in comparison with the expected 
size of RAGE 930bp. (The molecular ladder used was a 1kb ladder) 
 
The predicted length of RAGE PCR product is 930bp and analysis of the PCR-product on 
the agarose gel in figure 9B shows a single band just below the marker at 1018bp 
suggesting the PCR reaction amplified the region of interest. The PCR product was 
extracted from the gel in figure 9B and digested with Kpn I and Xho I generating sticky 
ends that permit directional ligation within the digested pSec Tag2 expression plasmids 
digested and isolated.  
2.6.3 Sub-cloning RAGE into pSec Tag 2 expression plasmids 
Ligation of the purified RAGE PCR product with digested pSec Tag 2 expressions 
plasmids occurred at a molar ratio of 3:1.  Following ligation the product was transformed 
into competent Novablue cells and selected on agar plates containing the antibiotic zeocin.  
Individual resultant colonies were grown over night and small scale preparations of DNA 
        RAGE PCR product 
1 90 1020 
1268 
2036 
1636 
 
RAGE 1018 
 
  506 
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purified.  To confirm the identity of colonies containing the RAGE insert, plasmid DNA 
was isolated and digested with Kpn I and Xho I (figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Digestion of ligation products for detection of RAGE insert 
Competent cells were transformed with pSec Tag 2A, B and C containing the RAGE 
insert. Bacterial cells were cultured, plasmid DNA purified and digested with Xho I and 
Kpn I to confirm the presence of the RAGE insert.  (8 colonies for each plasmid (pSec Tag 
2 A, B, C were prepared). The predicted RAGE insert size is 930bp. 
 
Agarose gel analysis of the midi preps in figure 10 was used to identify bacterial cultures 
containing plasmid with RAGE insert.  Samples from cultures A2, B3 and C4 were used to 
inoculate 50mL Zeocin-selective cultures for large scale preparations of plasmids and 
sequencing. Having identified colonies of interest and prepared plasmids containing the 
putative insert in each of the reading frames (pSec Tag 2 A, B and C) it was necessary to 
assess the ability of the clones following transfection to produce sRAGE.  Sequence 
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analysis predicted clone B would produce sRAGE protein whilst A and C were cloned out 
of frame. 
2.6.3.1 Indirect ELISA for detection of sRAGE 
To establish which plasmid contained sRAGE within the correct reading frame, each of the 
plasmids isolated from cultures A2, B3 and C4 were transiently transfected into HEK293 
and cultured for 72 hours. Following incubation cell culture supernatants were collected 
and the presence of sRAGE confirmed by indirect ELISA (figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Detection of sRAGE by indirect ELISA 
HEK293 were transiently transfected using calcium phosphate with 2µg of pSec Tag 2 A, 
B and C containing the RAGE insert or no DNA.  Cells were cultured in sfDMEM for 
three days and the supernatants collected for analysis. ELISA plate were coated with 100μl 
of supernatant and incubated at 4°C overnight. Following washing the plate was incubated 
with rabbit polyclonal anti-RAGE antibody or negative control pre-immune rabbit serum 
(control). Any binding was detected using anti-rabbit HRP conjugated antibody and the 
ELISA plate was developed with OPD and read at 490nm.  The data shown are the mean ± 
SD of triplicate well and is representative of two independent experiments. Statistical 
analysis was conducted using ANOVA followed by Bonferroni post-test. (***P<0.001). 
 
Soluble RAGE was detected in supernatant taken from HEK293 transfected with pSec Tag 
2B (figure 11). Further sequence analysis of the sRAGE insert confirmed that the N-
terminus of the RAGE insert was in frame to allow expression but the reverse primer 
resulted in an out of frame C-terminus. Therefore the RAGE protein expressed did not 
contain c-myc epitope or polyhistidine tags making purification and detection difficult. The 
reverse primer was redesigned and sRAGE subcloned into pSec Tag2B, expression was 
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verified following sequence analysis and ELISA following transfection. The control 
plasmid pSec Tag2/PSA which expressed the prostate-specific antigen upstream of c-myc 
epitope and polyhistidine tag was also transformed ready for transfection. 
2.6.4 Cloning of tagged RAGE 
To produce sRAGE with the polyhistidine tags for purification and detection, another 
reverse primer was designed and used to clone sRAGE into expression plasmid PSec Tag 
2B, in frame with the C-terminal producing the myc-epitopes and tags.  The PCR product 
was run on agarose cell to confirm that the PCR reaction had amplified the RAGE DNA 
and that it was the expected size (figure 12).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Producing tagged RAGE: Agarose gel analysis of PCR product 
The forwards primer and a new reverse primer were used to amplify the extracellular 
domain of RAGE. The PCR product was run on a 1% agarose gel to ensure the PCR 
reaction was successful and had produced a single band of the expected size. 
 
The gel in figure 12 shows a single band for RAGE PCR product just below the molecular 
marker at 1018bp which corresponds with the expected size of 930bp of RAGE therefore 
suggesting that PCR reaction was successful and that RAGE has been digested. The RAGE 
PCR product was isolated from the gel, purified and then sequentially digested with Xho I 
and Kpn I. 
2.6.4.1 Preparation of plasmid (only pSec Tag 2B) 
The expression plasmid pSec Tag 2B was digested with restriction enzymes Xho I and Kpn 
I then subsequently treated with Antarctic phosphatases (2.5.7.1) to remove the phosphate 
from the 5’ end nucleotide of the plasmid therefore preventing self-ligation.   
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2.6.4.2 Cloning tagged RAGE 
Following ligation (2.5.8) the plasmids were transformed in DH5  cells (2.5.10.1) and 
selected for by ampicillin resistance as this plasmids also contains an ampicillin resistance 
gene. Colony PCR (2.5.4.1) was conducted using T7 promoter and BGH reverse primers 
and the results revealed which bacterial colonies contain the plasmid with the RAGE insert 
(figure 13).  
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Gel analysis of colony PCR 
DH5 were transformed with pSec Tag 2B containing the RAGE insert then cultured with 
ampicillin selection.  Several colonies were screened using colony PCR for the presence of 
the RAGE insert using T7 promoter and BGH reverse primers. (C is the empty plasmid, 
and the bands circled represent self-ligation of plasmid). 
 
The PCR products from bacterial colonies that contain plasmid and insert will generate 
products over 1031bp in size, those bands that are around 300bp in size are empty plasmid 
products. Therefore the results suggested that cultures 1-4, 7, 8 and 10-13 contained the 
inserts.  One of the colonies containing the RAGE insert was used to prepare mini preps 
(2.5.11) and the DNA isolated was sequenced (2.5.9) then a large scale preparation of the 
plasmid produced (2.5.12). 
2.6.5 Preparing control plasmid, pSec Tag2/PSA 
The control plasmid pSec Tag2/PSA expressed and secreted the prostate-specific antigen 
(PSA) upstream of c-myc epitope and the polyhistidine tag. The control plasmid was first 
transformed into DH5α cells (2.5.10.1) and selected on ampicillin plates. Single colonies 
were used to inoculate 50ml cultures for large scale plasmid preparation (2.5.12) ready for 
transfection into mammalian cells. 
2.7 Preparing membrane CD14 mutants 
2.7.1 Human CD14-Ig plasmids received 
A number of plasmids encoding for CD14-Fc constructs that contained single amino acid 
replacement within the NH2-terminus of CD14 were generated and kindly received from 
Culture number: 
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Richard Darveau (University of Washington, USA) (Table 1).The plasmids received were 
constructed by subcloning the extracellular region of wtCD14 upstream of cDNA encoding 
H, CH2 and CH3 domains of human IgG1, into the expression plasmid CDM7B. The 
mutations were then introduced at specific site by oligonucleotide-directed mutagenesis 
(Cunningham et al., 2000) 
 
 
Human fusion proteins received Location of mutation (LPS binding regions 
Wt CD14 wildtype 
E11A 
E11D 
E11R 
1
st
 LPS binding region 
R14A 
R14K 
Outside 1
st
 LPS binding region 
E37D 
E37Q 
3
rd
 LPS binding region 
D59A 
D59N 
4
th
 LPS binding region 
Table 1: CD14-Fc constructs received from R. Darveau (Washington Univ) 
pcDNA 3.1 (+) expression plasmid cut with the restriction enzymes Hind III and Xba I to 
allowing insertion of hCD14 and Ig. Restriction enzymes Hind III and Xho I were used to 
replace 5’ fragment of wild-type CD14 with mutated fragments producing mutated soluble 
CD14-Fc proteins. 
2.7.2 Making CD14 mutants membrane-bound 
Membrane wtCD14 has previously been subcloned into pcDNA3 and supplied courtesy of 
Christopher Gregory (figure 14). Absence of the Fc tag will allow the addition of a 
glycosylphosphatidylinositol tail onto the C-terminus of the protein during post-translation 
(Bufler et al., 1995) and therefore will anchor CD14 to the membrane of the mammalian 
cells transfected. 
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   Extracellular-binding Fc region 
signal Extracellular-binding Membrane anchor 
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A. Membrane Wt human CD14 plasmid 
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B. Subcloning membrane-bound CD14 point mutants 
 
 
 
 
Donar plasmid 
(sCD14-Fc)  
 
 
 
 
 
 
 
 
 
 
Acceptor plasmid 
(mCD14) 
 
 
Figure 14: Subcloning wildtype and mutant mCD14  
A. Devitt et al.(2004) previously used human CD14 ligated into pcDNA3 which following 
transfection results in the addition of glycosylphosphatidylinositol tail therefore anchoring 
CD14 to the membrane. B. To generate membrane-bound CD14 point mutations, 
restriction enzymes Hind III and Nhe I were consecutively used to excise the 5’ mutated 
region from sCD14-Fc plasmids and were ligated into a similarly cut mCD14 vector.   
 
Hind III 
 
CD14 
pcDNA 3 
 
+ CD14 
Point-mutation 
Nhe I 
   5’ fragment containing mutation (411bp) 
(includes wtCD14) 
Ligated into acceptor plasmid 
Hind III Nhe I 
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2.7.2.1 Preparing the acceptor plasmid 
1µg of the mCD14 plasmid DNA (figure 14a) was digested with 5 units of Hind III and 4 
units of Nhe I in Buffer M (Roche) overnight at 37°C (figure 15). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Digesting the mCD14 (acceptor plasmid) 
1µg of the mCD14 plasmid was digested with Hind III and Nhe I overnight at 37°C then 
run on a 1% agarose gel to ensure digestion. Uncut and digested mCD14 pcDNA3 was run 
alongside each other for comparison. The molecular ladder used was 1kb ladder. 
 
The mCD14 plasmid is approximately 6785bp and following digestion with Hind III and 
Nhe I a small segment of CD14 DNA containing the mutation, estimated at 411bps in 
length was excised. Following digestion the acceptor plasmid was treated with Antarctic 
phosphatase to prevent self-ligation and reforming of the original WT-expressing plasmid.  
Antarctic phosphatase removes the phosphate on the 5’ digested mCD14 plasmid; to 
ensure only plasmids containing mutated CD14 inserts produce colonies. The digested 
mCD14 plasmid was then gel purified to remove contaminating restriction enzymes to 
allow future ligation.   
2.7.2.2 Purification of 5’fragments for subcloning  
5µg of wildtype and mutant sCD14 plasmids were digested with Hind III and Nhe I as 
outlined above, and incubated at 37°C overnight (figure 16).   
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Figure 16: producing 5’ fragments from donor sCD14 plasmids 
1µg of donor wt CD14 and point-mutants was digested with Hind III and Nhe I overnight 
at 37°C. Following incubation DNA was ethanol precipitated and run on a 1% agarose gel 
to ensure digestion. The molecular ladder used was 1kb ladder. 
 
Once digestion had been determined, DNA was ethanol precipitated, resuspended in a 
smaller volume of water to allow all DNA to be loaded and run on a 1% agarose gel.  The 
lower bands corresponding to the mutated 5’ fragment was excised from the gel and 
purified using Quiagen gel purification kit to remove contaminating restriction enzymes. 
2.7.2.3 Subcloning membrane-bound CD14 point mutants 
Having excised the 5’ fragment from donor plasmids (containing point-mutations) the next 
stage was ligation (section 2.5.8). Following ligation plasmids was transformed into DH5α 
cells (section 2.5.10.1) and colonies selected by ampicillin resistance. Colony PCR (section 
2.5.5.2) was then used for sequencing the plasmids to verify the 5’ fragment within 
mCD14 plasmids and also for large scale preparations of plasmids (section 2.5.12). 
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Results  
Results 1: A THP-1-derived macrophage model system  
3.1 Introduction 
Macrophages are multifunctional cells that play a vital role in both the regulation of 
immune responses and tissue homeostasis (Hou et al., 2000 & Mosser and Edwards, 2008). 
Interaction between macrophages and pathogens has been extensively studied, with many 
advances in the understanding of macrophage-host defences.  However the macrophage is 
also considered the professional scavenger of apoptotic cells (Gregory and Devitt, 2004) 
and therefore has a vital role in homeostasis. The engulfment of apoptotic cells is crucial 
for many biological processes including, resolution of immune responses, tissue modelling 
or simply, removal of cells that are diseased or damaged (reviewed by Mosser and 
Edwards, 2008 & Kozmar et al., 2010).  In order to carry out these roles, macrophages are 
armed with a series of PRR; well characterised for their participation in host defence, but 
also identified as key receptors in the clearance of apoptotic cells (Reviewed in Savill et 
al., 2002 & Grimsley, 2003). Furthermore apoptotic cell uptake by macrophages has been 
shown to actively inhibit inflammation and produce anti-inflammatory mediators (Voll et 
al., 1997, Fadok et al., 1998b & Savill et al., 2002). This has led to the suggestion that 
apoptotic cell clearance by macrophages can shape the immune response and induce 
resolution (reviewed by Bratton and Henson, 2011). 
 
The prototypic PRR, CD14 is well characterised for its ability to recognise PAMPs, most 
notably, LPS (Wright et al., 1990 & Ziegler-Heitbrock and Ulevitch, 1993). Ligation of 
CD14 with LPS mediates inflammation, characterised by the release of proinflammatory 
cytokines including TNF-  (Cuschieri et al., 2006).  CD14 has also been implicated in the 
removal of apoptotic cells by macrophages, first demonstrated by transiently expressing 
CD14 in COS cells, which caused an increase in their phagocytic ability to uptake 
apoptotic cells (Devitt et al., 1998). This suggested that CD14 is involved in the assembly 
of two distinct ligand-dependent macrophage responses. The aim of this chapter is to 
characterise the role of CD14 in macrophage responses to LPS and apoptotic cells, in 
order to establish an understanding of the molecular mechanisms employed by CD14 
to generate two distinct ligand-dependent macrophages responses. 
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3.2 Phenotypic characterisation of THP-1-derived macrophages 
THP-1 are a human monocytic leukaemia cell line that, following differentiation, produce 
macrophage-like cells, which are commonly used to model macrophage function 
(Schwende et al., 1996, Park et al., 2007b & Daigneault et al., 2010). Here three different 
cell differentiation strategies were used and in each case the resultant macrophage-like 
cells were characterised. Cells were characterised phenotypically for changes in 
morphology, adherence and CD14 expression but also functionally, with respect to LPS-
responsiveness and ability to bind apoptotic cells in a CD14-dependent manner. Monocyte 
differentiation was induced by treatment of the cells with 1,25-dihydroxyvitamin D3 
(VD3), phorbol-13-acetate (PMA) or both (double-stimulation, DS) for 72 hours.    
3.2.1 Morphology  
Differentiation of monocytes to macrophages involves a number of morphological 
changes. Such changes include an increase in cell size and adhesion, a reduction in nuclear: 
cytoplasmic ratio and an increase in granularity, caused by an increased number of 
membrane-bound organelles (Hou et al., 2000 & Daigneault et al., 2010). Here 
microscopic analysis was used to detect changes in morphology and profound differences 
between the various differentiation treatments were noted (figure 17). PMA and double-
stimulation induced extensive morphological changes, including an increase in cell size 
and shape. Differentiation induced cells to spread, become irregular in shape and produce 
extensions from the cells known as pseudopodia. Microscopic analysis also illustrated an 
increase in cytoplasm which was consistent with a reduction in nuclear to cytoplasmic 
ratio. No consistent difference in cell morphology was observed between vitamin D3 and 
untreated THP-1 (figure 17a).  
 
With respect to adhesion, cells were considered adherent if they were resistant to washing 
by pipetting with growth medium. THP-1 and vitamin D3 macrophages were semi-
adherent and removed by washing. Differentiation induced with PMA or double-
stimulation caused an increase in cell adhesion and the removal of these cells required 
EDTA treatment and extensive washing. 
 
Flow cytometric analysis was used to determine differences in volume and granularity 
between the THP-1-derived macrophages (figure 17b). Again PMA and double-stimulated 
macrophages consistently demonstrated an increase in electronic volume which correlated  
D3 PMA 
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with an increase in side scatter, suggesting increased volume and granularity. Also 
differentiation of macrophages is reported to cause a slight increase in autofluorescence 
(van Haarst et al., 1994). The flow cytometric analyses suggested that differentiation of 
THP-1 caused an increase in the autofluorescence of unstained cells, with PMA and 
double-stimulated macrophages being substantial more fluorescent (figure 17c).  Taken 
together, these data suggest that PMA and double-stimulated macrophages were larger in 
volume with increased granularity, characteristic traits of macrophages (Natale and 
McCullough, 1998 & Daigneault et al., 2010). Increased granularity is caused by a greater 
number of organelles such as lysosomes and mitochondria, and secretory vesicles, 
allowing macrophages to be functionally active effector cells (Natale and McCullough, 
1998 & Daigneault et al., 2010). 
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Electronic volume 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Microscopic and flow cytometric analysis of THP-1-derived macrophages 
THP-1 were seeded to plastic tissue culture plates in the absence (THP-1) or presence of 100nM vitamin D3 (VD3), 250nM PMA (PMA) or both 
(vitamin D3 and PMA) for 72h. Post-stimulation microscopic analysis or flow cytometric analysis was conducted. A. (63x) DIC images of 
representative macrophages were taken (Scale bar =16µm). Post-stimulation cells were stripped up using 5mM EDTA and analysed by flow 
cytometry. B. Electronic volume against side scatter plots were generated from 10,000 events and C. histograms of auto-fluorescence FL1 channel 
(wavelength 530nm) generated using VenturiOne flow cytometric analysis software. (The x-axis is a log scale and y axis event number).
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3.2.2 Cell surface CD14 expression 
The function of CD14 in mediating response to LPS or apoptotic cells was central to this 
programme of work.  Therefore the assessment of surface expression of CD14 in each 
macrophage model was vital. Cell surface expression of CD14 was assessed using indirect 
immunofluorescence staining of viable cells with established CD14 mAb 63D3 followed 
by flow cytometric analysis (Devitt et al., 1998) (figure 18).   
 
 
 
Figure 18: Cell surface expression of CD14 on THP-1-derived macrophages 
THP-1 was differentiated with vitamin D3 (VD3), PMA or both (VD3/PMA) for 72 hours.  
Surface expression of CD14 on untreated THP-1 and resultant macrophages was detected 
with flow cytometric staining using indirect immunofluorescence with the monoclonal 
antibody 63D3 (red) or MOPC 21, isotype-control (filled grey). The percentage of cells 
gated and the mean fluorescence intensity is shown for both the total (black line) and 
positive cell regions (red line). The positive region was established by setting a 2-3% false-
positive gate on MOPC 21 plot for each macrophage model using venturiOne analysis 
software. The results are representative of four independent experiments. 
 
Constitutive expression of CD14 was not detected on the surface of THP-1 (THP-1 MFI 
2.0 compared to MOPC 21 MFI=2.0), this is in agreement with previous studies 
(Schwende et al., 1996 & Hmama et al., 1999). Differentiation of THP-1 with vitamin D3 
caused the population to increase in fluorescence, suggesting that CD14 expression on all 
cells had increased. The MFI was also considerably higher than the control, suggesting that 
both the number and level of CD14 expression on these cells had increased. These findings 
are in agreement with previous studies by Sadeghi et al. (2006) and Hmama et al.(1999) 
which also found that vitamin D3 treatment of THP-1 increased cell surface expression of 
CD14. CD14 expression on PMA macrophages was undetectable (PMA MFI=4.0 
compared to MOPC 21 MFI= 3.8), this agrees with previous data published by Daigneault 
et al.(2010). Following double-stimulation at least 28% of the population of cells increased 
in fluorescence and the MFI of the cells also increased (VD3/PMA MFI= 52 compared to 
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MOPC 21 MFI=11.4). This suggests differentiation increases the number of cells 
expressing CD14 as well as increasing the level of expression on a per-cell basis. 
3.3 Functional characterisation of THP-1-derived macrophages 
Given the variation in CD14 expression data (figure 18), the ability of each THP-1-derived 
macrophage model to interact with LPS and apoptotic cells in a CD14-dependent manner 
was compared. Any variation in the interaction of these two ligands within a particular 
macrophage model may provide an understanding of the mechanistic difference underlying 
the role of CD14 in contrasting macrophage responses. To this end, preliminary work was 
necessary to establish a cell-based system that would permit this comparison.  
3.3.1 LPS responsiveness 
3.3.1.1 Establishing an LPS response  
Preliminary experiments were conducted to examine macrophage responses to LPS by 
measuring TNF-  production in cell culture supernatants. Initial experiments involved 
seeding THP-1 at 1x10
5
 cells per well and inducing differentiation. Following 
differentiation for 72 hours, macrophages were stimulated with 10ng/ml of LPS, incubated 
for 24 hours and TNF-  levels analysed by capture ELISA (figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Establishing LPS responses for THP-1-derived macrophages 
THP-1 were seeded in 24 well plates at a density of 1x10
5
 cells per well in cRPMI and 
induced to differentiate with vitamin D3 (VD3) PMA or both (VD3/PMA).  Following 
differentiation for 72 hours, cells were stimulated with LPS at a final concentration of 
5ng/well for 24 hours.  Phagocyte response was assessed by measuring the production of 
TNF-  in the supernatants using capture ELISA.  Mean ± SD for triplicate wells, each 
assayed by ELISA in triplicate are shown and results are representative of two independent 
experiments. Statistical analysis was conducted using ANOVA followed by Bonferroni post 
test (**P<0.01). 
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Following LPS stimulation, the results in figure 19 demonstrate that PMA and double-
stimulated macrophages are LPS responsive, with PMA being the most sensitive to LPS 
treatment. Comparison of figure 19 with CD14 expression (figure 18) suggests expression 
of CD14 was not required for PMA macrophage to respond to LPS. CD14 is expressed on 
vitamin D3 macrophages however figure 19 suggests that these cells are not LPS 
responsive under these conditions. Therefore it was considered that the results (figure 19); 
particularly the vitamin D3 results, were possibly a reflection that the experiment was 
suboptimal. Therefore it was suggested that the experimental design be modified with 
regards to cell density and LPS response of each macrophage model titrated. 
3.3.1.2 Optimising Cell density 
Monolayer formation was assessed by seeding cells at a range of densities then following 
cell density over the differentiation period of 72 hours.  The density of each macrophage 
model was assessed microscopically at 24h, 48h and 72h and scored qualitatively.
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Figure 20: Microscopic analysis of THP-1-derived macrophages, for the formation of a monolayer 
THP-1 were seeded at 1x10
5
, 2x10
5
, 4x10
5
 and 6x10
5
 cells per well in 24 well plates and stimulated to differentiate with vitamin D3, PMA or both 
(VD3/PMA). Cells were microscopically analysed for the formation of a monolayer and scored as follows: + very low density, ++ low density, 
+++ medium density, ++++ high density, +++++ very high density. Images of densities identified in red are also shown as examples of scores. 
(20x) DIC Images (scale bar = 20µm). Those scored as +++ (medium density) were considered to form a suitable monolayer.       
 
 
Seeding densities 
(cells/well) 
24 hours post-stimulation  48 hours post-stimulation 72 hours post-stimulation 
THP-1 VD3 PMA VD3/PMA THP-1 VD3 PMA VD3/PMA THP-1 VD3 PMA VD3/PMA 
1 x 10
5
 + + + + ++ ++ +/++ +/++ +++ +++ ++ ++ 
2 x 10
5
 ++ ++ + + +++ +++ ++ ++ +++++ +++ ++ ++ 
4 x 10
5
 +++ +++ ++ ++ ++++ +++ ++ ++ ++++ +++ ++ ++ 
6 x 10
5
 +++ +++ ++ ++ +++++ ++++ +++ +++ +++++ +++++ +++ +++ 
      +               ++           +++            ++++             +++++ 
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The results in figure 20 generally suggest that the agents used to simulate differentiation 
generated cultures with profoundly different cell densities following 72 hours of 
differentiation. The profound differences in cell densities could be a result of varying cell 
divisions, differential loss or possibly fusion of cells. Untreated THP-1 and vitamin D3 
macrophages increased in cell number over 72 hours causing overcrowding especially 
within the centre of the wells. Furthermore PMA and double-stimulated macrophages 
appeared not to change in cell density following 24 hours of differentiation. However PMA 
and double-stimulated macrophages produce a monolayer when initially seeded at 6x10
5
 
cells per well. A flow cytometric-based assay of this seeding density was conducted to 
assess changes in cell number between macrophages models, post differentiation (figure 
21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Flow-based analysis of cell number following differentiation 
THP-1 was seeded at 6x10
5
 cells per well and stimulated to differentiate with vitamin D3 
(VD3), PMA (PMA) or both (VD3/PMA). Prior to seeding, cells were counted using flow 
cytometry. Following incubation for 72 hours the cells were treated with trypsin: EDTA 
until detached and cell number was measured.  Mean ± SD for triplicate wells, each 
assayed in duplicate are shown and results are representative of two independent 
experiments. Statistical analysis conducted was T-test ( ***P<0.001). 
 
The flow-based analyses (figure 21) confirmed a significant increase in cell number within 
untreated THP-1 and vitamin D3 wells. Taken together this data suggests that untreated 
THP-1 and vitamin D3 macrophages demonstrate growth. While the data suggests that 
PMA and double-stimulated macrophages have decreased in cell number possible as a 
result of increased cell adhesion, cell fusion or even death. However cells were treated with 
5mM EDTA and washed several time to remove all adherent cells and microscopic 
analysis did not suggest cell death. Therefore the data in figures 20 and 21 may suggest 
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that differentiation induced with PMA or double-stimulation caused a reduction in cell 
proliferation which is a characteristic feature of macrophage differentiation. 
3.3.1.3 Seeding THP-1-derived macrophages 
The results in figures 20 and 21 suggest that differentiation induced with vitamin D3 does 
not affect cell proliferation while treatment with PMA may have inhibited proliferation or 
potentially induce cell fusion. However in order to ensure cell density following 72 hours 
of differentiation is similar, a seeding protocol was established.  THP-1 were seeded at 
6x10
5
 cells per well in 24 well plates and induced to differentiate for 72 hours. Following 
differentiation, THP-1 and vitamin D3 macrophages were reseeded at original density 
6x10
5
 to ensure all macrophages models had similar cell densities. 
 
3.3.2 Titrating LPS responsiveness of macrophages 
Having established a suitable seeding protocol, macrophage response to varying 
concentrations of LPS in the presence of LBP was assessed (figure 22).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: LPS-induced TNF-α response of THP-1-derived macrophages 
Following differentiation THP-1-derived macrophages were challenged for 4h with 
increasing concentrations of LPS in 500µl of cRPMI containing 10% (v/v) NHS. TNF-  
released was quantified using a capture ELISA. Mean ± SD for triplicate wells, each 
assayed in duplicate are shown. These results are representative of three independent 
experiments. 
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The results in figure 22 illustrate that PMA and double-stimulated macrophages are very 
LPS responsive and agrees with previous data by Park et al.(2007) and Daigneault et 
al.(2010).  The results also suggest that THP-1 and vitamin D3 macrophages, when 
stimulated with LPS produced low levels of TNF-  compared to PMA macrophage and 
agrees with findings by Daigneault et al.(2010).  
3.3.3 Cell surface expression of TLR4 
TLR4 is required for LPS signalling as shown by Hoshino et al., 1999) that demonstrated 
mice lacking TLR4 are hyporesponsive to LPS. Given the LPS response data (figure 22) 
cell surface expression of TLR4 on THP-1-derived macrophages was assessed using direct 
immunofluorescence staining followed by flow cytometric analysis (figure 23). 
 
 
 
Figure 23: Cell surface expression of TLR4 on THP-1-derived macrophages  
THP-1 was differentiated with vitamin D3 (VD3), PMA or both (VD3/PMA) for 72 h.  
Surface expression of TLR4 on resultant macrophages was detected with flow cytometric 
staining using direct immunofluorescence with the monoclonal antibody HTA125 (orange) 
or isotype-control (blue).  The mean fluorescence intensity of 100% of the population of 
the cells region is also shown. The results are representative of four independent 
experiments. 
 
Flow cytometric results in figure 23 suggest that only double-stimulated macrophages 
expressed detectable levels of cell surface TLR4. While cell surface expression of TLR4 
was undetectable on THP-1 and VD3 macrophages, the flow cytometric data suggests that 
a small population of PMA macrophage express TLR4. These findings are supported by 
Sadeghi et al.(2006) that found treating monocytes with vitamin D3 causes an increase in 
CD14 expression and a decrease in TLR4 expression, therefore causing cells to become 
hyporesponsive to LPS stimulation.  
3.3.4 CD14-dependent macrophage response to LPS 
Having demonstrated the LPS-sensitivity of each THP-1-derived macrophage, the 
involvement of CD14 in cellular response to LPS was assessed using the mouse anti-
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human CD14 mAb MEM18, a known blocker of LPS-induced inflammation (Juan et al., 
1995a) (figure 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: The role of CD14 in macrophage response to LPS 
THP-1, vitamin D3, PMA and double-stimulated macrophages were incubated with 10% 
NHS and stimulated with LPS (THP-1 and VD3 25ng/ml, PMA 5ng/ml and VD3/PMA 
1ng/ml) in the presence or absence of the established CD14-blocking mAb MEM18 
(10µg/ml) in a final volume of 500µl/well. Following incubation at 37°C for 4 h plates 
were frozen at -20°C until TNF-  production was measured by capture ELISA. Each 
treatment was repeated in duplicate on 24 well plates and each well analysed in triplicate 
on 96 well ELISA plate. The results shown are from six separate experiments and 
normalised to LPS alone for each experiment. Statistical analysis was conducted using 
AVOVA with Bonferroni post test. (*P<0.05, ***P<0.001). 
 
As shown in figure 24, MEM18 inhibits CD14-dependent LPS responses produced by both 
PMA and double-stimulated macrophages which suggests that CD14 is required for the 
LPS responsiveness of these cells.  Notably flow cytometric data suggests that CD14 
expression (figure 18) on PMA cell is low but cells are LPS responsive. Therefore 
collectively, these data support the theory that LPS responses produced by PMA 
macrophages are due to a potent, but low level of CD14 expression, undetectable by flow 
cytometry. CD14 expression on THP-1 was undetectable and these cells were not as LPS 
responsive as other macrophage-like cells. Furthermore vitamin D3 macrophages 
expressed relatively high levels of CD14 but were not as LPS responsive as expected. 
3.3.4.1 LPS-FITC binding to vitamin D3 macrophages 
Given the involvement of CD14 in LPS response by macrophages (figure 22) the ability of 
LPS to bind to THP-1-derived macrophages was assessed. Previous data found that 
vitamin D3 macrophages expressed the highest surface level of CD14 (figure 18) therefore 
* *** 
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cells were incubated with increasing concentrations of LPS-FITC and binding detected 
using flow cytometry (figure 25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: LPS-FITC binding to CD14 expressed on vitamin D3 macrophages 
THP-1 was stimulated to differentiate with vitamin D3 for 72 hours.  A. Cell surface 
expression of CD14 was assessed using indirect immunofluorescence staining with 
MEM18 (red) or MOPC 21 iostype negative control (grey). B. Vitamin D3 macrophages 
were incubated with indicated concentrations of LPS-FITC in 10% NHS in a final volume 
of 500µl for 15 min on ice. Following incubation cells were washed and LPS-bound 
detected using flow cytometry. C. The mean fluorescence intensity (MFI) of cells 
incubated with increasing concentrations of LPS-FITC. D. The % of cells that have 
increased from 1.9% false positive gate set against cells alone (grey). Representative of 
four independent experiments. 
 
The data in figure 25 suggests that LPS binds to vitamin D3 macrophages in a dose-
dependent manner. The flow cytometry results shows that as the percentage of cells 
binding LPS reach 100% the mean fluorescence intensity then increased, suggesting more 
LPS bound on a per/cell basis.  A maximal MFI was not reached as concentration over 
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1mg/ml of LPS-FITC were toxic to the cells and resulted in lysis as denoted by a change in 
the electronic volume and side scatter of the population. 
3.3.4.2 MEM18 inhibition of LPS-FITC binding 
Having established that LPS-FITC binds to vitamin D3 macrophages, CD14-dependent 
binding of LPS was assessed using CD14-blocking mAb MEM18 (Juan et al., 1995). Here 
vitamin D3 macrophages were incubated with LPS-FITC in the presence or absence of 
MEM18 and detected using flow cytometry (figure 26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: CD14-dependent binding of LPS to vitamin D3 macrophages 
THP-1 were stimulated to differentiate with vitamin D3 and incubated for 72 h.  A 
Following differentiation, cell surface expression of CD14 was analysed using indirect 
immunofluorescence staining with MEM18 (orange) or isotype-control MOPC 21 (blue). 
B&C. vitamin D3 macrophages were incubated in absence or presence of 10µg/ml of 
MEM18 (orange) or MOPC 21 (blue) for 15 min at 4°C. Prior to incubation with flow 
buffer containing 10%NHS and 1mg/ml B. or 125µg/ml C. of LPS-FITC (green) for 15 
min on ice. Following incubation LPS-FITC binding was detected using flow cytometry. 
Vitamin D3 macrophages without LPS or mAb staining are shown in grey.  The results 
shown are representative of two independent experiments. 
 
The data here suggests that MEM18 does not inhibit 1mg/ml or 125µg/ml of LPS-FITC 
binding despite clear CD14 expression detected by flow cytometry (figure 26a). As 
previously shown (figure 25) both concentrations of LPS-FITC bind to CD14 expressed by 
vitamin D3 macrophages, with a significant increase in the percentage of cells binding 
1mg/ml LPS-FITC. Interpretation of the data may suggest that the concentration of 
MEM18 used to block LPS binding was not saturating. However the concentration of 
MEM18 was titrated against vitamin D3 macrophages using flow cytometry to ensure a 
saturating concentration of antibody was used for all experiments. Therefore results here 
may suggest that MEM18 does not block LPS binding but blocks LPS response by 
inhibiting interaction with signalling molecule.  
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3.3.5 Apoptotic cell clearance 
Having characterised the role of CD14 in LPS responses of macrophages, the THP-1-
derived macrophages were used to assess the role of CD14 in apoptotic cell interaction. 
3.3.5.1 THP-1-derived macrophages interact with apoptotic cells 
Firstly the ability of the THP-1-derived macrophages to interact with apoptotic cells was 
established. This was conducted by co-culturing THP-1-derived macrophages with UV-
induced apoptotic Mutu (figure 27). The ability of untreated THP-1 to interact with 
apoptotic cells was not considered due to poor adhesion to glass slides and removal during 
the washing stages of the protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Interaction of apoptotic cells with THP-1-derived macrophages  
Following differentiation THP-1-derived macrophages were co-cultured with apoptotic 
Mutu for 1 h at 37°C. Macrophages were washed in cold PBS, fixed in methanol and 
Jenna-Giemsa stained before being scored by light microscopy. The results shown are the 
mean ± SEM of seven independent experiments. 
 
All THP-1-derived macrophage interact with apoptotic cells (figure 27). Furthermore there 
is no significant difference in the percentage of apoptotic cells interacting with each THP-
1-derived macrophage. This may suggest that all THP-1-derived macrophage utilise the 
same receptors to interact with apoptotic cells. However as previously shown (figure 18) 
each THP-1-derived macrophage expresses different levels of surface CD14. Therefore the 
next logical step was to assess the role of CD14 in the clearance of apoptotic cells by THP-
1-derived macrophages.  
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 3.3.5.2 CD14-dependent clearance of apoptotic cells 
To investigate the involvement of CD14 in the clearance of apoptotic cells by THP-1-
derived macrophages, an interaction assay was conducted including the inhibitory 
monoclonal antibody 61D3 (Devitt et al., 1998) (figure 28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28:CD14-dependent apoptotic cell clearance 
Following differentiation, macrophages were co-cultured with apoptotic Mutu for 1 h at 
37°C alone or with CD14-blocking antibody 61D3 or isotype-control. Macrophages 
interacting with apoptotic cells were scored by light microscopy. The results shown are the 
mean ± SEM of seven separate experiments and normalised to apoptotic cells alone. 
Statistical analysis used was unpaired T-test * P<0.05, ** P<0.01, P< 0.001. 
 
All THP-1-derived macrophages use CD14 to clear apoptotic cells, but the level of CD14-
dependent clearance varies between the macrophages.  The results in figure 28 show a 50% 
reduction in the clearance of apoptotic cells by vitamin D3 and PMA macrophages and a 
25% reduction by double-stimulated macrophages. The results also suggest that all 
macrophages express other receptors also involved in the clearance of apoptotic cells. 
3.3.5.3 Macrophage response to LPS in the presence of apoptotic cells 
The clearance of apoptotic cells by macrophages has been reported to be a tolerogenic 
process that actively inhibits the production of proinflammatory cytokines following LPS 
stimulation (Voll et al., 1997 & Fadok et al., 1998b). This dominant anti-inflammatory 
response produced by macrophages is considered to be caused, at least in part by the 
secretion of anti-inflammatory cytokines released as a result of the interaction with 
apoptotic cells (Fadok et al., 1998b). Here the ability of THP-1-derived macrophages to 
inhibit LPS induced inflammation following incubation with apoptotic cells was 
considered (figure 29). 
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Figure 29: Apoptotic cell clearance inhibits LPS-induced TNF-α response 
LPS-induced TNF- released by THP-1-derived macrophages was assessed following 18h 
co-cultured with apoptotic Mutu. TNF-  released was quantified by ELISA. The results 
shown are the mean ± SEM or triplicate wells, each assayed in triplicate by ELISA and 
normalised to LPS alone for four independent experiments. Statistical analysis used was 
ANOVA followed by Bonferroni post test (** P<0.01, ***P<0.001). 
 
THP-1-derived macrophages were incubated with apoptotic cells for 18 hours prior to LPS 
stimulation. Following incubation macrophages were stimulated with LPS for 4 h and 
TNF-α produced was measured by assaying cell supernatants using a TNF-α capture 
ELISA. The results (figure 29) suggest that the clearance of apoptotic cells by THP-1-
derived macrophages did not stimulate the release of TNF-α. Furthermore incubation of 
apoptotic cells with PMA or double-stimulated macrophages inhibited TNF-α production 
to basal levels (No LPS), compared to THP-1 and vitamin D3 macrophages. However the 
basal expression of TNF-α produced was higher in PMA and double-stimulated possible as 
a consequence of PMA induced differentiation. 
3.4 RAGE: another PRR involved in apoptotic cell clearance? 
Another innate immune molecule that may be involved in the clearance of apoptotic cells 
is the receptor for advanced glycation end-products (RAGE).  Given that RAGE, like 
CD14 can bind LPS (Yamamoto et al., 2011) and previous findings here that suggest 
apoptotic cells expose LPS-like patterns on the surface (figure 50), the role of RAGE in the 
binding and subsequent clearance of apoptotic cells was assessed. 
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3.4.1 Cell surface expression of RAGE on THP-1-derived macrophages 
To assesse a role for RAGE in apoptotic cell clearance, the expression of RAGE on THP-
1-derived macrophage was assessed using indirect immunofluorescence and subsequent 
flow cytometry (figure 30). 
 
 
Figure 30: Cell surface expression of RAGE on THP-1-derived macrophages 
THP-1 was differentiated with vitamin D3 (VD3), PMA or both (VD3/PMA) for 72 hours.  
Cell surface expression of RAGE on THP-1-derived macrophages was detected with flow 
cytometric staining using indirect immunofluorescence with the polyclonal anti-RAGE 
antibody (red) or pre-immune rabbit serum as negative control (grey).  The percentage of 
positive cells gated and the mean fluorescence intensity are shown. The results are 
representative of three independent experiments. 
 
Flow cytometric analysis in figure 30 show all THP-1-derived macrophages expressed 
surface RAGE to a small degree though differentiation induced with PMA or both agents 
(vitamin D3/PMA) caused a sub-population of cells to express high levels of RAGE. 
3.4.2 Subcloning and expression of sRAGE  
To identify a possible role for RAGE in the clearance of apoptotic cells, a mAb approach 
was considered where anti-RAGE mAbs would be screened for their ability to block 
apoptotic cell clearance. Such studies used for the identification of a number of apoptotic 
cell clearance receptors, including CD14, are potentially limited by the available mAbs and 
the presence of epitopes in crucial functional sites on the protein. However many studies 
into the function of membrane RAGE (mRAGE) use soluble RAGE (sRAGE) as a 
competitive, neutralising ligand along with polyclonal antibodies to block mRAGE (Foell 
et al., 2006, Hofmann et al., 1999, Schmidt et al., 2001, Toure et al., 2008, Lutterloh et al., 
2007). Therefore in order to assess the role of RAGE in the clearance of apoptotic cells, 
sRAGE was produced as a decoy for mRAGE (section 2.6). Following transfection and 
subsequent culturing, the expression of sRAGE into culture supernatant was confirmed by 
indirect ELISA (figure 11). 
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3.4.3 Binding of sRAGE to LPS 
LPS is known to bind CD14 (Wright et al., 1990 & Ziegler-Heitbrock and Ulevitch, 1993), 
however binding is facilitated by the serum protein LBP (Tobias et al., 1986). A study by 
Wurfel et al.(1997) found that LBP-deficient mice retained their ability to respond to LPS, 
in vivo, suggesting an LBP-independent mechanism of cellular response to LPS existed. 
Furthermore, Youn et al.(2008) found that HMGB1 competed with LBP for binding to 
CD14 and also facilitated the transfer of LPS to CD14. RAGE is also reported to bind LPS 
therefore to establish if RAGE will bind LPS-like structure presented on the surface of the 
cells as previously found (figure 50), the ability of sRAGE to bind LPS was first assessed, 
using an ELISA based assay (figure 31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: sRAGE binds to LPS 
LPS was immobilised to an ELISA plate overnight and non-specific binding blocked with 
0.005% (w/v) Tween (PBS) for 2h at 37°C. Following incubation, 100μl of supernatant 
taken from HEK293 transfected with sRAGE or control (non-RAGE expressing pSec 
Tag2A plasmid) was added to wells.  The plate was washed and bound sRAGE was first 
detected with polyclonal anti-RAGE antibody or control (pre-immune) rabbit serum then 
subsequently bound-antibody was detected with anti-rabbit HRP. OPD substrate was added 
to plate and optical density was read at 490nm. The results shown are the mean ± SD of 
quadruplet wells from two independent experiments. Statistical analysis was conducted 
using AVOVA followed by Bonferroni post-test. (*** P<0.001). 
 
Having immobilised LPS to an ELISA plate and established a suitable blocking agent 
(0.005% (w/v) Tween) to reduce non-specific binding, the ability of sRAGE to bind to LPS 
was assessed. The results in figure 31 suggest that supernatant taken from HEK293 
transfected with pSec Tag 2B containing the sRAGE insert, bound LPS to a higher degree 
than supernatant taken from cells transfected with pSec Tag 2A, that contains the sRAGE 
insert out of frame. Given the limitations of the experiment, the results may suggest that 
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sRAGE binds LPS, in agreement with findings by Yamamoto et al. (2011). As supernatant 
from transfected HEK293 was used as a source of RAGE, it is possible that some of the 
RAGE was pre-bound to HMGB1, released from transfected cells.  
3.4.4 Binding of sRAGE to apoptotic cells 
Previous data in figure 50, has suggested that that apoptotic cells display LPS-like patterns 
on the cell surface and are most likely epitopes recognised by CD14. Given previous data 
(figure 31) that suggests sRAGE binds LPS, the ability of sRAGE to bind apoptotic cells is 
assessed (figure 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Flow cytometric analysis of apoptotic cells stained with sRAGE 
Mutu were induced to undergo apoptosis following UV treatment and incubated overnight 
prior to assay. Mutu were classified as apoptotic following flow cytometric analysis of 
electronic volume and side scatter.  Apoptotic Mutu were incubated with supernatant from 
HEK293 transfected with sRAGE or control (non-RAGE expressing pSec Tag 2A 
plasmid) for 30 min on ice. Following incubation, bound RAGE was detected using 
polyclonal anti-RAGE antibody (blue) or (negative control) pre-immune rabbit serum 
(grey) bound antibody was subsequently detected with anti-rabbit PE and cells were 
analysed by flow cytometry. The percentage of cells and the mean fluorescence intensity of 
the cells within the positive gated region are shown. The results are representative of two 
independent experiments. 
 
The ability of sRAGE to bind apoptotic cells was examined by immunofluorescence 
staining of apoptotic Mutu with sRAGE or control (non-RAGE expressing pSec Tag 2A 
plasmid). The flow cytometric histograms, shown in figure 32 appear identical and suggest 
that the secondary antibody (anti-rabbit PE) bound non-specifically to the cells. However 
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regardless of the limitations of the assay the results suggest that sRAGE did not bind to 
apoptotic cells. 
3.4.5 Role of RAGE in the clearance of apoptotic cells 
Previously all THP-1-derived macrophages were shown to interact with apoptotic cells 
(figure 27) and express varying levels of mRAGE (figure 30). In previous studies sRAGE 
has been used as competitive, inhibitor of mRAGE (Foell et al., 2006, Hofmann et al., 
1999) therefore to assess the ability of sRAGE to interact with apoptotic cells, THP-1-
derived macrophages were co-cultured with apoptotic cells in the presence or absence of 
sRAGE (figure 33).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: The role of sRAGE in the clearance of apoptotic cells 
THP-1-derived macrophages were co-cultured with apoptotic Mutu for 1 h at 37°C in the 
presence of sRAGE or control (PSA). Macrophages were washed in cold PBS, fixed in 
methanol and Jenna-Giemsa stained before being scored by light microscopy. The results 
shown are the mean ± SEM of three independent experiments.  Statistical analysis was 
conducted using ANOVA followed by Bonferroni post-test  
 
As an initial assessment of the role of RAGE in the clearance of apoptotic cells supernatant 
taken from HEK 293 expressing PSA or sRAGE was incubated with apoptotic cells prior 
to co-culturing with THP-1-derived macrophages. The results shown in figure 33, support 
previous findings that all THP-1-derived macrophages interact with apoptotic cells though 
in this particular example PMA and double-stimulated macrophages were most efficient at 
interacting with apoptotic cells relative to vitamin D3 macrophages. Flow cytometric 
staining in figure 30 illustrates that THP-1-derived macrophages express different levels of 
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mRAGE. Analyses of the results in figure 33 suggest that incubation with sRAGE or PSA 
increased the ability of vitamin D3 macrophages to interact with apoptotic cells. Also 
sRAGE reduced the level of apoptotic cell interaction with double stimulated 
macrophages. However taken together the data suggests that incubation with sRAGE had 
no significant effect on the ability of THP-1-derived macrophages to interact with 
apoptotic cells. This may suggest that sRAGE is not involved in the clearance of apoptotic 
cells or that sRAGE may also participate in clearance of apoptotic cells. Therefore whilst 
the use of sRAGE may block mRAGE function, if sRAGE is also involved in apoptotic 
cell clearance the result would be a null effect. 
3.4.6 sRAGE contains mutations 
 RAGE is a 45kDa cell surface transmembrane receptor that belongs to the 
immunoglobulin superfamily (Park et al., 2010). It consists of an extracellular domain, a 
transmembrane domain and a C-terminus cytoplasmic tail required for signalling (Dattilo 
et al., 2007,Matsumoto et al., 2008 & Park et al., 2010). The extracellular domain consists 
of three immunoglobulin-like domains of which the first and second domain (figure 34) 
function as one component responsible for ligand binding properties of RAGE (Dattilo et 
al., 2007& Park et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: The crystal structure of the 
ligand-binding domains of RAGE 
Ribbon diagram based on the X-ray 
crystallography of human RAGE. RAGE 
consists of an extracellular region, a 
transmembrane region and a C-terminus 
cytoplasmic tail. The extracellular region 
is composed of three immunoglobulin-like 
domains, with domains 1 and 2 required 
for ligand-binding as shown. Helices are 
shown in purple, β-strands are in cyan and 
loops in grey. Adapted from Park et al., 
2010. 
Domain 1 
Domain 2 
Residue 204 
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Sequence analysis of sRAGE produced revealed two single point mutations within the 
parental DNA sequence that codes for the extracellular ligand-binding domain. The first 
single point mutation occurs at nucleotide position 635 and is caused by a cytosine to 
thymine substitution, as a result the amino acid proline at position 204 is replaced with a 
leucine. The cyclic structure of the side chain on proline disrupts the secondary structure of 
proteins and therefore proline is often required to initiate the rolling required to form α-
helixes. Loss or replacement of proline is likely to change the three-dimensional 
conformation of the local surrounding region. As shown in figure 34 (yellow residue 
highlighted) the mutation is within the second domain on a loop between β-stands.  
Furthermore the second single point mutation occurs at nucleotide position 915 and 
adenine is substituted for a guanine, however this mutation is silent. Both mutations were 
present in the parental DNA received and there is no record of these point mutations within 
NCBI library consequently the effects on ligand binding of RAGE are unknown. 
3.5 Discussion 
The rapid removal of apoptotic cells by professional phagocytes involves an array of 
macrophage receptors, apoptotic cell associated-molecules and soluble bridging molecules 
(Savill et al., 2002). Of particular interest is CD14, a PRR expressed on monocytes and 
macrophages and well characterised for its ability to recognise the PAMP, LPS and 
promote inflammation (Wright et al., 1990, Ziegler-Heitbrock and Ulevitch, 1993 & Park 
et al., 2007b).  However Devitt et al. (1998) transiently expressed CD14 in non-myeloid 
cells and found that CD14 was also involved in the clearance of apoptotic cells, a process 
known to be immunosuppressive and anti-inflammatory (Voll et al., 1997& Fadok et al., 
1998b). This led to the suggestion that CD14 was involved in the assembly of two distinct 
ligand-dependent macrophage responses. In order to understand the binding patterns 
underlying the molecular mechanisms employed by CD14 in innate immune responses, 
several THP-1-derived macrophages were used to characterise the responses of CD14 to 
LPS or apoptotic cells.  
3.5.1 Characterisation of THP-1-derieved macrophages 
THP-1 are a human monocytic leukaemia cell line, which following differentiation  
produced macrophage-like cells that are commonly used to model macrophage functions 
(Schwende et al., 1996, Park et al., 2007b & Daigneault et al., 2010). Here monocyte 
differentiation was induced by treatment of the cells with 1,25-dihydroxyvitamin D3 
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(vitamin D3), phorbol-13-acetate (PMA) or both (vitamin D3/PMA) for 72 hours. 
Resulting macrophages were characterised phenotypically and functionally with respect to 
morphology, CD14 expression, LPS responsiveness and ability to interact with apoptotic 
cells.  PMA and double-stimulation induced profound changes in morphology, cells 
increased in size, granularity, began spreading and induced lamellipodia formation, 
characteristic traits of macrophages.  However no morphological differences between 
vitamin D3 and untreated THP-1 were observed, furthermore an increase in cell adhesion 
was noted with all treatments. 
 
CD14 is not expressed by early progenitor stem cells but expressed by mature blood 
monocytes and macrophages suggesting that monocyte differentiation causes an 
upregulation in CD14 expression (Zhang et al., 1994b, Ziegler-Heitbrock and Ulevitch, 
1993, Hmama et al., 1999). CD14 is also up-regulated following LPS stimulation without 
the need for protein synthesis (Marchant et al., 1992). Studies have found that CD14 
expression is up-regulated at an mRNA level on THP-1 following differentiation with the 
steroid hormone, vitamin D3 (Schwende et al., 1996). Treatment results in a complex with 
nuclear vitamin D3 receptor that binds to specific response elements that promoter the 
expression of monocytic genes and up-regulates monocytic markers including CD11b and 
CD14 (Hmama et al., 1999). THP-1 differentiation can also be induced with PMA 
treatment (Schwende et al., 1996), phorbol esters are analogues of diacylglycerol and 
therefore activates protein kinase C and influences various cellular process including 
maturation, differentiation and proliferation (Monick et al., 1998 & Lin et al., 2007). Here 
differentiation induced with vitamin D3 or double-stimulation caused an increase in cell 
surface expression of CD14, while expression was undetected on PMA macrophages. 
These profound changes in morphology along with flow cytometric analysis of CD14 
expression are supported by Schwende et al.(1996) and Daigneault et al.(2010). However 
Park et al.(2007) report that PMA macrophages do not express surface CD14, but RT-PCR 
found that PMA upregulated CD14 expression at an mRNA level. Furthermore Bazil and 
Strominger (1991) found that differentiation of human monocytes with LPS or PMA 
induced shedding of CD14 and therefore may be responsible for undetectable cell surface 
levels of CD14 on PMA macrophages. PMA treatment also had a profound effect on cell 
density following incubation for 72 hours. THP-1 and vitamin D3 macrophages increased 
in cell number over the incubation period while the number of PMA and double-stimulated 
macrophages decreased. A decrease in cell number was not caused by an increase in 
adherence of macrophages to flasks, as cells were treated with EDTA until detached. 
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Previously studies have reported that PMA treatment induced cell fusion resulting in multi-
nucleated, giant cells. Mystkowska and Sawicki (1987) found that embryonic cells treated 
with PMA produced binuclear cells, possibly by inhibition of cytokinesis or causing 
structural changes in the phospholipid bilayer permitting fusion.  The fusion of monocyte-
derived macrophages was also described by Hassan et al.(1989) that observed cell fusion 
in blood-derived macrophages following PMA treatment for 5 to 7 days. 
3.5.2 Role of CD14 in LPS responses of THP-1-derived macrophages 
Having characterised the expression of CD14 on each THP-1-derived macrophage the 
ability of these cells to respond to the PAMPs LPS, was assessed. LPS response data 
(figure 22) showed that vitamin D3 macrophages, with high surface expression of CD14, 
were not as LPS responsive as PMA or double-simulated macrophages that expressed low 
levels of CD14. However TLR4 expression data (figure 23) revealed that although CD14 
expression on vitamin D3 macrophages is high, the signalling partner TLR4; required for 
propagation of LPS response (Hoshino et al., 1999), was not detected. These finding were 
supported by Sadeghi et al.(2006) that used RT-PCR and found human monocytes, 
following vitamin D3 treatment increased CD14 expression but diminished TLR4 and 
TLR2 expression at mRNA level. Sadeghi et al.(2006) suggests that both CD14 up-
regulation and TLR4 down-regulation are induced following vitamin D3 receptor complex 
assembly, suggesting that vitamin D3 treatment has immunosuppressive effects. These 
immunosuppressive effects were also reported by Rosenblatt et al.(2010) that found 
vitamin D3 treatment of dendritic cells impaired maturation and reduced the expression of 
co-stimulatory molecules subsequently reducing T cell-mediated alloreactive responses. 
Therefore the hyporesponsiveness of vitamin D3 macrophages to LPS is most likely due to 
down-regulation of TLR4 caused by vitamin D3 treatment. These data support previous 
findings that TLR4 is required for CD14 to propagate an inflammatory response (Hoshino 
et al., 1999). 
 
Double-stimulated macrophages expressed TLR4 and relatively low levels of CD14 and 
were very LPS responsive (compared to other THP-1-derived macrophages), 
demonstrating the potency of CD14 to generating an LPS response.  PMA macrophages 
present an anomaly, as CD14 and TLR4 expression was undetectable by flow cytometry 
but macrophages were more LPS responsive than vitamin D3 macrophages. This led to the 
suggestion that CD14 and TLR4 may be expressed at levels undetectable by flow 
cytometry and therefore the LPS response produced could be the potent effects of CD14 
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and TLR4 expressed at very low levels. Further analysis with CD14-blocking mAb 
MEM18 revealed that the LPS response produced by PMA macrophages was CD14-
dependent. This supports the suggestion that PMA macrophages express undetectable 
levels of surface CD14. Further analysis of the mRNA levels of CD14 and TLR4 would be 
required to detect true changes in receptor expression. Park et al.(2007) found that 
treatment of THP-1 cells with 5ng/ml of PMA was sufficient in induce an increase in 
expression of CD14 and cells became responsive to LPS at concentrations ranging from 
10-100ng/ml.  Park et al.(2007) also found that differentiation induced with concentrations 
of PMA higher than 5ng/ml caused a reduction in CD14 mRNA expression although cells 
were still LPS responsive. However a reduction in mRNA expression may not reduce cell 
membrane expression but in combination with previous findings that PMA causes 
shedding of membrane CD14 (Bazil and Strominger, 1991) would suggest that CD14 
expression is undetectable on PMA-induced macrophages. However epithelial and 
endothelial cells do not express CD14 but are reported to use sCD14 to produce an LPS 
response (Frey et al., 1992, Pugin et al., 1993). This could suggest that following PMA-
induced shedding macrophages use sCD14 to facilitate an LPS response though a rational 
for shedding to then use sCD14 to promote an LPS response would be questionable. Haziot 
et al.(1996) found that CD14-deficient macrophages could use sCD14 to produce an LPS 
response, when stimulated with concentrations over 100ng/ml. Although PMA 
macrophages here were sensitive to LPS at concentrations as low as 5ng/ml suggesting that 
sCD14 may not be used by these macrophages to generate an LPS response.  
 
Another interpretation of these findings is that PMA macrophages induce inflammation in 
a CD14-independent manner. Lynn et al.(1993) suggested that CD14-independent LPS 
signaling pathways exist in monocytes and macrophages with receptors including 
scavenger receptor, β2-integrins and L-selectins reported to bind LPS (Fenton and 
Golenbock, 1998 &  Peppelenbosch et al., 1999). Though β2 integrins and L-selectins are 
considered to have a low-affinity for LPS with high concentrations required for activation 
(Peppelenbosch et al., 1999). Alternatively LPS binding is also reported to induce CD14-
independent phagocytosis and pinocytosis (Peppelenbosch et al., 1999, Latz, 2002, 2003 & 
Pei et al., 2007). Pinocytosis of macrophage cell membranes is a constrictive process 
which is enhanced by phobol esters, including PMA (Peppelenbosch et al., 1999). 
Therefore cellular-pinocytosis may resulting in LPS loaded vesicles within monocytes and 
macrophages which are rapidly trafficked to the golgi and could activate intracellular 
TLR4 (Peppelenbosch et al., 1999, Latz, 2002, 2003 & Pei et al., 2007).  
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Due to the hyporesponsive nature of vitamin D3 macrophages, the ability of LPS to bind 
these cells was assessed. Vitamin D3 induces a large increase in the surface expression of 
CD14 compared to PMA or double-stimulation of THP-1. The flow cytometric results 
shown in figure 25, suggests that LPS-FITC bound to vitamin D3 macrophages in a dose-
dependent manner. Therefore the role of CD14 in LPS binding was assessed using CD14-
blocking mAb MEM18 (Juan et al., 1995). Blockade of CD14 on vitamin D3 macrophages 
had no effect on LPS-FITC binding (figure 26) which may suggest that LPS binding to 
cells is CD14-independent. Alternatively this data may suggest that the concentration of 
MEM18 used to inhibit LPS binding was not saturating. However prior to this assay, 
MEM18 binding was titrated using vitamin D3 macrophages and a saturating concentration 
of MEM18 established. Furthermore as illustrated in figure 25, incubation with 
concentrations of LPS-FITC below 62.5µg/ml were not detected by flow cytometry but 
data in figure 22 suggests that concentrations above 25ng/ml induced a small but 
measurable TNF-α response.  This suggests that the binding of lower concentrations of 
LPS-FITC is undetectable by flow cytometry, possibly due to inefficient FITC labelling of 
LPS. Previous attempts to saturate CD14-dependent binding of fluorescein-labelled LPS is 
described by Troelstra et al.(1997) as poor due to inefficient conjugation of FITC. 
Therefore incubation with LPS at concentrations of 125µg/ml may induce LPS to integrate 
into cellular membranes due to the amphiphilic nature of the molecule and induce cell 
lysis. This is supported by the inability of high concentrations of LPS to induce receptor 
saturation due to cell lysis, as assessed by changes in electronic volume and side scatter. 
An alternative method of examining LPS binding to CD14 expressed by THP-1-derived 
macrophages may be to use radioactively-labelled LPS.  
3.5.3 Role of CD14 in apoptotic cell clearance by THP-1-derived 
macrophages 
Having characterised the role of CD14 in the LPS responses of THP-1-derived 
macrophages the ability of these cells to interact with apoptotic cells was assessed. All 
THP-1-derived macrophages interacted with apoptotic cells in a similar manner (figure 
27). The role of CD14 in the clearance of apoptotic cells by THP-1-derived macrophages 
was assessed with CD14-blocking mAb 61D3 (Devitt et al., 1998). The data (figure 28) 
illustrates that while all macrophages use CD14 to interact with apoptotic cells, the level of 
CD14-dependent interaction varied between macrophages. Incubation of apoptotic cells 
with vitamin D3 or PMA macrophages, in the presence of 61D3 resulted in 50% reduction 
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in interaction. Furthermore CD14 expression data (figure 18) shows that vitamin D3 
induced a large increase in surface expression of CD14 compared to PMA and double-
stimulated macrophages. Therefore the result may suggest that CD14 expressed on PMA 
macrophages is more efficient at clearing apoptotic cells compared to vitamin D3 and 
double-stimulated macrophages. This may suggests that PMA treatment enhances 
phagocytosis of apoptotic cells compared to vitamin D3 macrophages with CD14 recycled 
to the cell surface quicker. This theory is supported by Schwende et al.(1996) and 
Daigneault et al.(2010) that reported differentiation of THP-1, with PMA for 72 hours 
enhanced the phagocytic activity of cells compared to vitamin D3 macrophages. Phaire-
Washington et al.(1980) also reported that PMA enhanced pinocytosis along with the turn 
over and recirculation of membrane constituents. Double-stimulated macrophages, due to 
treatment with both agents may have a membrane turnover rate similar to vitamin D3 
macrophages and therefore a low expression of CD14 on the surface will translate into less 
CD14-dependedent apoptotic cell interaction and uptake. However due to the expression of 
other molecules, double-stimulated macrophages are relatively efficient at interacting with 
apoptotic cells compared to PMA and vitamin D3 macrophages. 
3.5.4 Immunosuppressive properties of apoptotic cells  
Voll et al.(1997) found that monocytes stimulated with LPS in the presence of apoptotic 
cells secreted anti-inflammatory and immunosuppressive cytokines and reduced pro-
inflammatory cytokine secretion. Fadok et al.(1998) proposed that it was the release of 
TGF-β following apoptotic cell uptake that acted in an autocrine or paracrine fashion to 
suppress LPS-induced inflammation. While CD14 is known and previously found to 
interact with apoptotic cells, the involvement of CD14 in the anti-inflammatory effects 
promoted by the uptake of apoptotic cells by macrophages is unknown. Therefore THP-1-
derived macrophages were stimulated with LPS, following incubation with apoptotic cells 
and the release of the pro-inflammatory cytokine, TNF-α measured. The results (figure 29) 
show that the interaction of apoptotic cells with THP-1-derived macrophages prior to LPS 
stimulation has an immunosuppressive effect. PMA and double-stimulated macrophages 
express relatively little CD14 at the cell surface compared to vitamin D3 cell. This 
suggests that the immunosuppressive effects of apoptotic cell uptake, by THP-1-derived 
macrophages is independent to CD14 expression. With respect to TLR4 expression, THP-1 
and vitamin D3 macrophages are hyporesponsive to LPS in comparison to PMA and 
double-stimulated macrophages due to a lack of TLR4.  CD14 and TLR4 are required for 
LPS signalling and Tapping et al.(2000) showed that by transfecting TLR4 into THP-1 
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cells expressing CD14, increased LPS induced inflammation. The immunosuppressive 
effects of apoptotic cell interaction inhibited the small but measurable TNF-α response 
produced by THP-1 and vitamin D3 macrophages. Therefore these data may suggest that 
TLR4 is not required for the immunosuppressive effects of apoptotic cells clearance. 
3.5.5 The role of CD14 in innate immune responses 
Hoffmann et al.(2001) found that the binding and phagocytic uptake of apoptotic cells by 
macrophages could be separated into two separate events and suggested that receptors for 
tethering and engulfment were required. Hoffmann et al.(2001) proposed the “tether and 
tickle” model to describe the binding and uptake of apoptotic cells required to generate an 
anti-inflammatory and immunosuppressive response.  This was supported by Lucas et al. 
(2006) that found that TGF-β alone was insufficient to inhibit LPS-induced inflammation 
and contact with the dying cell was also required for the anti-inflammatory response. Lucas 
et al. (2006) speculated that the first signal is generated following direct contact of the 
macrophage with the dying cells denoted as ‘tether’. This event stimulates the 
phagocytosis and TGF-β mediated priming events required for the second signal. The 
second signal, known as “tickle”, is generated following the phagocytosis of apoptotic cells 
and results in the production and response to TGF-β (Lucas et al., 2006). 
 
Hoffmann et al.(2001) suggested several receptors were involved in tethering apoptotic 
cells to phagocytes but found that uptake was inhibited in the absence of PS.  Fadok et al. 
(1992) illustrated the important of PS exposure following activation of apoptotic 
programme and how failure to expose PS resulted in defective clearance.  However 
Hoffmann et al.(2001) found that PS alone was not sufficient to induce uptake but in 
combination with known tethering receptor, engulfment was enhanced. The clearance of 
apoptotic cells is now considered to involve four phases: 1. Recognition of apoptotic cells 
possible due to a loss of ‘don’t eat me’ signals and an increase in ‘eat me’ signals 
(Grimsley, 2003), 2 Tethering of the receptor to the phagocyte, 3. Signalling and 4. 
Phagocytic uptake of apoptotic cell (Gregory and Devitt, 2004).  Results illustrated by 
Hoffmann et al.(2001) and conclusions made by Devitt et al.(2004) suggest that CD14 
functions as a tethering receptor which facilitates the phagocytic uptake of apoptotic cells.   
 
Furthermore CD14; located within micro-domains in the plasma membrane, upon ligation 
with LPS induces several molecules including TLR4 to cluster and propagate a signal 
(Triantafilou et al., 2002). These molecules include heat shock proteins 70 and 90, 
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chemokine receptor 4 and growth differentiation factor 5 (Triantafilou et al., 2001 and 
Triantafilou and Triantafilou, 2002). It was suggested (Triantafilou et al., 2001 and 
Triantafilou and Triantafilou, 2002) that LPS is released from CD14 and diffuses laterally 
within the micro-domain to newly recruited core receptor cluster and activate several pro-
inflammatory pathways including NF-κB, and ERK1/2. Therefore ligand interaction with 
CD14 may dictate receptor clustering and therefore signalling pathways activated. 
 
Previous findings (Devitt et al., 1998) and data shown within this thesis also suggest that 
CD14 functions to tether apoptotic cells to the phagocyte.  However the exact role of CD14 
in the anti-inflammatory consequences of apoptotic cell clearance is unknown. Several 
models are possible (figure 5): 1) Apoptotic cells and LPS bind to different regions of 
CD14 that, upon ligation, interact with proinflammatory or anti-inflammatory receptor 
clusters. 2) Alternatively LPS and apoptotic cells interact with the same region of CD14 
which indiscriminately activates pro-inflammatory receptor clustering. However 
interaction of additional ACAMPs with other phagocyte receptors causes 
immunosuppressive and anti-inflammatory signalling. 3) CD14 functions simply as a 
tethering receptor for apoptotic cells and surrounding receptors within the micro-domain of 
CD14 are responsible for phagocytic uptake and anti-inflammatory signalling events. 
Hoffmann et al.(2001) suggests that the PS-dependent uptake of apoptotic cells requires a 
tethering receptor. 
3.5.6 RAGE 
RAGE, another PRR expressed by monocytes and macrophages, shares many similarities 
with CD14, RAGE too is known to bind LPS and activate TLR4 (Bianchi, 2009, Park et 
al., 2004, Youn et al., 2008, Hofmann et al., 1999 & Ziegler-Heitbrock and Ulevitch, 
1993).  Furthermore, HMGB1, a ligand for RAGE, was found to compete with LBP for 
binding to CD14 and also facilitated the transfer of LPS to CD14 (Youn et al., 2008). 
However little is reported about the ability of RAGE to bind apoptotic cells. While 
previous data (figure 50) has led to the suggestion that apoptotic cells display LPS-like 
structures which function as the epitope recognised by CD14. Here RAGE, another LPS-
binding molecule is assessed for its ability to bind apoptotic cells and facilitate clearance. 
Prior to this study research by several groups has led to the suggestion that RAGE may 
potentially facilitate apoptotic cells clearance. A study by Liu et al.(2008) reported that 
HMGB1 binds to PS on the surface of apoptotic neutrophils and inhibits the phagocytic 
uptake by mouse peritoneal macrophages in vitro and in vivo. Moreover Banerjee et 
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al.(2010) found that loss of acidic C-terminus of HMGB1 diminished both the inhibitory 
effects on apoptotic cell clearance and ability to bind RAGE. Taken together this data may 
suggest that HMGB1 and apoptotic cells compete for binding to RAGE. Therefore this 
could suggest that ligand-binding to RAGE potentially has a role in modulating 
macrophage responses.  
3.5.7 Role of RAGE in LPS and apoptotic cell binding 
Previously THP-1-derived macrophages models have been a useful tool to facilitate the 
study of CD14 and therefore were also used to characterise the role of RAGE in the 
clearance of apoptotic cells. Little is documented about the expression of RAGE during 
monocyte maturation but generally RAGE expression is described as low on mononuclear 
phagocytes (Raucci et al., 2008). All THP-1-derived macrophages expressed RAGE while 
differentiation induced with PMA or double-stimulation produced a sub-population with a 
high surface expression of RAGE. Raucci et al.(2008) also reported that THP-1 expressed 
low levels of membrane and sRAGE. However PMA treatment is known to activate 
protein kinase C which causes phosphorylation of inhibitor, IκB leading to NF-κB 
activation (Bomsztyk et al., 1991). Due to the presence of a positive feedback loop, RAGE 
expression is regulated by NF-κB activation (Li and Schmidt, 1997). This positive 
feedback loop is important for host defence as HMGB1 released from damaged cells binds 
RAGE and triggers an immune response which sustains inflammation and therefore stems 
invasion of pathogens and reduces tissue damage (Raucci et al., 2008). Previously Bazil 
and Strominger (1991) found that PMA induced shedding of membrane-bound proteins. 
Raucci et al.(2008) also found that PMA treatment induced proteolytic shedding of 
mRAGE, therefore this data suggested that PMA treatment increased both mRAGE and 
most likely led to shedding.  
 
Previous studies have used sRAGE as a decoy for the membrane form (Foell et al., 2006, 
Hofmann et al., 1999) therefore sRAGE was produced by sub-cloning the extracellular 
domain, containing the ligand-binding regions, into the expression vector pSec Tag2. 
Having expressed sRAGE, its ability to bind LPS was assessed as previous results (section 
5.7) have suggested that apoptotic cells express LPS-like structures at the cell surface 
(figure 50). The results presented here suggested that sRAGE may bind to immobilised 
LPS and is supported by Yamamoto et al.(2011) who used surface plasmon resonance and 
found that LPS bound directly to RAGE. Furthermore following LPS-induced stimulation, 
mouse-macrophages taken from wildtype mice (expressing mRAGE) produced 
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significantly more TNF-α compared to RAGE-deficient mice (Yamamoto et al., 2011). 
However having looked at this study, a possible concern was the level of HMGB1 in these 
mice following LPS stimulation, serum levels of HMGB1 increased in wildtype but not 
RAGE deficient mice therefore it is possible that HMGB1 facilitated the transfer of LPS to 
CD14 which enhanced cellular responses in wildtype. 
 
Having expressed sRAGE the ability of RAGE to bind apoptotic cells was assessed. 
Immunofluorescence staining suggested that sRAGE did not bind apoptotic cells. 
Therefore having established that THP-1-derived macrophages express different levels of 
mRAGE the ability of each macrophage model to clear apoptotic cells in a RAGE-
dependent manner was assessed. Prior to co-culturing with macrophages, apoptotic cells 
were incubated with sRAGE as a competitive inhibitor of mRAGE and the results 
illustrated that sRAGE did not block apoptotic cell clearance.  This led to the suggestion 
that either RAGE is not involved in clearance or alternatively that sRAGE also facilitates 
the clearance of apoptotic cells. 
 
Sequence analysis of sRAGE cloned revealed two single point mutations within the 
parental DNA sequence that codes for the extracellular ligand-binding domain and 
consequently the effects on ligand binding of RAGE is unknown. Previous results 
suggested that sRAGE bound LPS therefore suggesting that the ligand-binding site is 
possibly unaffected. This would support the suggestion that sRAGE does not bind 
apoptotic cells. However studies conducted following this research by Banerjee et 
al.(2010) and Friggeri et al.(2011) implicated RAGE in the phagocytic uptake of apoptotic 
cells. Friggeri et al.(2011) found that macrophages taken from mice deficient in RAGE 
showed a decreased ability to phagocytose apoptotic cells. Furthermore over-expressing 
RAGE in amateur phagocytes increased their ability to take up apoptotic cells. With 
respect to the soluble form, Friggeri et al.(2011) also illustrates that incubation of 
macrophages with sRAGE increased phagocytosis of apoptotic cells. It was suggested that 
RAGE participates in clearance by binding to PS in a dose-dependent manner that could be 
blocked by incubation with annexin V, this along with in vitro studies reported that RAGE 
is involved in the phagocytosis of apoptotic cells (Friggeri et al., 2011). Ligation of RAGE 
is well characterized for producing inflammation therefore causing upregulation of 
receptor expression (Schmidt et al., 2000). Friggeri et al.(2011) speculates that RAGE is 
involved in the uptake of apoptotic cells in order to reduce further inflammation and 
facilitate resolution.  
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Here the ability of RAGE to bind to apoptotic cell was assessed using flow cytometry and 
findings suggested that sRAGE did not bind to apoptotic cells. This may suggest that the 
affinity for apoptotic cells is low and subsequent washing removed bound sRAGE. 
However the role of RAGE in the clearance of apoptotic cells was assessed using sRAGE 
as a competitive inhibitor of mRAGE and the findings contrast with published data by 
Friggeri et al.(2011). Friggeri et al.(2011) found that sRAGE bound to PS and facilitated 
clearance most likely by a different manner to the membrane form. Therefore suggesting 
that sRAGE is not a suitable decoy to examine the role of mRAGE in the clearance of 
apoptotic cells. An alternative method to examine the role of RAGE in the clearance of 
apoptotic cells may be to use small interfering RNA (siRNA) to silence wildtype mRAGE. 
This would avoid the use of knock-out mice which may develop very differently in the 
absence of mRAGE.  
 
The lack of sRAGE binding to apoptotic cells could be a result of the effects of the single-
point mutations within the ligand-binding domain of sRAGE used. This mutation is likely 
to effect the three dimensional shape of the surrounding regions. It is possible that sRAGE 
used within this study did not bind to the apoptotic cells due to disruption of the three-
dimensional shape of the ligand-binding domain. However sRAGE used within this study 
bound to LPS immobilised to an ELISA plate suggesting the ligand-binding domain of 
RAGE retained some of its ability to bind ligands. This may suggest that different ligands 
interact with different residues within RAGE. Another factor to consider is the size of the 
ligands, LPS is a small molecule compared to an apoptotic cell, and although RAGE 
recognises PS on the surface of an apoptotic cell the ligand-binding domain may have to 
accommodate part of the apoptotic cells. Therefore any mutation within the ligand binding 
domain that affects the three-dimensional shape may sterically hinder the docking of an 
apoptotic cell. One way to examine the effects of the mutation on the ligand-binding of 
RAGE would be to conduct and ELISA with HMGB1.  
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Results 2: Clearance of apoptotic cells by non-myeloid cells 
4.1 Introduction 
Macrophages are considered the professional scavengers of apoptotic cells as they are 
recruited to sites of apoptosis when amateur phagocytes are overwhelmed (Gregory and 
Devitt, 2004). These cells, unlike amateur phagocytes are highly motile, phagocytic and 
can uptake apoptotic cells upon first contact (Parnaik et al., 2000 & Grimsley, 2003). 
Macrophages also have a large repertoire of PRR that are involved in the uptake of 
apoptotic cells as well as host defence, permitting adaptation within any internal 
environment (Savill et al., 2002 & Monks et al., 2005). However at normal rates of 
apoptosis, neighbouring cells (i.e. amateur phagocytes) are capable of clearing apoptotic 
cells (Parnaik et al., 2000, Gregory and Devitt, 2004). 
 
The receptors used by amateur phagocytes to clear apoptotic cells is largely unknown 
however previous findings (Wood et al., 2000, Parnaik et al., 2000 & Monks et al., 2005) 
may suggest that the repertoire of receptors available are limited and saturable. Monks et 
al.(2005) showed that mammary epithelial cells clear apoptotic cells in a PS-dependent 
manner, using receptors also used by macrophages. Blocking-antibodies to calreticulin, 
CD91 and the vitronectin receptor were used, which reduced phagocytosis of apoptotic 
cells by mammary epithelial cells. Therefore given these findings and previous 
observations within our laboratory group; that found respiratory epithelial cells were LPS 
responsive, it is hypothesised that CD14 is expressed by epithelial cells, within specific 
sites with an intended role in modulating immune responses. 
4.2 Cell surface expression of CD14 on amateur phagocytes 
Here the role of CD14 in innate immune responses by non-myeloid, amateur phagocytes is 
considered. Therefore the assessment of cell surface CD14 on various tissue epithelial cells 
and human pulmonary fibroblasts was assessed by indirect immunofluorescence staining of 
viable cells with established mAb 63D3 followed by flow cytometric analysis (figure 35). 
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Figure 35: Surface expression of CD14 on epithelial cells 
Surface expression of CD14 on pulmonary (Beas 2B and Calu-3), oral (H400), mammary 
(MCF-7) and cervical (HeLa) epithelial cell lines, along with human pulmonary fibroblast 
(HPF), was detected with flow cytometric staining using indirect immunofluorescence with 
the mAb 63D3 (blue) or isotype-matched control MOPC 21 (grey).  The mean 
fluorescence intensity of the population is shown the top corner of each histogram. The 
results are representative of three independent experiments. 
 
Flow cytometric analysis suggests that CD14 is only expressed on pulmonary epithelial 
cells, Beas-2B and Calu-3. Surface expression of membrane CD14 was undetectable on 
cervical (HeLa), oral (H400), mammary (MCF-7) epithelial cells and HPF.  
4.2.1 LPS-responsiveness of CD14-expressing epithelial cells 
CD14 is well characterised for its ability to bind LPS released during Gram negative 
bacterial infections and promote inflammation (Wright et al., 1990 and Ulevitch and 
Tobias, 1999). Given previous flow cytometric findings that suggest Beas-2B and Calu-3 
pulmonary epithelial cells express significant levels of membrane CD14, the ability of 
these cells to response to LPS-stimulation was assessed (figure 36). 
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Figure 36: LPS-stimulation of pulmonary epithelial cells 
Cells were seeded at 1x10
5
cells per well in 24 well plates and incubated overnight. 
Following incubation cells were stimulated with increasing concentrations of LPS in the 
presence of 10% NHS for 24 h prior to analysis for IL-8 by ELISA. The results shown are 
the mean ± SD of quadruplet wells. Statistical analysis conducted was compared to no LPS 
using ANOVA followed by Dunnetts post test and result (*P<0.05, **P<0.01) 
 
The results in figure 36 suggest that LPS-induced stimulation of Beas-2B resulted in a 
dose-dependent increase in IL8-released following stimulation with 1µg/ml of LPS. LPS-
induced stimulation of Calu-3 (above of 1µg/ml) also resulted in IL-8 response but, unlike 
Beas-2B, did not appear dose-dependent and basal levels were much higher. This may 
suggest that the level of mCD14 expressed by Calu-3 but not Beas-2B was a limiting 
factor. CD14 expression along with LPS response data may suggest that pulmonary 
epithelial cells respond to LPS in a CD14-dependent manner.  
4.2.2 TLR4 expression on pulmonary epithelial cells 
Previous data has suggested that Beas-2B and Calu-3 express cell surface CD14 (figure 35) 
and are LPS-responsive (figure 36) possibly in a CD14-dependent manner. However 
mCD14 does not contain a cytosolic signalling domain therefore a signalling partner is 
required for cellular response. Typically TLR4 is required to confer an LPS-dependent 
response (Hoshino et al., 1999,Miyake, 2004) therefore the expression of TLR4 on Beas-
2B and Calu-3 was assessed with direct immunofluorescence staining (figure 37). 
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Figure 37: Surface expression of TLR4 on Beas-2B and Calu-3 
Surface expression of TLR4 on a variety of cells was detected with flow cytometric 
staining using direct immunofluorescence with the monoclonal antibody HTA125-PE 
(green) or IgG2a-PE (Isotype-matched control, (grey)). U937 cells were used as a positive 
control. The results are representative of three separate experiments. 
 
Cell surface expression of TLR4 was undetectable on Beas-2B and Calu-3 following flow 
cytometric analysis. This data is supported by Guillot et al.(2004) that used RT-PCR and 
found that in Beas-2B, TLR4 is expressed at mRNA level but was not found at the cell 
surface.  
4.3 The clearance of apoptotic cells by amateur phagocytes 
Little is known about the receptors utilised by amateur phagocytes to bind and engulf 
apoptotic cells. Monks et al.(2005) found that mammary epithelial cells used the same 
receptors as macrophages to clear apoptotic cells. Furthermore Devitt et al.(2004) found 
that in CD14-deficient mice, the clearance of apoptotic cells at specific sites was reduced 
suggesting that CD14 may be involved in the removal of apoptotic cells by amateur 
phagocytes. Therefore here the ability of amateur phagocytes to interact with apoptotic 
cells was assessed along with the role of CD14 in clearance (figure 38). 
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Figure 38: CD14-dependent apoptotic cell clearance by amateur phagocytes 
All epithelial cell and fibroblasts were seeded on four-well glass slides and incubated 
overnight to allow for adhesion. Following incubation cells were incubated with medium 
or co-cultured with apoptotic Mutu for 1 h at 37°C alone and with CD14-blocking mAb 
61D3 or non-blocking mAb 63D3.  Slides were then washed in ice-cold PBS and fixed in 
1% (v/v) formaldehyde prior to Jenner-Giemsa staining. Phagocyte interaction with 
apoptotic cells was assessed by light microscopy and values scored as a percentage. The 
results shown are the mean ± SEM of three independent experiments. Statistical analysis 
conducted was ANOVA followed by Bonferroni post-test (** P<0.01). 
 
The results in figure 38 suggest that all amateur phagocytes analysed interacted with 
apoptotic cells. The percentage of H400, HPF, MCF-7 and HeLa cells interacting with 
apoptotic cells is 75% (approximately the same), which may suggest that the receptors or 
mechanisms to remove apoptotic cells is the same.  While the percentage of Beas-2B and 
Calu-3 interacting with apoptotic cells is 50%, the level of interaction is lower than other 
amateur phagocytes shown (HeLa, MCF-7, H400 and HPF).  The ratio of apoptotic cells to 
phagocytes remained constant therefore any variation in the level of interaction is 
dependent on the receptors or mechanisms used by each cell type to clear apoptotic cells. 
Previous data showed that pulmonary epithelial cells expressed cell surface CD14 and as 
shown in figure 35, CD14-blocking mAb 61D3 inhibited apoptotic cell clearance by both 
Beas-2B and Calu-3 cells by around 50%. This suggests that pulmonary epithelial cells 
utilised CD14 to clear apoptotic cells unlike fibroblast, oral, mammary and cervical 
epithelial cells. 
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4.4 Conclusion 
4.4.1 LPS responses in non-myeloid cells  
The expression of membrane CD14 was originally considered to be limited to myeloid 
cells, B cells and mammary cells (Ziegler-Heitbrock and Ulevitch, 1993). However Fearns 
et al.(1995) found that CD14 RNA was expressed in murine tissues within various organs, 
including, the lung, spleen, heart and thymus. Within these tissues, CD14 RNA was 
detected within epithelial cells, suggesting these cells may function as more than simply a 
physical barrier. Therefore recent findings within our research laboratory group, that 
suggested pulmonary epithelial cells were LPS-responsive was of great interest, as the role 
of CD14 in the innate immune response of non-myeloid cell was unclear. Consequently a 
range of human epithelial cells from different tissue origins was obtained and cell surface 
CD14 expression assessed. Flow cytometric analysis suggests that pulmonary epithelial 
cells express mCD14 while expression was not detected on oral, mammary and cervical 
epithelial cells as well as pulmonary fibroblasts tested. Given previous findings that CD14 
is required for LPS responsiveness of cells, the ability of pulmonary epithelial cells to 
respond to LPS was assessed and shown to induce an IL-8 response. The role of CD14 in 
LPS-responses within the lungs is supported by Brass et al.(2007) who observed that 
CD14-deficient mice were hyporesponsive to LPS inhalation but intratracheal treatment 
with sCD14 restored inflammation to that of wild-type. Furthermore findings by 
Jeyaseelan et al.(2005) suggest that CD14 and TLR4 are required for LPS responses within 
the lungs. However here cell surface expression of TLR4 was not detected on pulmonary 
epithelial cells but may suggest that cell surface levels were below the limits detectable by 
flow cytometry. These findings are supported by Guillot et al.(2004) who suggested that 
TLR4 was not expressed at the surface of Beas-2B cells but using RT-PCR found that 
TLR4 was expressed at an mRNA level. Furthermore immunoblotting of cellular lysates 
from Beas-2B cells suggested that TLR4 was present in intracellular compartments 
(Guillot et al.2004). Findings by Triantafilou and Triantafilou (2002) suggested that TLR4 
is not present at the cell surface, unlike CD14, but is recruited to lipid rafts following LPS 
stimulation. However Guillot et al.(2004) found that LPS-stimulation did not induce cell 
surface expression of TLR4 at any point during stimulation but found that cellular response 
to LPS was TLR4-dependent. Guillot et al.(2004) suggested that the lack of cell surface 
TLR4 and failure of LPS to up-regulate CD14 expression on pulmonary epithelial cells 
may provide a protective mechanism against small doses of LPS contained with air 
inhaled. This may suggest that LPS-induced activation of pulmonary epithelial cells occurs 
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following internalisation of LPS caused by a receptor mediated event, which then 
encounters intracellular TLR4. A similar mechanism of LPS-induced TLR4 activation is 
reported within the gastrointestinal tract in the absence of cell surface TLR4. The absence 
of TLR4 has been linked to hyporesponsive of intestinal epithelium to resident enteric flora 
and therefore prevents unnecessary inflammation and local tissue damage (Hornef et al., 
2002). Hornef et al.(2002) identified that in intestinal epithelial cells, TLR4 is located 
within the golgi but furthermore found that LPS is also associated with TLR4 in this 
location too. Although findings by Latz et al.(2002) identified that in HEK293 and most 
likely all epithelial cells, TLR4 and CD14 are recycled from the golgi to the cell 
membrane. Latz et al.(2002) found that cross linking membrane TLR4 resulted in 
activation and concluded that TLR4 found in the golgi is not required for LPS-induced 
stimulation of these cells. However this study does not really address the role of 
intracellular TLR4 in LPS-mediated signalling in the absence of cell surface TLR4. The 
results by Latz et al.(2002) may suggest that if TLR4 and CD14 are present at the cell 
surface signalling occurs from the surface but in the absence of TLR4, LPS is internalized 
possible using CD14 and may result in TLR4 intracellular signalling. Some experiments to 
consider, as future work might be to establish if the LPS responsiveness of pulmonary 
epithelial cells is CD14-dependent. This could be established by stimulating Beas-2B and 
Calu-3 with LPS in the presence of CD14-blocking mAb MEM18. If the data suggests that 
CD14 is required for LPS responses then the role of TLR4 in LPS signalling could be 
assessed using small hairpin RNA to silence TLR4 expression. Subsequently if cells are 
hyporesponsive to LPS, in the absence of TLR4 this would suggest that both CD14 and 
TLR4 are required for the LPS responsiveness of pulmonary epithelial cells. Given the 
findings shown here, this would support the suggestion that LPS activates intracellular 
TLR4, following the CD14-dependent uptake of LPS. A possible method of assessing the 
role of LPS uptake in TLR4 activation may be to prevent membrane turnover then examine 
LPS-induced responses. 
4.4.2 Role of non-myeloid CD14 in apoptotic cell clearance 
While little is known about the receptors utilised by amateur phagocytes to mediate 
clearance, mammary epithelial cells were found to express and utilise CD36, the 
vitronectin receptor, calreticulin/CD91 and the PS receptor in the clearance of apoptotic 
cells (Monks et al., 2005). Other receptors analysed within the study included CD14, but 
flow cytometric analysis suggested that mammary epithelial cells did not express cell 
surface CD14 (Monks et al., 2005). Monks et al. (2005) reported that the anti-
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inflammatory effects of apoptotic cell clearance occurs in amateur phagocytes, as 
stimulation with LPS in presence of apoptotic cells, inhibited TNF-α production. Given 
these findings, here a series of amateur phagocytes were screened for their ability to 
interact with apoptotic cells in a CD14-dependent manner. The data suggested that oral, 
mammary and cervical epithelial along with pulmonary fibroblasts, interacted with 
apoptotic cells to the same level (75%). This may suggest that the mechanisms of clearance 
used by these phagocytes are the same and lack of inhibition with CD14-blocking mAb 
61D3, suggests that clearance is not CD14-dependent. The percentage of pulmonary 
epithelial cells (Beas-2B and Calu-3) interacting with apoptotic cells was lower than other 
phagocytes analysed; suggesting that the clearance of apoptotic cells by pulmonary 
epithelial cells was not as efficient. This suggests that the mechanisms used by pulmonary 
epithelial cells to remove apoptotic cells from the lungs differ from other sites within the 
body. However apoptotic cells are rarely observed in healthy human lungs (Vandivier et 
al., 2006), suggesting that the level of cell death is either lower in vivo or that apoptotic 
cells are rapidly removed. The assay used here to measure apoptotic cell interaction is a 
snap shot at a one hour time point, with pulmonary epithelial cells appearing to have less 
apoptotic cells bound. Therefore this data may indicate that interaction of pulmonary 
epithelial cells with apoptotic cells is lower due to more efficient uptake and digestion, 
indicated by less surface-bound apoptotic cells. However Parnaik et al.(2000) reported that 
while both professional and amateur phagocytes bound apoptotic cells it took several hours 
for amateur phagocytes to engulf apoptotic cells but digestion time was the same. Parnaik 
et al. (2000) suggested that the uptake of apoptotic cells was not mediated until additional 
cell surface changes had occurred. Therefore the events within the later stages of apoptosis 
such as PS exposure may be required for uptake of apoptotic cells by amateur phagocytes.  
However the clearance of apoptotic cells by phagocytes can be separated into two distinct 
phases, tethering and uptake (Hoffmann et al., 2001 and Lucas et al., 2006). Parnaik et 
al.(2000) findings suggests that amateur phagocytes have the receptors for tethering 
apoptotic cells but either the receptors that mediate uptake are limited or only recognise 
late apoptotic cells. Alternatively rearrangement of cytoskeleton within amateur 
phagocytes may take several hours to allow uptake. However the persistence of apoptotic 
cells is considered to lead to secondary necrosis and possibly inflammation (Erwig and 
Henson, 2007). In the lung particularly, failed clearance of cells such as, neutrophils would 
be massively detrimental with proinflammatory consequences.  While innate immune 
components within the lungs provide defence against invading pathogens, many have been 
implicated in the clearance of apoptotic cells, including, the mucociliary escalator, 
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immunoglobulins, complement factors, surfactant proteins A and D along and alveolar 
macrophages. Therefore pulmonary epithelial cells may maintain mucosal integrity by 
modulating immune responses. Pulmonary epithelial cells express a variety of innate 
immune receptors to mediate host defence (Diamond et al., 2000). Several innate immune 
receptors are known also to be involved in the clearance of apoptotic cells, therefore it is 
likely that pulmonary epithelial cells utilise multiple receptors to interact with and mediate 
uptake of apoptotic cells. This may suggest that pulmonary epithelial cells either express 
receptor also found on macrophages to mediate uptake upon contact or can facilitate 
uptake quicker than other amateur epithelial cells. 
4.4.3 Role of CD14 in innate immune responses of pulmonary epithelial 
cells 
LPS data presented here suggests that the pulmonary epithelial cells, Beas-2B and Calu-3 
express mCD14 and are responsive to LPS stimulation. CD14 is also involved in the 
clearance of apoptotic cells (Devitt et al., 1998), findings by Devitt et al.(2004) suggested 
that CD14-deficient mice have persistent apoptotic cells within specific tissue, including, 
the lungs. Taken together, these findings may suggest that the expression of CD14 by 
alveolar macrophages and pulmonary epithelial cells is required for the efficient clearance 
of apoptotic cells within the lungs. Furthermore the binding of apoptotic cells to CD14 was 
uncoupled from the anti-inflammatory consequences of apoptotic cell clearance, as 
persistence of apoptotic cells did not induce inflammation (Devitt et al., 2004). This led to 
the suggestion that CD14 functioned as a tethering receptor in apoptotic cell clearance.  
Here the requirement of CD14 in the clearance of apoptotic cells by pulmonary epithelial 
cells has been shown in the absence of cell surface TLR4. This data therefore supports 
previous findings within this thesis that have suggested that TLR4 is not required for the 
clearance of apoptotic cells by CD14.  
 
In conclusion, the data presented here may suggest that the presence of CD14 on 
pulmonary epithelial cells facilitated efficient and rapid removal of apoptotic cells. The 
proposed theoretical mechanism is that apoptotic cells are rapidly tethered to mCD14, 
which enhances apoptotic cell interaction with engulfment receptors such at TIM-4 or Mer, 
subsequently promoting rapid uptake. Given findings here that suggest pulmonary 
epithelial cells express receptors also utilised by macrophages to bind apoptotic cells and 
that epithelial cells efficiently clear apoptotic cells, what dictates the level of 
professionalism of a phagocyte? If non-resident macrophages are only recruited to sites site 
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of apoptosis, when neighbouring phagocytes are overwhelmed this may suggest that non-
resident macrophages are the ‘amateurs’? 
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Results 3: The mapping of soluble CD14 point-mutants 
5.1 Introduction 
As previously mentioned CD14 is also expressed in a soluble form lacking the 
phosphatidylinositol tail which anchors the receptor to the membrane. Soluble CD14 can 
be produced following secretion of the protein, prior to addition of the phosphatidylinositol 
tail during post-translational modifications in the golgi, or by enzymatic digestion of 
membrane CD14 (Bufler et al., 1995).  While little is currently known about the role of 
sCD14 in the clearance of apoptotic cells, several groups (Frey et al., 1992 &Pugin et al., 
1993) have reported that sCD14 enables endothelial and epithelial cells that do not express 
mCD14, to respond to LPS. Frey et al.(1992) reported that human umbilical vein 
endothelial cells (HUVEC) and U393 astrocytoma cells require sCD14 along with LBP to 
respond to LPS.  Frey et al.(1992) also suggested that following LPS binding, sCD14 
propagated a stimulatory signal by interacting with a cell surface bound receptor; this was 
prior to the discovery of TLR4. The principles of this work were then used to underpin the 
studies used by several groups (Darveau et al., 1998, Cunningham et al., 1999,Shapiro et 
al., 1997 & Juan et al., 1995c) along with mutagenesis studies to map the regions of CD14 
required for LPS binding. Devitt et al.(1998) reported that CD14 is also involved in the 
clearance of apoptotic cells and shows that mAbs 61D3 and MEM18 blocked both LPS 
responses and apoptotic cell binding to CD14. This lead to the suggestion that the same 
region of CD14 bound LPS and apoptotic cells and was able to facilitate contrasting 
ligand-dependent responses (Devitt et al., 1998 & Gregory and Devitt, 2004). However 
apoptotic cell binding to CD14 has not been mapped therefore the divergence in 
macrophage response to apoptotic cells and LPS could be caused by a variation in the 
residues involved in ligand (LPS and AC) binding. If apoptotic cells interact with the 
same regions of CD14 as LPS, then any differences in response would most likely be 
caused by the activation of contrasting signalling partners. Therefore the aim of this 
chapter is to test the hypothesis that residues within CD14 required for LPS binding, are 
also involved in apoptotic cell binding.  This will establish an understanding of the 
molecular mechanism employed by CD14 to generate two distinct ligand-dependent 
macrophages responses. Devitt et al. (2004) also found that sCD14 bound apoptotic cells 
but not live cells. Therefore here a series of sCD14, point-mutants are used to consider the 
key residues involved in the binding of LPS and apoptotic cells. 
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5.2 Introducing the soluble CD14 mutants  
sCD14 point-mutants were used in studies to map E.coli, P.gingivalis and H.pylori LPS 
binding to CD14 and kindly received from Richard Darveau (Washington University, 
USA) (Darveau et al., 1995, Shapiro et al., 1997, Cunningham et al., 1999, 2000). The 
plasmids encode for human CD14 containing single residue mutation within the N-
terminal 60 amino acids of the protein upstream of cDNA encoding for hinge, CH2 and 
CH3 domains of human IgG1 in the mammalian expression plasmid pcDNA3.1. All 
mutations are within the N-terminal region of CD14, (figure 39) as this region is required 
for the binding of LPS (Viriyakosol and Kirkland, 1995). More specifically the mutations 
are within three of the four LPS binding regions previously identified for E.coli LPS 
binding (Juan et al., 1995a, Stelter et al., 1997, Shapiro et al., 1997 & Cunningham et al., 
2000).  
 
 
 
 
Figure 39: The LPS binding regions of CD14 are located within the N-terminal 
All four LPS binding regions of CD14 as shown in red (labelled R1-R4) are located within 
the first 66 amino acids of CD14 Previous work with the CD14-blocking antibody 61D3 
and MEM18 have suggested that apoptotic cells also bind within the N-terminus of 
CD14(Juan et al., 1995a, Stelter et al., 1997, Shapiro et al., 1997 & Cunningham et al., 
2000). Arrows indicate where the point-mutations received are located,  in relation to-LPS 
binding regions of CD14.  
 
The ten soluble CD14-point mutants received (table 2) are alanine replacement and same 
charge mutations with the exception of E11R which is a charge reversal mutation (Table 
2). 
Human   PEPCELDDEDFRCVCNFSEPQPDWSEAFQCVSAVEVEIHAGGLNLEPFLKRVDADADPRQYA 
PEPCELDEE--SCSCNFSDPKPDWSSAFNCLGAADVELYGGGRSLEYLLKRVDTEADLGQFT 
*******:*   * ****:*:****.**:*:.*.:**::.** .** :*****::**  *:: 
 
R1 R2 R3 R4 
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Native amino acid 
 
 
Position 
 
 
Substituted Amino acids/ 
Name mutation 
(E)Glutamic Acid 
 
 
 
 
 
 
Hydrophilic 
Negative 
 
 
 
 
 
11 
(A)Alanine 
 
 
 
 
Hydrophobic 
Neutral 
E11A 
(D)Aspartic 
Acid 
 
 
 
 
 
 
 
Hydrophilic 
Negative 
E11D 
(R)Arginine 
Hydrophilic 
Positive 
E11R 
(R)Arginine 
Hydrophilic 
Positive 
 
 
 
14 
(A)Alanine 
 
 
 
 
 
 
 
Hydrophobic 
Neutral 
R14A 
(K)Lysine 
 
 
 
 
 
Hydrophilic 
Positive 
R14K 
(E)Glutamic Acid 
Hydrophilic 
Negative 
 
 
37 
(D)Aspartic Acid 
 
 
 
 
 
 
 
Hydrophilic 
Negative 
E37D 
(Q)Glutamine 
Hydrophilic 
Neutral 
E37Q 
(D)Aspartic Acid 
 
 
 
 
 
Hydrophilic 
Negative 
 
 
59 
(A)Alanine 
Hydrophobic 
Neutral 
D59A 
(N) Asparagine 
 
 
 
Hydrophilic 
Neutral 
D59N 
 
Table 2: The structure and charge details of each mutated sCD14 received 
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5.3 Establishing a method of transfection 
Having acquired the glycerol stocks of wildtype and mutant sCD14, the first task was to 
produce all sCD14 mutant plasmids suitable for transfection into mammalian cells.  
Following culturing, plasmid DNA was recovered and sequenced to confirm the presence 
of the mutation. 
 
HEK293 are routinely used for the transient transfection of plasmids expressing soluble 
protein. HEK293 are easy to culture and transfect, especially with calcium phosphate-
mediated transfection, one of the first methods explored due to its simplicity and cost-
effectiveness. The efficiency of calcium phosphate-mediated transfection of DNA was 
assessed (figure 40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Calcium phosphate-mediated transfection of HEK293 
HEK293 were transfected using calcium phosphate with 2µg of mCD14 or plasmid 
containing GFP and incubated for 24h post-transfection. Following incubation A. CD14 
expression was analysed using indirect immunofluorescence with mAb 63D3 or control 
mAb BU65 (anti-ICAM-3 was used as isotype-matched control) (grey) and analysed using 
flow cytometry. B. HEK293 transfected with a plasmid expressing GFP (green) or mock 
transfection were also analysed using flow cytometry. The percentage of cells and the 
mean fluorescence intensity of the population within the positive gated region are shown. 
 
The results in figure 40 suggest calcium phosphate-mediated transfection of plasmid DNA 
was successful. Both CD14 expression (as detected by indirect immunofluorescence) and 
GFP expression show an increase in the mean fluorescence intensity compared to the 
control. However the results suggested that the transfection efficiency was lower with GFP 
compared to mCD14 as the percentage of cells having increased in fluorescence was lower. 
Any differences in transfection efficiency may cause a variation in the yield of sCD14 
mutants produced, while attempts were made to optimise calcium phosphate-mediated 
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transfection method, each experiment varied in the efficiency. Therefore a more robust and 
consistent method of transfection was required. 
 
LT1-mediated transfection was previously used within the laboratory and found to produce 
reproducibly high transfection efficiencies. Therefore LT1-mediated transfection was used 
to transfect HEK293 with a plasmid expressing GFP at different ratios of reagent to DNA 
to optimise expression of antigen (figure 41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Optimisation of LT1-mediated transfection of HEK293  
HEK293 were seeded at 3x10
5
per well in 6 well plates and incubated overnight. Different 
ratios of LT1 was mixed with 2µg of plasmid DNA within 250μl of sfRPMI and incubated 
for 15-30min to allow for the formation of DNA-complexes. Following incubation, the 
transfection mixture was added drop-wise to the HEK293 and incubated for 24-72 h.  Cells 
were then analysed using flow cytometry for an increase in the mean fluorescence intensity 
for 100% of the population. The results are representative of two independent experiments. 
 
The results in figure 41 suggest that as the ratio of LT1 to DNA increased, the mean 
fluorescence intensity of HEK293 also increased. The increase in the mean fluorescence 
intensity of the population suggests a greater uptake of cDNA per cell. This method was 
found to be more efficient and reproducible than calcium phosphate-mediated transfection, 
as the mean fluorescence intensity of the whole population always increased. The ratio, 
3.5μl:2μg ratio of LT1 reagent to DNA was chosen and mutant sCD14-Fc plasmids were 
transfected into HEK293. 24 hours following transfection, the medium was changed to 
sfDMEM and the cells are incubated for a further 72 hours to maximise protein production. 
The transfection supernatant was harvested, centrifuged to remove cells then a capture 
ELISA conducted to verify the expression of wtCD14 and mutants (figure 42). 
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Figure 42: ELISA of sCD14-Fc production 
Following transfection, sCD14 expression and release was verified by capture ELISA. 
sCD14-Fc mutants were immobilised from supernatants, by capture with 5μg/ml of sheep 
anti-human Fc thus capturing the mutants by the Fc tags.  Bound sCD14 was detected with 
mAb 63D3 using MOPC 21 as isotype negative control.  Purified sCD14-Fc previously 
used within our laboratory was used as a positive control while supernatant taken from 
cells transfected with no DNA (non-transfected) was used as a further negative control.  
The data shown is the mean ± SD of duplicate wells and representative of three 
independent experiments. Statistical analysis used was ANOVA followed by Dunnetts post-
test (**P< 0.01)  
 
The ELISA results in figure 42 suggest that wtCD14 and mutants were successfully 
expressed in HEK293. 63D3 binds towards the C-terminus of the protein (Viriyakosol et 
al., 2000) away from the suggested LPS or apoptotic cell binding regions of CD14. As the 
results show, 63D3 binds all of the mutants tested, suggesting that no mutant induced a 
profound conformational change that altered the epitope of 63D3 binding to the C-terminus 
of CD14. Any variation in 63D3 binding was therefore likely to be a result of varying 
concentrations of protein. 
5.4 Mapping LPS binding 
The highly conserved lipid A region of LPS (figure 3) provides the molecular motif 
recognised by the innate immune system and is responsible for the inflammatory properties 
of LPS (Rietschel et al., 1994). CD14 is well characterised for its ability to bind the lipid A 
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region of LPS (Fenton and Golenbock, 1998), however at concentration above 11µg/ml 
LPS forms micelles preventing binding to CD14 (Aurell and Wistrom, 1998).  The lipid 
transfer protein, LBP is required for shuttling LPS monomers from micelles to CD14 
(Fenton and Golenbock, 1998 &Viriyakosol and Kirkland, 1995). The resulting complex is 
recognised by TLR4 and causes the generation of a proinflammatory event (Hoshino et al., 
1999 & Lien et al., 2000).  
 
Previous research (Juan et al., 1995a, Stelter et al., 1997, Shapiro et al., 1997 & 
Cunningham et al., 2000) using LPS blocking mAbs, truncated and mutated versions of 
CD14 has identified four regions involved in LPS binding. All four LPS binding regions of 
CD14 are located within the first 65 amino acids of the amino-terminal of the protein 
(Viriyakosol and Kirkland, 1995). The crystal structure proposed by Kim et al.(2005) 
identified this region of CD14 as a hydrophobic pocket that contains all four LPS binding 
regions (figure 43).  Juan et al.(1995) reported that mAb MEM18 competed with LPS for 
binding to residues 57-64 of CD14. Furthermore Devitt et al.(1998) found that both 61D3 
and MEM18 blocked apoptotic cell binding and competed with each other for binding to 
CD14. Devitt et al.(1998) also found that 61D3 blocked LPS responses and taken together 
these data suggest that the binding sites of LPS, MEM18, 61D3 and apoptotic cells are 
closely associated or possibly the same. This raises the suggestion that the N-terminal 
pocket of CD14, which contains the LPS binding sites (figure 43) also contains the 
apoptotic cell binding sites. Therefore the aim of this chapter is to compare and 
contract LPS and apoptotic cell binding to sCD14 mutants.  
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Figure 43: The sequence alignment of human and mouse CD14 and the crystal 
structure of mouse CD14 
A. Sequence alignment of the NH2-terminal region of CD14 reveals 67% homology 
between human and mouse. The nucleotides within the LPS binding regions, outlined in 
red are identical (*) or highly conserved (:). B. The crystal structure of mouse CD14 shown 
suggests CD14 forms a horse-shoe shaped dimer in solution, with each monomeric unit 
composed of thirteen β-strands containing a similar number of LRRs similar to TLR4. C. 
The N-terminus (yellow) of each monomeric unit (grey) contains a hydrophobic pocket 
(labelled with arrows) responsible for LPS binding. Closer analysis of the pocket revealed 
four regions (shown in red and labelled R1-R4) that are required for LPS binding.  The 
location the residues E11, E37 and D59 are shown in orange as these residues are located 
within the first, third and fourth LPS binding regions of CD14. R14 is shown in purple as 
this residue is outside the first LPS binding region. Adapted using Mol ICM browser from 
Kim et al., 2005. 
 
A) Sequence alignments 
 
Human   PEPCELDDEDFRCVCNFSEPQPDWSEAFQCVSAVEVEIHAGGLNLEPFLKRVDADADPRQYA 
Mouse    PEPCELDEE--SCSCNFSDPKPDWSSAFNCLGAADVELYGGGRSLEYLLKRVDTEADLGQFT 
       *******:*   * ****:*:****.**:*:.*.:**::.** .** :*****::**  *:: 
 
N-terminal pocket 
B) Mouse CD14 dimer 
C) N-terminal pocket 
R1 
R2 
R4 
E11 
R3 
R14
11 
E37 
D59 
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Also shown in figure 43 is the location of each residue that has been mutated in generating 
the sCD14 point-mutants used within this study. Previously Cunningham et al. (2000) used 
capture ELISA to measure and block LPS binding to wildtype sCD14 and mutants. 
Therefore the ability of each sCD14 mutant to bind LPS was examined in a capture ELISA 
format (figure 44). 
Figure 44: LPS binding ELISA required a blocking agent 
Soluble CD14-Fc mutants or mock (non-transfected) were immobilised from supernatants 
by capture with 5μg/ml of sheep anti-human Fc for 1 h at 37°C.  Following incubation 
10µg/ml of LPS in 10% NHS or 63D3 was added to wells in triplicate and incubated at 
37°C for 1 h. The plate was washed and LPS bound was detected first with polyclonal anti-
LPS antibody then with anti-Rabbit HRP or anti-mouse HRP for 63D3 binding. OPD 
substrate was added to the plate and the optical density read at 490nm.  
 
As shown in figure 44, detectable binding of LPS in all wells, including the control 
supernatant (containing no CD14) was equivalent, suggesting a lack of specific interaction 
with CD14, under the conditions used. Due to the sticky nature of LPS, previous 
experiments conducted and studies have required a blocking agent when conducting an 
LPS ELISA. Cunningham et al.(2000) used 0.5% BSA in PBS. However a study by Péterfi 
and Kocsis (2000) compared various blocking agents for use in LPS binding ELISA 
format. The results of the study suggested normal goat serum (NGS) was the most 
effective agent at reducing non-specific binding of LPS. Taking this into consideration the 
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LPS binding ELISA was repeated and following incubation of LPS for 1 h at 37°C the 
ELISA plate was washed three times and incubated with NGS at room temperature 
overnight (figure 45). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: LPS-binding ELISA, goat serum was used as blocking agent 
Wildtype sCD14-Fc or mock transfection (control containing no CD14) were immobilised 
from supernatants by capture with 5μg/ml of sheep anti-human Fc for 1 h at 37°C.  
Following incubation the plate was blocked with 300µl of NGS at 20°C. The next day 
63D3 or 10µg/ml of LPS in 10% NHS was added to wells in triplicate and incubated at 
37°C for 1h.  Any LPS bound was detected first with polyclonal anti-LPS antibody then 
with anti-Rabbit HRP or anti-mouse HRP for 63D3 binding.  OPD substrate was added to 
the plate and the optical density read at 490nm. The data shown is the mean ± SD of 
triplicate well and is representative of four independent experiments. Statistical analysis 
was conducted using T-test. (*** P<0.001). 
 
As shown in figure 45, goat serum reduced non-specific binding of LPS to the control 
supernatant coated wells. Comparison of figures 44 and 45 suggest that incubation with 
goat serum caused an increase in LPS binding to sCD14 that was reproducible. Initially it 
was considered that the increase in signal in CD14 following the blocking stage due to the 
goat serum containing endotoxin. However following contact with Sigma Aldrich, the 
concentration of endotoxin in goat serum supplied was described as less than 5EU/ml, 
equivalent to 0.5ng/ml of LPS. This concentration of endotoxin is negligible, as it is 
1:20000 of the total of LPS added (10µg/ml). Another possible explanation considered was 
that goat serum was a second source of LBP that may have first bound CD14 then LPS 
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following incubation. As shown in figure 45, 63D3 binding to CD14 were used as a 
positive control. 
 
Given the benefits of goat serum as a blocking agent, the panel of sCD14 mutants were 
immobilised to ELISA plates and LPS binding measured (figure 46). In order to rule out 
any variation in binding as a consequence of the concentrations of each mutant, LPS 
binding results were normalised to 63D3 then wildtype sCD14. Therefore 63D3 binding 
was used as a surrogate for estimating concentration as it binds towards the C-terminus of 
CD14, away from LPS binding regions (Viriyakosol et al., 2000). However this makes the 
assumption that the confirmation of the C-terminus of each mutation remains unchanged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46: LPS-binding to sCD14 mutants 
Soluble CD14-Fc mutants were immobilised from supernatants by capture with 5μg/ml of 
sheep anti-human Fc for 1 h at 37°C.  Non-specific binding was blocked with 300μl of 
NGS and the plates were incubated with 10µg/ml of LPS in 10% NHS. Bound LPS was 
detected with polyclonal anti-LPS. The location of the single mutated residue with respect 
to the LPS binding regions of CD14 is identified as R1-4. The data shown is the mean ± 
SEM of seven independent experiments, with the OD of each mutant was first normalised 
to 63D3 binding then normalised to wildtype. Statistical analysis conducted was ANOVA 
followed by Dunnetts post test (**P<0.01 comparison to wtCD14).  
 
The results in figure 46 demonstrate that single residue mutations within the first LPS 
binding regions of CD14, significantly reduce LPS binding. Alanine replacement of 
glutamic acid (E11A) has no significant effect on LPS binding to sCD14 despite the loss of 
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charge. However a same charge mutation (E11D) and a charge reversal mutation (E11R) 
caused a significant reduction in LPS binding to E11 when compared to wtCD14. R14, 
E37 or D59 mutants analysed had no significant effect on LPS binding compared to 
wtCD14.    
5.5 MEM18 and 61D3 compete for binding to wildtype sCD14 
Devitt et al.(1998) found that 61D3 and MEM18 were CD14 mAb that competed for 
binding to CD14 and both blocked LPS responses and apoptotic cell interaction. 
Furthermore Juan et al. (1995) mapped the epitope of the MEM18 to the fourth LPS 
binding region of CD14 and reported that MEM18 and LPS compete for binding to 
residues 57-64. This suggests that a region of CD14 defined for its ability to bind LPS may 
also bind apoptotic cells. The binding of mAb 61D3 has not been mapped to CD14 using a 
point mutant approach. Here we examine that possibility that, like LPS, 61D3 also 
competes with MEM18 for binding suggesting that apoptotic cells and LPS share common 
binding sites within CD14 (figure 47).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: MEM18 and biotinylated-61D3 compete for binding to wildtype 
sCD14.Wildtype sCD14–Fc was immobilised from supernatant by capture with 5μg/ml of 
sheep anti-human Fc for 1 h at 37°C. Following incubation 100ng/ml of 61D3 (biotin) was 
added to every well then varying concentrations of unlabelled MEM18 was added and 
incubated for an h at 37°C. Biotinylated 61D3 bound to CD14 was detected with 
streptavidin-HRP for 1 h. Following incubation OPD substrate was added to the plate and 
the optical density read at 490nm. The data shown is the mean ± SD of triplicate wells and 
is representative of three independent experiments. Statistical analysis conducted was 
unpaired T-test (**P<0.01 comparison to 61D3-bio). 
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The results in figure 47 suggest that as the concentration of MEM18 increase there is a loss 
in the binding of the biotinylated mAb 61D3. This data along with previous findings by 
Juan et al. (1995) suggest that the epitopes of 61D3, MEM18 and LPS within CD14 are 
closely associated or the same. However previous data shown here has suggested that 
61D3 and MEM18 block apoptotic cell interaction therefore these data suggest that the 
epitopes of LPS and apoptotic cells are closely associated or the same. Therefore if both 
ligands (LPS and apoptotic cells) interact with the same regions of CD14 any variation in 
ligand-dependent response may be due to variation in signalling. 
 
5.6 61D3 and MEM18: Surrogate markers for apoptotic cell binding 
5.6.1 Mapping 61D3 binding to sCD14 mutants 
The N-terminal pocket of CD14 is important for LPS binding as all four LPS binding 
regions are within or clustered around the pocket (Kim et al., 2005, Cunningham et al., 
2000and Viriyakosol & Kirkand). Previously MEM18 and 61D3 have been shown to block 
both LPS responses and apoptotic cell interaction (Devitt et al., 1998), suggesting that the 
N-terminal pocket of CD14 is involved in the binding of apoptotic cells.  Therefore here 
sCD14 point mutants were used to map the binding of 61D3 and MEM18 as surrogate 
markers of apoptotic cell binding (figure 48). 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
Figure 48: Mapping 61D3 binding to sCD14 mutants 
Soluble CD14–Fc mutants were immobilised from supernatants by capture with 5μg/ml of 
sheep anti-human Fc for 1 h at 37°C. Bound sCD14 was detected with mAbs 61D3, 63D3 
as a positive control or MOPC 21 as isotype-matched control. Binding was detected with 
anti-mouse-HRP for 1h at 37°C. Following incubation OPD substrate was added to the 
** 
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** ** 
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plate and the optical density read at 490nm. The data shown is mean ± SEM of three 
independent experiments and 61D3 binding has been normalised to 63D3 then wtCD14 
binding. Statistical analysis conducted was AVOVA followed by Dunnetts post test 
(**P<0.01 comparison to wtCD14)  
 
The epitope of 61D3 is unknown but is suggested as a region of CD14 important for LPS 
and apoptotic cell binding. As previously stated 63D3 binding is considered to be 
unaffected by mutations within the C-terminus of CD14 therefore is used as a positive 
control and to standardise protein concentration. The results in figure 48 show a loss of 
61D3 binding to CD14 upon substitution of residue 11. Replacement with alanine (E11A) 
or a charge reversal mutation (E11R) results in a loss of 61D3 binding, while replacement 
with aspartic acid (E11D), another acidic residue had no effect on 61D3 binding. This 
suggests that residue 11 is a contact residue required for binding of 61D3. The results also 
show an increase in 61D3 binding to CD14 upon alanine replacement at residue 14 but not 
upon lysine replacement. This suggests that a loss of the positive charge at residue 14 
increases 61D3 binding. The data also shows replacement of glutamic acid at residue 37 
with aspartic acid or glutamine causes a loss in 61D3 binding. The results suggest that 
residue 11, 14 and 37 may be required for apoptotic cell binding however it was noted that 
a loss is 61D3 binding is caused by a change in the charge of these key residues. 
5.6.2 Mapping MEM18 binding to sCD14 
MEM18 is reported to bind to CD14 between residue 57 and 64, defined as the fourth LPS 
binding region of CD14 (Juan et al., 1995a). Previous result here have shown that MEM18 
and 61D3 compete for binding to CD14 therefore suggesting that the epitopes are within 
close proximity. Here MEM18 binding was mapped to sCD14 mutants as a surrogate 
marker of apoptotic cell binding to CD14 (figure 49). 
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Figure 49: Mapping MEM18 binding to sCD14 mutants 
Soluble CD14–Fc mutants were immobilised from supernatants by capture ELISA with 
5μg/ml of sheep anti-human Fc for 1 h at 37°C. Bound sCD14 was detected with mAbs 
MEM18, 63D3 as a positive control or MOPC 21 as negative control. Binding was 
detected with anti-mouse-HRP for 1 h at 37°C. Following incubation OPD substrate was 
added to the plate and the optical density read at 490nm. The data shown is mean ± SEM 
of three independent experiments where the OD of MEM18 binding has been normalised 
to 63D3 and then wtCD14. Statistical analysis conducted was ANOVA followed by 
Dunnetts post test (**P<0.01 comparison to wtCD14) 
 
MEM18 bound all E11, R14 and E37 mutations suggesting that none of the mutations 
cause a detrimental conformation change within the protein to prevent binding (unlike 
61D3). A loss of MEM18 binding was observed upon mutation of residue 59 as previously 
reported (Juan et al., 1995a) and suggests this residue is required for apoptotic cell binding 
to CD14. However both alanine and asparagine have no overall charge, unlike aspartic 
acid, emphasising the importance of the negative charge at position 59 required for 
MEM18 binding.  
5.7 LPS-like structures on the surface of apoptotic cells 
The first, third and fourth LPS binding regions of CD14 are located on the same surface of 
N-terminal pocket. This region is rich in electrostatic charges that are considered to 
facilitate the capture of CD14 ligands (Cunningham et al., 2000).  The data above supports 
the suggestion that CD14 employs charged residues to interact with apoptotic cells and 
LPS. Due to similarities in binding patterns identified it was considered that apoptotic cells 
may have LPS-like structures on the surface that are recognised by CD14 (Gregory and 
** ** 
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Devitt, 2004). Therefore induced and non-induced cells were examined for LPS-like 
structures using indirect immunofluorescence staining with polyclonal anti-LPS antibodies 
and analysed by flow cytometry (figure 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50:  Analysis of LPS-like structures on the surface of apoptotic cells 
Mutu were induced to undergo apoptosis by exposure to UV radiation and incubated 
overnight (induced). Plasma membrane integrity of both non-induced (green) and induced 
(blue) cells was assessed with propidium iodide staining (PI-staining) and histograms 
overlaid. Both non-induced and induced cells were analysed for LPS-like patterns on the 
surface (α-LPS-staining), with indirect immunofluorescence using anti-LPS polyclonal 
antibody (green/blue) or normal Rabbit serum (grey). Following staining of induced cells, 
a second peak was observed and a region denoted by a single green line was drawn to 
calculate the % gated and mean fluorescence intensity of the population shown in the top 
right of each histogram. This data is representative of four independent experiments.  
 
Following UV treatment and incubation overnight, apoptosis was assessed by flow 
cytometry and the results suggest that 68% of the cells induced to undergo apoptosis, have 
increased in side scatter and decreased in electronic volume. Apoptosis was also assessed 
using the vital dye, propidium iodide (PI), which upon entry into cells, intercalates with 
DNA and was therefore used to assess plasma membrane integrity. Live cells and early 
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apoptotic cells have an intact plasma membrane and therefore are considered PI negative, 
however later stages of apoptosis causes loss of plasma membrane integrity and therefore 
the cells become PI positive.  The PI staining results in figure 50 suggest that non-induced 
cells did not stain with PI indicating an intact plasma membrane. While induced cells 
stained with PI produced a peak suggesting that the plasma membrane of these cells was 
not intact therefore confirming that these cells were within the later stages of apoptosis. 
Both induced and non-induced cells were then stained with anti-LPS antibodies or rabbit 
serum as a negative control. The non-induced cells increased in fluorescence when stained 
with anti-LPS antibodies compared to rabbit serum suggesting binding. However two 
populations of cells were identified following staining of apoptotic cells with anti-LPS 
antibodies.  The first population corresponded to the population seen when non-induced 
cells were stained with anti-LPS antibodies but the second population were more 
fluorescent.  The results support findings by Tennant. (2005) that following apoptosis, cells 
demonstrated an increased ability to bind anti-LPS antibodies and therefore those apoptotic 
cells may share common epitopes with LPS.  
5.8 Mapping apoptotic cell binding to soluble CD14 mutants 
Devitt et al.(2004) found that sCD14 bound to apoptotic cells, therefore sCD14 point 
mutants was considered to map the binding of apoptotic cells. Here apoptotic Mutu were 
stained with soluble wtCD14-Fc and binding detected by flow cytometry (figure 51). 
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Figure 51: Analysis of apoptotic cells stained with wildtype sCD14-Fc  
Mutu were induced to undergo apoptosis with UV treatment and incubated overnight prior 
to immunofluorescence staining. Cells were gated based on side scatter and electronic 
volume as shown above (R1/R2). Induced cells were incubated with supernatant from 
HEK293 transfected with soluble WtCD14-Fc (orange) or mock (no DNA) (blue) or wash 
buffer (grey) for a minimum of 30 min on ice. A) Cell bound-Fc was detected with anti-
human FITC for 30 min on ice. B) Prior to the addition of (goat) anti-human FITC cells 
were washed twice with 5% NGS in PBS to reduce non specific binding. 5000 events 
within the gated region R1 were analysed for surface bound sCD14-Fc and the mean 
fluorescence intensity of each peak is shown on top right of the overlays.  
 
This was first attempted by simply incubating apoptotic cells with supernatant harvested 
from HEK293 transfected with sCD14-Fc plasmid or no DNA (mock) (figure 51A). The 
flow cytometric results suggest that there was limited sCD14 bound to apoptotic cells, 
however there was also a significant amount of non-specific binding of anti-human FITC. 
Therefore following staining of apoptotic cells with sCD14 or mutants, cells were washed 
in 5% NGS prior to addition of anti-human Fc FITC in an attempt to reduce non-specific 
binding (figure 51B). Comparison of the flow cytometric results (figure 51) shows that the 
log fluorescence intensity of induced cells stained with sCD14-Fc was reduced following 
washing with 5% goat serum. Therefore it was decided that incubation with 20% goat 
serum for 15 minutes at 4 °C prior to incubation with sCD14 may be required to further 
reduce non-specific binding of (goat) anti-human-FITC (figure 52). 
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Figure 52: Mapping apoptotic cell binding with soluble CD14 mutants 
A. Mutu was induced to undergo apoptosis with UV treatment and incubated overnight 
prior to immunofluoresence staining. Cells were gated based on side scatter and electronic 
volume as shown above (R1). Induced cells were incubated with 20% goat serum prior to 
incubation with sCD14 mutants (orange) or mock supernatant (blue)(taken from HEK293 
transfected with no DNA) for 30 min on ice. Following incubation cells were washed twice 
with 5% goat serum then incubated with (goat) anti-human FITC. 5000 events within R1 
were analysed for surface bound sCD14-Fc, only wildtype sCD14-Fc shown above and the 
mean fluorescence intensity of wtCD14-Fc is shown in top right of the overlay. B. Having 
successfully shown that wildtype sCD14-Fc bound to apoptotic cells, the sCD14 point 
mutants were used to map apoptotic cell binding. In order to compare the level of binding 
of each sCD14 mutants to apoptotic cells, the percentage of positive cells were normalised 
to wildtype sCD14-Fc. The results shown are the mean ± SD of two independent 
experiments. 
 
 
Devitt et al.(2004) found that sCD14-Fc bound to apoptotic cells, therefore sCD14 mutants 
were considered, to map apoptotic cell binding to CD14. However due to the level of non-
specific binding of (goat) anti-human Fc-FITC to apoptotic cells, binding of sCD14-Fc was 
obscured. Previously apoptotic cells were washed with 5% goat serum prior to incubation 
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with anti-human Fc-FITC to reduce non-specific binding. The results suggest that this 
treatment alone was insufficient to reduce non-specific binding therefore prior to 
incubation with sCD14-Fc the cells were pre-incubated with 20% goat serum and all 
washes were conducted with 5% goat serum. The flow cytometric results shown in figure 
52 suggested that pre-incubating the cells with 20% goat serum reduced non-specific 
therefore binding of sCD14-Fc to cells was shown. Having established that wildtype 
sCD14-Fc bound to apoptotic cells, the level of binding of  each CD14 point mutant was 
compared in an attempt to map apoptotic cell binding to CD14 (figure 52B). As shown in 
figure 52B the binding of wildtype and mutant sCD14-Fc to apoptotic cells varied each 
time the experiment was conducted. Therefore this could suggest that all sCD14 point 
mutations analysed, with the exception of R14K affected apoptotic cell binding to sCD14. 
However the level of R14K binding to apoptotic cells seemed persistently high suggesting 
that this mutation had no effect on apoptotic cell binding to sCD14. 
5.9 Discussion 
CD14 is well characterised for its ability to bind LPS and promote inflammation (Wright et 
al., 1990, Ulevitch and Tobias, 1999).  Mutagenesis studies and mAb mapping have 
identified four regions within the first 65 amino acids of CD14 that are required for LPS 
binding and responses (Viriyakosol and Kirkland, 1995, Juan et al., 1995a, Stelter et al., 
1997, Shapiro et al., 1997 & Cunningham et al., 2000). The sequence alignment of human 
and mouse CD14 shared 67% homology and function the same in terms of LPS response 
(Haziot et al., 1996) and apoptotic cell clearance (Devitt et al., 2004). While the crystal 
structure of human CD14 is unknown, the crystal structure of mouse CD14 has identified a 
large hydrophobic pocket within the N-terminus which contains all four LPS binding 
regions. The crystal structure of CD14 developed by Kim et al.(2005) identifies the first, 
third and fourth LPS binding region of CD14 as being located on the same side of the 
pocket, within close proximity. Furthermore each of the LPS binding regions is 
predominantly composed of hydrophilic residues exerting an overall negative charge.  
Therefore the pocket is considered to display several charged residues to non-specifically 
capture LPS (Cunningham et al., 2000).  
 
While apoptotic cell binding to CD14 has not been previously mapped, previous work by 
Devitt et al.(1998), found that mAb 61D3 and MEM18 blocked both LPS responses and 
apoptotic cells interaction. This implies that the same regions of CD14 may be involved in 
both LPS and apoptotic cell binding and are capable of producing contrasting macrophage 
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responses. Therefore here a series of sCD14 point mutants were used to map LPS and 
apoptotic cell binding, in order to understand the mechanistic differences underlying the 
response of CD14 to PAMPs and ACAMPs. 
5.9.1 Mapping LPS binding to sCD14 
The sCD14 point mutants were first used to map LPS binding and the results were 
supported by previous findings that mutations within the four LPS binding regions of 
CD14 reduced LPS binding (Cunningham et al., 2000, Juan et al., 1995b and Stelter et al., 
1997). The first LPS binding region of CD14 spans residues 9-12 with the amino acid 
sequence DDED. Due to the acidic nature of aspartic and glutamic acid, this region is 
hydrophilic and predominantly negatively charged. Alanine replacement of glutamic acid 
(DDAD) has no significant effect on LPS binding to sCD14 despite the loss of charge. This 
is probably due to the small, uncharged nature of alanine being masked by the surrounding 
acidic residues exerting a dominant negative charge. However the results suggest that 
glutamic acid within this position is significant, as a same-charge replacement with 
aspartic acid; (DDDD) causes a reduction in LPS binding.  Glutamic acid and aspartic acid 
are amino acids with acidic side chains (table 2) that vary in length by one carbonyl group.  
Glutamic acid has a slightly longer side chain than aspartic acid, suggesting that this 
residue may protrude from this highly negative region of CD14, possibly to capture LPS.  
Replacement with arginine (DDRD) is a charge-reversal mutation and this has the greatest 
effect on LPS binding causing a significant loss in binding.  Arginine is a basic residue but 
is of the same length as glutamic acid. It is likely that arginine has disrupted the negative 
charge and possibly the conformation of this region of CD14. The data shown here is 
consistent with previous data by Juan et al. (1995) that reported mutations within this 
region of CD14 impair the ability of LPS to mediate cellular responses suggestion that 
residues, 9-12 are required for LPS signalling.  As with this study, most of the previous 
work done by other groups used soluble CD14 therefore this region may simply be 
important for the transfer of LPS to cell membrane CD14. 
 
Residue 14 lies in close proximity to the first LPS binding region of CD14 therefore any 
mutation of this residue may affect the surrounding LPS binding site. However the results 
demonstrate that alanine or lysine replacement had no significant effect on LPS binding. 
Both alanine and lysine have side groups that are shorter than arginine suggesting that a 
loss of charge or a reduction in dimension of this residue has no effect on the surrounding 
LPS binding regions. After considering the crystal structure of CD14 (figure 43) it is likely 
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that due to the location of residue 14, away from the surface of CD14 that contains most of 
the LPS binding regions, that it has no effect on LPS binding. This theory could be further 
examined by using a charge reversal mutation within this region, as charge reversal 
mutations are known to have the most significant effects. 
 
The third proposed LPS binding region (AVEVE), spans residue 35-39, is located on the 
same surface of the pocket as the first and fourth LPS binding regions. These regions share 
similar properties with region one, as both are hydrophilic with an overall negative charge.  
Residue E37 upon replacement with aspartic acid, another acidic residue with a slightly 
shorter side chain causes a slight (but not significant) increase in LPS binding.  However 
replacement with glutamine, an uncharged residue of the same length at native residue, 
causes a slight reduction in LPS binding. This may suggest that the charge at residue 37 is 
required for LPS binding and a loss of a carbonyl group protruding into this region 
facilitates LPS binding. 
 
The fourth LPS binding region of CD14 spans residues 57-63 and is located on the same 
side of the N-terminal pocket as regions one and three. However residue 59 is located on 
the loop of the pocket considered as the rim of the pocket. The amino acid sequence 
DADPROY in this region is predominantly amphipathic like LPS (Juan et al., 1995). The 
data suggests that alanine replacement at residue 59 has no effect on LPS binding while 
asparagine replacement caused a slight (but not significant) reduction in LPS binding. Both 
alanine and asparagine are neutrally charged amino acids therefore a loss of the charge at 
residue 59 does not prevent LPS binding. Asparagine and glutamic acid are of similar 
length, however glutamic acid is negatively charged, suggesting that the negatively 
charged side group may be required to capture LPS. To further this study a charge reversal 
mutation at position 59 may assist in determining the importance of this residue within this 
LPS binding region of CD14. 
 
Collectively these data support previous work by Cunningham et al.(2000) and suggests 
that it is the tertiary structure of the N-terminal pocket of CD14 that is important for LPS 
binding, with many hydrophilic resides within these regions interacting with LPS.  The 
crystal structure suggests that the first, third and fourth LPS binding region of CD14 are 
located on the same surface of the pocket also suggested by Cunningham et al. (2000). 
Therefore it is possible that due to the close proximity of these negatively charged regions; 
CD14 displays several charged regions on one surface of protein to bind LPS. 
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 Lipid A is a highly conserved portion of LPS that is responsible for the biological activity 
of LPS. Lipid A is an amphipathic molecule that consists of six hydrophobic C12-C14 
fatty acids chains linked to a hydrophilic phosphorylated D-glucosamine disaccharide head 
group. Considering the hydrophobic nature of lipid A it would be predicted that a 
positively charged hydrophobic region of CD14 would be used to capture LPS. However a 
study by Rietschel et al.(1994) examined the relationship between the molecular structure 
and function of LPS and found that changing the hydrophilic backbone of lipid A reduced 
the ability of LPS to bind to monocytes and macrophages. The results suggested that while 
the hydrophobic region of lipid A was central to the activation of cells, it was the 
hydrophilic backbone of lipid A that was required for binding. Rietschel et al. (1994) 
found that deacylated LPS was inactive and removal of 1 or 4 phosphate groups on 
diglucosamine head group also reduced LPS binding. Darveau et al.(1998) along with 
Cunningham et al.(1999,2000) described the low biological activity of LPS from 
P.gingivalis and H.pylori. Cunningham et al.(2000) described how the binding 
characteristic of LPS varied depending on the structure of LPS, suggesting that LPS from 
P.gingivalis is less potent than from E.coli due to the absence of a ester-linked phosphate 
group at position 4 on diglucosamine head group of lipid A. Furthermore  Coats et al. 
(2011) found that phosphate position of lipid A determined TLR4 response to LPS. Taken 
together these findings suggest that the LPS binding site of CD14 is a conformational 
epitope composed of several hydrophilic regions though the N-terminal pocket. This is 
consistent with previous findings by others (Cunningham et al., 2000, Viriyakosol and 
Kirkland, 1995 & Stelter et al., 1997) therefore suggesting that LPS interacts with several 
charged residues in a non-specific manner as found with other PRR such as the scavenger 
receptor (Krieger et al., 1993).  
5.9.2 MEM18 and 61D3, surrogate markers of apoptotic cell binding 
Given the suggestion that MEM18 and 61D3 compete for binding to the same regions of 
CD14 (figure 47) and block both LPS responses and apoptotic cell interaction here we 
sought to map the binding of 61D3 and MEM18 to sCD14 mutants. 61D3 mapping data 
suggests that residue 11, within the first LPS binding region of CD14 is a contact residue 
required for 61D3 binding. Comparison of 61D3 binding with LPS binding data may 
suggest that a loss of the charge at residue 11 cause a reduction in 61D3 binding but not 
LPS binding.  Whist the charge of residue 11 predetermines 61D3 binding and possibly 
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apoptotic cell binding, it is the effects of the three dimensional changes induced by the side 
groups that may affect LPS binding. 
 
Analysis of the crystal structure (figure 43) suggests that residue 14 is away from the 
surface of the protein used to capture ligands and therefore mutation of this residue did not 
affect LPS binding.  However 61D3 mapping suggests that a loss of the positive charge at 
residue 14 increases 61D3 binding, while LPS binding data suggests that alanine or lysine 
replacement of residue 14, has no effect on LPS binding. Taken together this may suggest 
that while R14 is not required for LPS binding it may facilitate 61D3 binding and possibly 
apoptotic cell binding to CD14. 
 
Glutamic acid at residue 37 is within the third LPS binding region of CD14 and 
replacement with aspartic acid or glutamine causes a loss in 61D3 binding. Glutamine has 
a similar structure to glutamic acid however it contains a carboxylic acid group, while 
glutamine contains an amine group giving the residue an overall neutral charge. Aspartic 
acid causes a loss in 61D3 binding but an increase in LPS binding which may suggest that 
the protruding negative charge is required for 61D3 binding and possibly apoptotic cells 
but not LPS. However these data may suggest that it is predominantly the charge that 
effects 61D3 binding, while the three dimensional shape of these region predetermines the 
effects on LPS binding. Furthermore the loss of the negative charge at residue 59 also 
caused a loss in MEM18 binding. While comparison with LPS binding suggested that the 
change is charge at residue 59 was not sufficient to inhibit LPS binding. Collectively this 
may simply suggested that mAb are more sensitive to changes in charge of the epitope 
rather than a change in three-dimensional shape of the LPS binding regions. 
 
61D3 mapping data suggests that the epitope of mAb 61D3 is within the first LPS binding 
region of CD14. While MEM18 binding was previously mapped to the fourth LPS binding 
region of CD14 (Juan et al., 1995). With respect to competition for binding to CD14, 
antibodies have a molecular weight of approximately 150kDa in comparison to CD14 with 
a molecular weight of 55kDa. Therefore it may be that the binding of 61D3 to the first LPS 
binding region of CD14, sterically hinders the binding of MEM18 to the fourth LPS 
binding regions, due to the close proximity of these regions within the N-terminal pocket 
of CD14. This suggests that 61D3 and MEM18 inhibit LPS interaction by blocking the 
first and fourth LPS binding region of CD14. As surrogate markers of apoptotic cell 
binding, these data suggests that residues 11 and 59 may be required for apoptotic cell 
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binding. Therefore if apoptotic cells and LPS-binding sites have a common conformational 
epitope within CD14, any variation in macrophages response may be due to interaction 
with differing residues within that conformational epitope. However if both ligands (LPS 
and apoptotic cells) are only tethered by CD14 it may be the patterns displayed, once 
bound to CD14 that employ the signalling partners that are responsible for the ligand-
dependent response produced. 
5.9.3 Mapping apoptotic cell binding with sCD14 
Considering findings that suggest both LPS and apoptotic cells share common binding site 
within CD14 it was suggested that apoptotic cells expose surface patterns similar in 
structure to LPS. This suggestion was supported by Gregory & Devitt (2004) that 
suggested apoptotic cells have patterns on the surface that resemble the three dimensional 
shape of LPS.  Apoptotic cells, like pathogens are considered to present three dimensional 
motifs at the surface, termed apoptotic-cell-associated molecular patterns (ACAMPS) 
(Franc et al., 1999 & Gregory et al., 2000). ACAMPs are considered to share structural 
homologies with PAMPs and DAMPs and are recognised by PRR (Savill et al., 2002 & 
Gregory and Devitt, 2004). In the case of CD14, Gregory and Devitt (2004) speculate that 
ACAMPs recognised by CD14 are LPS-like. Following immunofluorescence staining of 
apoptotic cells with LPS-polyclonal antibodies the data here suggested that the three-
dimensional patterns displayed by LPS and apoptotic cells are the same. This may support 
the suggestion that CD14 uses the closely associated or the same region to capture both 
ligands and may suggest that CD14 function as a tethering receptor for both ligands. 
Therefore it may be the signalling partners within the local region that recognise the 
patterns displayed by CD14 in order to promote macrophage responses.  Alternatively 
specific residues within these common ligand-binding regions of CD14 may be responsible 
for recruiting the signalling partners following ligand (LPS or apoptotic cell) binding. 
 
Previously Devitt et al.(2004) found that sCD14-Fc bound to apoptotic cells, therefore here 
sCD14 and point mutants was considered to map apoptotic cell binding to CD14. 
Supernatant taken from HEK293 transfected with sCD14-Fc plasmid was used as a source 
of sCD14-Fc to stain apoptotic cells. However the ability of sCD14 to bind to apoptotic 
cells was inconsistent and due to the level of variation no significant differences in the 
binding of apoptotic cells to CD14 point mutants was observed.  Any variation in the 
binding of sCD14-Fc could be a result of varying batch and possibly concentration.  
However when considering CD14 binding to LPS in vivo, CD14 is considered to cluster 
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within lipid raft at the cell surface and form a dimer (Kim et al., 2005, Pfeiffer et al., 2001, 
Triantafilou et al., 2002). Therefore variation in binding may be due to lack of CD14 
clustering however due to the Fc regions present, it is possible that sCD14-Fc may form a 
dimer in solution. CD14 may need to aggregate and form clusters to bind and possibly 
tether apoptotic cells, like membrane-bound form. Therefore in order to map the binding of 
CD14 to apoptotic cells, making each of the sCD14 point-mutants membrane-bound was 
considered. 
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Results 4: Mapping apoptotic cell binding to mCD14 
6.1 Introduction 
LPS binding studies coupled with mutagenesis have identified four regions of CD14 
(figure 43) required for LPS binding (Juan et al., 1995a, Juan et al., 1995b, Stelter et al., 
1997, and Cunningham et al., 2000), while apoptotic cell binding to CD14 has not been 
mapped. Previous data has shown that 61D3 and MEM18 block both LPS responses and 
apoptotic cell binding (Juan et al., 1995a, Devitt et al., 1998). Furthermore data here has 
shown that 61D3 and MEM18 compete for binding to CD14 which suggests that both 
apoptotic cells and LPS bind to the same or closely associated regions of CD14. 61D3 and 
MEM18 were used as surrogate markers, to map apoptotic cell binding to sCD14 point-
mutants.  The data suggested that residues E11, and D59 of CD14 may be required for 
apoptotic cells and LPS binding. Furthermore apoptotic cells have been suggested to 
display cell surface markers, termed ACAMPs that share common structural homologies 
with PAMPs therefore allowing phagocyte to recognise and engulf dying cells. Previous 
data here suggests that apoptotic cells display LPS-like patterns at the surface that may be 
recognised by CD14. This implies that three-dimensional patterns displayed by LPS and 
apoptotic cells are, to some degree, similar and both ligands therefore may bind to the 
same regions of CD14.  If LPS and apoptotic cells interact with the same regions of CD14, 
it suggests that CD14 functions as a tethering molecule. Consequently any variation in 
response would most likely be caused by interaction with different signalling partners. 
However if both ligands display LPS-like pattern then apoptotic cell ligation with CD14 
may also result in the activation of an inflammatory signalling pathway. While interaction 
with another phagocyte receptor, such as Mer may produce a dominant anti-inflammatory 
signal that intercepts, the inflammatory signalling and reprograms phagocyte response. 
 
Alternatively apoptotic cells may interact with different residues within the LPS binding 
regions of CD14. This idea is supported by findings by Darveau et al.(1998) and 
Cunningham et al.(1999,2000) that reports that the low biological activity of some species 
of LPS is dependent on slight variations in the structure of LPS. Cunningham et al.(1999) 
suggested that LPS from P.gingivalis is less potent than E.coli due to the absence of an 
ester-linked phosphate group at position 4 on the diglucosamine head group of lipid A. 
This was also supported by a previous study by Coats et al. (2011) that found that the 
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phosphate position of lipid A determined the TLR4 response to LPS.  Therefore any 
variation in the residues within CD14 that LPS and apoptotic cells interact with may result 
in activating inflammatory or anti-inflammatory signalling pathways. However due to the 
limitations posed by sCD14 in section 5.8 the mutations were expressed as membrane-
bound CD14. Therefore having generated membrane versions of all the CD14 point 
mutants the aim of this chapter was to map apoptotic cells binding in order to identify 
key residues in CD14 required for the binding of apoptotic cells.  
6.2 Expressing the mCD14 mutants 
Gene transfection efficiency is often dependent on cell type, with epithelial cells regarded 
as being easily transfectable, while myeloid cells in particular are more difficult to 
transfect (Dokka et al., 2000, Schnoor et al., 2009). Myeloid cells are resistant to 
transfection due to their viral-defence and high levels of DNAases (Dokka et al., 2000).  
However with the aim of trying to map apoptotic cell binding and LPS responses to CD14, 
myeloid cells were first considered as CD14 would be expressed within a normal situation 
with the required signalling partners. 
6.2.1 THP-1 
THP-1 are a human monocyte cell line that has been previously characterised for their LPS 
responsiveness (section 3.3.1) and ability to bind and clear apoptotic cells (section 3.3.5). 
Furthermore cell surface expression of CD14 was undetectable on THP-1 by flow 
cytometry, therefore THP-1 transfection was considered. However THP-1 are difficult to 
transfect and transfection is often reported to result in a loss of viability and functionality 
(Schnoor et al., 2009). Where gene transfection in monocytes is successful, it is known to 
produce low transfection efficiencies and be highly toxic to the cell or induce maturation 
(Dokka et al., 2000).  Data here has shown that maturation of THP-1 produces 
macrophage-like cells that express surface CD14. Dokka et al.(2000) compared several 
methods of transfecting monocytes and macrophages and found that lipofectAMINE was 
the most effective method of gene transfection assessed. 
 
LT1 was previously used within this study and found to be an effective and efficient 
method of transfecting cells, which is non-toxic.  As a preliminary experiment LT1 was 
used to transfect THP-1 with a reporter plasmid, expressing GFP and cell-associated 
fluorescence was determined by flow cytometry (figure 53). The spontaneous 
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differentiation of THP-1 following transfection was monitored by assessing cell surface 
CD14 expression. 
 
    
 
 
 
 
 
 
 
 
 
 
 
Figure 53: LT1-mediated transfection THP-1 with GFP 
A. THP-1 was transfected with 2µg GFP reporter plasmid (green) or no DNA (grey) using 
LT1. 48 h following transfection cells were analysed by flow cytometry for any increase in 
FL1 fluorescence. (Mean fluorescence intensity of total population shown). B. Cell surface 
expression CD14 on GFP or mock (no DNA) transfected THP-1 was also assessed using 
indirect immunofluorescence staining with mAb 63D3 (orange) or MOPC 21 (blue) as 
isotype-matched control and secondary antibody, anti-mouse PE detected on FL2. This 
data shown is representative of two independent experiments. 
 
GFP is frequently used as a reporter for protein expression as it is easily detectable using 
flow cytometry. The mean fluorescence intensity shown in figure 53 suggests a very slight 
increase in fluorescence of THP-1 transfected with GFP when overlaid with mock 
transfected cells (mock MFI=6.41 Vs GFP MFI=12.32). The effects of transfecting THP-1 
with foreign DNA was considered, as differentiation of THP-1was previously shown to up-
regulate CD14 expression. Therefore the spontaneous differentiation of THP-1, following 
transfection was assessed by assessing cell surface expression of CD14. The results in 
figure 53b suggests that transfection of THP-1 with GFP had no effect on cell surface 
expression of CD14. Overall the data in figure 53 suggest that THP-1 cells were 
successfully transfected and did not induce differentiation. Unfortunately the transfection 
efficiency was very low and whilst optimisation was considered, a more transfectable cell 
system was used. Also THP-1 are semi-adherent therefore the use of these cells in binding 
assays would have been difficult to undertake.  
6.2.2 COS-1  
Previously Devitt et al.(1998) transiently transfected COS-1 cells with mCD14 and 
observed an increase in interaction and phagocytosis of apoptotic cells, first implicating 
CD14 in apoptotic cell clearance. COS-1 cells are readily transfectable and have 
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previously been used to study CD14 function therefore here optimisation of transfection 
was sought. 
6.2.2.1 DEAE-Dextran transfection 
In order to optimise transfection efficiency, COS-1 was transiently transfected with a GFP 
reporter plasmid using DEAE-dextran-method of transfection at a range of co-incubation 
times. 24 hours following transfection cells were analysed by flow cytometry for any 
increase in fluorescence (figure 54). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54: Optimising DEAE-dextran-mediated transfection of COS-1 
COS-1 was transfected with 2µg of GFP reporter plasmid (green) or no DNA (grey) using 
DEAE-dextran transfection method. Cells were incubated in DEAE-dextran transfection 
mixture for 2, 3 or 4 h as indicated at 37°C before recovery in cDMEM for 24 h prior to 
analysis of GFP expression by flow cytometry. The percentage of cells and the mean 
fluorescence intensity of the positive gated cells are shown. 
 
The results in figure 54 suggest that COS-1 have been transfected following incubation for 
two, three and four hours. However the results suggest that incubating the transfection mix 
with COS-1 for 2 hours was the most efficient method. Generally the transfection 
efficiencies were low and therefore it was decided to seek alternative methods of 
transfecting COS-1. 
6.2.2.2 LT1-mediated transfection 
An alternative technology that has been widely used for transfecting cells producing high 
transfection efficiencies was transfection reagent LT1. Therefore COS-1 was transfected 
with 2µg of GFP using LT1 at various ratios in order to find the highest transfection 
efficiency (figure 55). 
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Figure 55: Optimising LT1-mediated transfection of COS-1 
COS-1 were seeded at 3x10
5
cells/well in 6 well plates overnight prior to LT1-mediated 
transfection of 2µg of GFP reporter plasmid (green) using the indicated ratios of LT1 to 
DNA, to establish the optimum transfection efficiency. As a negative control COS-1 cells 
were also transfected with no DNA (grey) using only 3µL of LT1. 24 h following 
transfection, the cells were analysed, using flow cytometry for any increase in 
fluorescence. The percentage of cells and the mean fluorescence intensity of the positive 
gated cells are shown. Mock 2.08% MFI: 20.88 
 
The flow cytometry results in figure 55 suggest that COS-1 are readily transfected with 
LT1 and produced high transfection efficiency particularly when used at the ratio of 
2µg:4µL of LT1 to DNA. In light of this result, LT-1 at 2µg:4µL of DNA was used to 
transfect COS-1 with wildtype mCD14. The transfection efficiency and expression levels 
of mCD14 were assessed using indirect immunofluorescence with mAb 63D3 (figure 56). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: LT1-mediated transfection of COS-1 with mCD14 
COS-1 was transfected with no DNA (Mock), mCD14 or reporter GFP (green) using LT1-
mediated transfection method. 24 hs following transfection COS-1 was analysed for any 
increase in fluorescence (A) or an increase in cell surface expression of CD14 (B) with 
mAbs 63D3 (red) or as isotype-matched control MOPC 21 (grey). These results are 
representative of three independent experiments. 
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The results in figure 56B suggest the percentage of COS-1 that had been successfully 
transfected with wildtype mCD14 was reproducibly low. Furthermore Devitt et al.(1998) 
reported that COS-1 transfected with CD14 were not as efficient at apoptotic cell clearance 
compared to macrophages. Therefore due to low expression levels of CD14 and poor 
interaction with apoptotic cells, COS-1 was considered unsuitable. 
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6.2.3 HeLa  
The human cervical epithelial cell line, HeLa had previous been used within our research 
group and are easily transfected with the transfection reagent LT1, producing very high 
transfection efficiencies. Subsequent data (figure 38) also suggested that HeLa interact 
with apoptotic cells in a CD14-independent manner. Therefore in order to map the binding 
of apoptotic cells to mCD14, HeLa were transfected with mCD14 mutants and expression 
assessed using indirect immunofluorescence staining with mAb 63D3 (figure 57). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57: Flow cytometric analysis of HeLa transfected with mCD14 mutants 
HeLa was transfected using LT1-mediated transfection with A. wildtype or mutant 
mCD14, B. reporter plasmid expressing GFP or C. no DNA (mock). 24 h following 
transfection, cell surface expression of CD14 was assessed on HeLa cells transfected with 
mCD14 and mutants using indirect immunofluorescence staining with the mAb 63D3 
(green) or isotype-matched control MOPC 21 (grey). B. HeLa was transfected with GFP 
reporter to assess transfection efficiency and compared to mock (blue). The results are 
representative of three independent experiments. 
B) GFP C) Mock 
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Flow cytometric results (figure 57) demonstrate the successful transfection and subsequent 
expression of all mCD14 mutants.  The mAb 63D3 binds to the C-terminus of CD14 
(Viriyakosol et al., 2000), away from the mutated N-terminal sites therefore this mAb was 
used to verify expression.  Following transfection, a bimodal distribution of HeLa was 
evident, which varied in the level of CD14 expressed and the populations are described as 
CD14 low or CD14 high. However a bimodal distribution was also observed following 
transfection with the reporter GFP plasmid suggesting that the distribution is not dependent 
on gene expression. It is likely that subpopulations produced by HeLa following 
transfection are caused by two heterogeneous strains which vary in the phase of the cell 
cycle. This may suggests that during a particular phase of the cell cycle HeLa may be more 
transfectable. Another possible explanations for the difference in protein expression 
between subpopulations of HeLa may include variations in the uptake of DNA, activity of 
enzymes used to replicate plasmid DNA or protein trafficking. 
6.3 MEM18 and 61D3: surrogate markers of apoptotic cell binding 
The N-terminal pocket of CD14 is known to contain all four regions required for LPS 
binding (Viriyakosol and Kirkland, 1995, Cunningham et al., 2000, Kim et al., 2005). Juan 
et al.(1995) found that residues 57-64 of CD14 were required for MEM18 binding and 
LPS responses, currently considered as the fourth LPS binding region of CD14.  
Previously Devitt et al.(1998) showed that both mAbs 61D3 and MEM18 blocked LPS 
responses and apoptotic cell interaction with macrophages, suggesting that the same or 
closely associated regions of CD14 interact with both ligands. MEM18 and 61D3 have 
been mapped to sCD14 as surrogate markers of apoptotic cell binding and data here has 
suggested that residues E11 and D59, within the first and fourth LPS binding regions of 
CD14 may be required for apoptotic cell binding. Therefore here we attempt to map the 
binding of these two mAbs, as surrogate markers for LPS and apoptotic cell binding, to 
membrane-bound CD14 using a panel of CD14 point mutants. 
6.3.1 Mapping 61D3 binding to mCD14 
As previously stated, the epitope of 61D3 is unknown but a major part of this epitope is 
considered to involve residue 11 of CD14 (figure 48), located within the first LPS binding 
region. 63D3 is known to bind towards the C-terminus (Viriyakosol et al., 2000) of CD14 
and previous findings (figure 57) have shown that 63D3 binding is unaffected by mutations 
at the N-terminus. Previously HeLa, following transfection were shown to express 
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wildtype mCD14 or mutants, therefore transfectants were used to map the binding of 
61D3, as a surrogate marker of apoptotic cell binding to membrane CD14 (figure 58). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: Mapping 61D3 binding to HeLa transfected with mCD14 mutants 
HeLa were transfected using LT1-mediated transfection with wildtype or mutant mCD14. 
24 h following transfection, cell surface expression of CD14 was assessed using indirect 
immunofluorescence staining with mAbs 61D3 (red), 63D3 (green) or isotype-matched 
control MOPC 21 (grey). Binding was detected using flow cytometry and the results are 
representative of four independent experiments. The locations of the amino acid residues 
with respect to the LPS binding regions of CD14 are shown. Residue R14 is not labeled as 
this residue is outside the first LPS binding region. 
 
The flow cytometric results (figure 58) show that all transfectants express membrane 
wtCD14 or mutants at the cell surface as denoted by 63D3 binding.  With respect to 61D3 
binding, substitution of glutamic acid at position 11 for aspartic acid had no overall effect 
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on 61D3 binding. However alanine replacement (E11A) caused a reduction in 61D3 
binding supporting the requirement of a negatively charged region for antibody binding. 
This is further demonstrated when glutamic acid is substituted for arginine, which has an 
overall positive charge, resulting in a complete loss of 61D3 binding. The flow cytometric 
data also suggests that mutations R14A and R14K also cause a slight reduction in 61D3 
binding when compared to wildtype CD14. Furthermore E37 an D59 mutations analysed 
had no effect on 61D3 binding to CD14. This data supports previous findings, that the first 
LPS binding region of CD14 is required for 61D3 binding and possibly apoptotic cell 
binding.  
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6.3.2 Mapping MEM18 binding to mCD14 
Previous studies have identified the requirement of residues 57-64; within the fourth LPS 
bind region, for MEM18 binding (Juan et al., 1995a and Juan et al., 1995b). However 
previous data (figure 47) suggested MEM18 and 61D3 compete for binding to CD14, 
suggesting that the epitopes were the same or closely associated. Having established that 
61D3 binds to residue 11 within the first LPS binding region of CD14 it was decided to 
map the binding of MEM18 using mutations within the first and fourth LPS binding 
regions of CD14 (figure 59). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59: Mapping MEM18 binding to HeLa transfected with mCD14 mutants 
HeLa were transfected using LT-mediated transfection with wildtype or mutant mCD14.  
24 h following transfection cell surface expression of CD14 was assessed using indirect 
immunofluorescence staining with the mAb MEM18 (blue), 63D3 (green) or isotype-
matched control MOPC 21 (grey). Binding was detected using flow cytometry and the 
results are representative of three independent experiments. The mean fluorescence 
intensity for MEM18 (blue) and 63D3 (green) is shown. 
 
The flow cytometric results shown in figure 59 suggest that all cells express wildtype or 
mutant mCD14 as denoted by 63D3 staining. With respect to MEM18, a reduction in 
binding was observed with mutations D59A and D59N compared to wtCD14. This data 
illustrates that mutation of residue 11 has no effect on MEM18 binding compared to 
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wtCD14, unlike 61D3 binding (figure 58). While substitution of residue 59 (aspartic acid) 
with alanine or asparagine was shown to reduce MEM18 binding in agreement with sCD14 
mapping data (figure 49). Alanine and asparagine are both neutrally charged amino acid, 
therefore it is possible that a loss of the negative charge associated with aspartic acid is 
responsible for reducing the level of MEM18 binding.   
6.4 Mapping apoptotic cell binding to mCD14 
The precise residues of CD14 responsible for apoptotic cell binding are unknown. 
However earlier data presented here have mapped MEM18 and 61D3 binding to msCD14 
and results have indicated that some of the region required for LPS binding may also be 
involved in apoptotic cell binding. Therefore in order to assess the binding of apoptotic 
cells to mCD14, HeLa were transfected with wildtype or mutant CD14 and the ability of 
cells to interact with apoptotic cells was assessed (figure 60). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: HeLa interact with apoptotic cells in CD14-independent manner 
HeLa were transfected using LT-mediated transfection with wildtype CD14 or no DNA 
(Mock). 24h following transfection HeLa, with and without CD14 were seeded onto four-
well glass slides and incubated overnight to allow for attachment. A. Cell surface 
expression of CD14 was assessed using indirect-immunofluorescence staining with mAb 
63D3 (red) or isotype-matched control MOPC 21 (grey). The results are representative of 
three independent experiments B. HeLa cells were co-cultured with apoptotic Mutu for 1 h 
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at 37°C. Slides were then washed in ice cold PBS and fixed in 1% (w/v) formaldehyde 
prior to Jenner-Giemsa staining. Interaction was assessed using light microscopy and 
values scored as a percentage of HeLa interacting with apoptotic cells. The results shown 
are the mean ± SEM of three independent experiments. Statistical analysis conducted was 
ANOVA followed by Bonferroni post-test.  
 
The flow cytometric data shown in figure 60a supports previous data (figure 35) that 
suggests HeLa express undetectable levels of mCD14. However following transfection cell 
surface expression of CD14 was assessed and the results suggest cells are expressing 
mCD14. The results shown in figure 60b support previous findings (figure 38) that suggest 
HeLa interact with apoptotic cells in a CD14-independent manner. Following transfection 
(HeLa/CD14) incubation with apoptotic cells in the presence of 61D3, caused a slight 
reduction in the level of interaction. Therefore in order reveal any contribution of CD14 in 
apoptotic cell clearance; the assay was conducted at 4°C, for various times to reduce the 
rate of interaction and to solely consider binding (figure 61). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61: The CD14-independent binding of apoptotic cells to HeLa  
HeLa was transfected using LT-mediated transfection with wildtype CD14 or no DNA 
(Mock). 24 h following transfection HeLa, with and without CD14 were seeded onto four-
well glass slides and incubated overnight to allow for attachment. A. Cell surface 
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expression of CD14 was assessed using indirect-immunofluorescence staining with 63D3 
(red) or isotype-matched control MOPC 21 (grey).B. HeLa was co-cultured with apoptotic 
Mutu for 15, 30, 45 or 60 min at 4°C. Prior to Jenner-Giemsa staining, slides were washed 
in ice cold PBS and fixed in 1% (w/v) formaldehyde. Interaction was assessed using light 
microscopy and values scored as a percentage of HeLa interacting with apoptotic cells. The 
results shown are the mean ± SD of four wells.  
 
The results in figure 61 suggest that co-culturing HeLa with apoptotic cells at 4°C causes a 
slight reduction in the level of binding, when compared to figure 60. Whilst the level of 
CD14-dependent binding of apoptotic cells at all incubation times was not statistical 
significant, some observations were made which allowed experimental development. As 
the incubation time increased, the level of interaction between HeLa (HeLa/Mock) and 
apoptotic cells increased, peaking at 45 minutes. However the level of CD14-dependent 
binding (HeLa/CD14) did not change with time, therefore suggesting that lower incubation 
times had a higher level of CD14-dependent binding. This would suggest that mCD14 
accelerates the initial binding of apoptotic cells to the phagocyte. Therefore to reveal the 
role of CD14 in the initial binding of apoptotic cells, the assay was conducted at 4°C and 
incubated for 5min and 15min to solely consider the initial binding events (figure 62). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 62: CD14 mediates initial binding of apoptotic cells to HeLa 
HeLa was transfected using LT-mediated transfection with wildtype CD14 or no DNA 
(Mock). 24h following transfection HeLa, with and without CD14 were seeded onto four-
well glass slides and incubated overnight to allow for attachment. A. Cell surface 
expression of CD14 was assessed using indirect-immunofluorescence staining with mAb  
63D3 (red) or isotype-matched control MOPC 21 (grey). The results are representative of 
three independent experiments B. Prior to the assay cells were incubated at 4°C for 30 min 
then co-cultured with cold apoptotic Mutu for 5 or 15 min, washed and incubated at 4°C 
for a further 30 min. Prior to Jenner-Giemsa staining, slides were washed in ice cold PBS 
and fixed in 1% (w/v) formaldehyde. Interaction was assessed using light microscopy and 
values scored as a percentage of HeLa interacting with apoptotic cells. The results shown 
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are the mean ± SEM of three independent experiments. Statistical analysis was conducted 
using ANOVA followed by Bonferroni post-test. (* ** P<0.001) 
 
The results in figure 62 show that following 5 min of incubation with apoptotic cells, the 
level of CD14-dependent binding doubled compared to CD14-independent binding. 
Following incubation for 15 minutes, the level of CD14-independent and CD14-dependent 
binding of apoptotic cells to phagocytes appears the same.  This supports the previous 
suggestion that mCD14 accelerates the initial binding of apoptotic cells to phagocytes. 
Therefore having established the assay conditions required to analyse the role of mCD14 in 
apoptotic cell binding the assay was used to map the binding of apoptotic cells to mCD14 
point mutants (figure 63). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63: Mapping the binding of apoptotic cell to mCD14 
HeLa was transfected using LT-mediated transfection with wildtype or mutant mCD14 or 
no DNA (Mock). 24 h following transfection HeLa were seeded onto four-well glass slides 
and incubated overnight to allow for attachment. Prior to assay, HeLa were incubated at 
4°C for 30 min then co-cultured with cold apoptotic Mutu for 5min. Slides were then 
washed in ice cold PBS and fixed in 1% (w/v) formaldehyde prior to Jenner-Giemsa 
staining. Interaction was assed using light microscopy and values scored as a percentage of 
HeLa interacting with apoptotic cells. The location of the residues mutated, with respect to 
four LPS binding regions of CD14 are also shown. The results shown are the mean ± SEM 
of three independent experiments that were first normalised to mock alone. Statistical 
analysis was conducted using ANOVA with Dunnets Post-test (wtCD14 and mutants 
compared to Mock) (*P<0.05, **P<0.01). 
 
Glutamic acid at residue 11 is within the first LPS binding region of CD14 (Cunningham et 
al., 2000). Replacement with alanine (E11A) or arginine (E11R) significantly reduced 
apoptotic cell binding when compared to wtCD14. However replacement of residue 11 
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with aspartic acid, (E11D) had no significant effect on apoptotic cell binding to CD14. 
This suggests that residue 11 is required for the binding of apoptotic cells to mCD14. 
Furthermore alanine replacement of residue 14 (R14A) caused a significant increase in 
apoptotic cell binding to CD14 while replacement with lysine had no effect on apoptotic 
cell binding to CD14 (compared to wtCD14). Mutation of residue 14 may affect apoptotic 
cell binding to CD14, due to the close proximity to residue 11. The mutations of E37 and 
D59 assessed, had no significant effect on apoptotic cell binding to wtCD14. 
6.5 Mechanistic differences underlying the response of mCD14 to PAMPs 
Vs ACAMPs  
CD14 is found within microdomains in the Triton-X 100-insoluble fraction of the plasma 
membrane (Pugin et al., 1998, Triantafilou et al., 2001b). Isolation of the microdomains 
containing CD14 led to the discovery other LPS-binding molecules, including Hsp60 and 
Hsp70 (Byrd et al., 1999, Triantafilou et al., 2002, Wallin et al., 2002). Following LPS 
stimulation MD2/TLR4 and other LPS-binding molecules (including CXCR4 and GDF5) 
required for both CD14-dependent and CD14-independent cellular activation, are recruited 
to the plasma membrane (da Silva Correia et al., 2001, Triantafilou et al., 2002). For 
CD14-dependent responses, LPS binds CD14 and recruits MD2/TLR4 resulting in the 
expression of TNF-α and other proinflammatory cytokines (Akira and Takeda, 2004 and 
Saitoh and Miyake, 2006).  
 
Having previously established LPS and apoptotic cells share conformational epitopes and 
bind a region of CD14 involved in TLR4 signalling (the first LPS binding region)( Juan et 
al., 1995b & Stelter et al., 1999) it seems logical to assess the possibility that like LPS,  
apoptotic cells may also activate LPS-signalling pathways.  
6.5.1 CD14-dependent IL-8 response 
To elucidate the role of CD14 in apoptotic cell clearance, the mechanistic differences 
underlying the responses of CD14 to LPS and apoptotic cells must be determined. 
Therefore here the ability of CD14, following ligation with apoptotic cells or LPS, to 
activate NF-κB-inducible genes was assessed. Having established the function of 
membrane wtCD14 in a HeLa-based assay sytem, this system was then used to investigate 
cellular response to LPS by measuring cytokine expression following LPS stimulation. 
Sharma et al.(2011) also used HeLa to examine the LPS-induced expression levels of 
cytokine (IL-6 and IL-1α) and chemokines (IL-8 and MCP-1) in culture medium and cell 
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lysates. Here the same method was used to seed and stimulate HeLa transfected with no 
DNA and wildtype mCD14, following LPS stimulation cellular response was measured by 
IL-8 ELISA on culture supernatants and cytoslic fractions (figure 64). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: LPS-responsiveness of HeLa in the absence or presence of mCD14 
Following transfection, HeLa with (orange) or without mCD14 (blue) were seeded in 
triplicate at a density of 3.5x10
5
/well in 96-well plates and incubated overnight to allow for 
attachment. A. Cell surface expression of CD14 was analysed using indirect-
immunofluorescence staining with 63D3 (red) or isotype-matched control MOPC 21 
(grey).B. Cells were stimulated with 200µl of medium alone, 1µg/ml, 10µg/ml or 
100µg/ml of LPS in the presence of 10% NHS for 24 h. Following incubation, secreted and 
cytosolic IL-8 was measured by ELISA. The data shown is the mean ± SD of triplicate 
well assayed in duplicate by ELISA and is representative of two independent experiments. 
 
The results in figure 64 suggest that in the absence or presence of mCD14 expression, 
HeLa are unresponsive to LPS stimulation. However following stimulation with 100μg/ml 
of LPS there is a insignificant trend upwards in IL-8 response produced from HeLa 
expressing mCD14. This would suggest that at high concentrations of LPS, HeLa produce 
a CD14-dependent IL-8 response. However this trend coincides with a decrease in the 
basal level of IL-8 produced by mock transfected HeLa. This may suggest that high 
concentrations of LPS are toxic and induce apoptosis which reduced basal IL-8 production, 
yet cells displayed no morphological signs of apoptosis. Given the lack of IL-8 response 
Log fluorescence Intensity 
0 1 10 100
0
100
200
300
400
Concentration of LPS ( g/ml)
S
ec
re
te
d
 I
L
-8
 (
p
g
/m
l)
0 1 10 100
0
100
200
300
400
Concentration of LPS ( g/ml)
C
y
to
so
li
c 
IL
-8
 (
p
g
/m
l)  
A) 
B) 
HeLa/Mock HeLa/CD14 
2% 
1% 
2% 
56% 
C
el
l 
n
u
m
b
er
 
153 
 
following LPS stimulation, another method of measuring LPS-induced activation of HeLa, 
in the absence or presence of mCD14 was explored.  
6.5.2 CD14-dependent NF-κB activation 
To characterise the role of CD14 in NF-κB-mediated inflammation to LPS, HeLa were 
transfected with mCD14 and a plasmid containing several NF-κB response element 
upstream of a luciferase reporter gene.  Following LPS stimulation, CD14-dependent 
responses was assessed by measuring luciferase activity and the light emitted (figure 65). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 65: Titrating an LPS-induced response in HeLa expressing mCD14 
A. HeLa was transfected with an NF-κB reporter using LT-mediated transfection along 
with wildtype mCD14 (red) or pcDNA3 (empty plasmid) (grey). Following transfection 
cells were seeded at a density of 1.5x10
4
/well in 96-well plates and incubated overnight to 
allow for attachment. Cell surface expression of CD14 was analysed using indirect-
immunofluorescence staining with 63D3 B. Cells were washed and then stimulated with 
100µl of medium alone, 10µg/ml, 100µg/ml or 1000µg/ml of LPS in the presence of 10% 
(v/v) NHS for 5 h.  Following incubation, 100µl of One-Glo was added to each well and 
the plate incubated for 3min prior to measuring luminescence. The data shown is the mean 
± SD of quadruplicate wells. Statistical analysis was conducted using ANOVA followed by 
Bonferroni post-test. (* P<0.05, *** P<0.001) 
 
The flow cytometric results shown in figure 65a suggest mCD14 expression is relatively 
low compared to previous experiments and is most likely due to the nature of the double 
transfection. However results in figure 65b suggest LPS stimulation of HeLa expressing 
mCD14 resulted in a dose-dependent increase in NF-κB activation. As a control, HeLa 
were transfected with an empty pcDNA3 plasmid but to ensure that NF-κB activation was 
specific to mCD14, another membrane protein, ICAM-3 was expressed (figure 66). 
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Figure 66: CD14-dependent LPS-induced response in HeLa expressing mCD14 
A. HeLa was transfected with an NF-κB reporter using LT-mediated transfection along 
with mCD14 (red) or pcDNA3(empty plasmid) (grey). Following transfection cells were 
seeded at a density of 1.5x10
4
/well in 96-well plates and incubated overnight to allow for 
attachment. Cell surface expression of CD14 was analysed using indirect-
immunofluorescence staining with mAb 63D3 B. Cells were washed and then stimulated 
with 100µl of medium alone or 100µg/ml of LPS in the presence of 10% (v/v) NHS for 5 
h.  Following incubation, 100µl of One-Glo was added to each well and the plate incubated 
for 3 min prior to measuring luminescence. The data shown is the mean ± SD of 
quadruplicate wells. Statistical analysis was conducted using ANOVA followed by 
Bonferroni post-test. (* P<0.05, *** P<0.001) 
 
As shown in figure 66 HeLa expressing both the NF-κB reporter and mCD14 are LPS-
responsive therefore suggesting that NF-κB activation is CD14-dependent. CD14 does not 
contain a cytosolic signalling domain and often TLR4 is required to confer an LPS-
dependent response (Hoshino et al., 1999,Miyake, 2004). The expression of TLR4 on 
HeLa was assessed with direct immunofluorescence staining (figure 67). 
 
  
 
 
 
 
 
 
 
 
 
Figure 67: Surface expression of TLR4 on HeLa 
Surface expression of TLR4 on HeLa was detected with flow cytometric staining using 
direct immunofluorescence with the monoclonal antibody HTA125-PE (Orange) or IgG2a-
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PE (Isotype-matched control, (grey)). U937 were used as a positive control. The results are 
representative of three separate experiments. 
 
Cell surface expression of TLR4 was undetectable on HeLa following flow cytometric 
analysis (figure 67). This data is supported by Guillot et al.(2002) that suggested lack of 
TLR4 expression on HeLa prevented constant inflammation when exposed to resident 
flora. Werner et al., (2011) also found that HeLa was unresponsive to LPS stimulation 
possibly due to lack of TLR4 expression. Both studies assessed expression of TLR4 by 
flow cytometry, however levels may be below the level of detection. Alternatively TLR4 
may be recruited to the surface following LPS binding to mCD14. CD14 is also considered 
to interact with heat shock proteins (Kol et al., 2000b), also found with microdomains 
(Byrd et al., 1999, Triantafilou et al., 2002, Wallin et al., 2002).  Therefore LPS ligation of 
CD14 may signal in a TLR4-independent manner though the inflammatory signalling 
pathway used by heat shock proteins. However Ohashi et al.(2000) found that heat shock 
protein 60 used a TLR4-dependent complex to induce inflammation. Taken together it 
seems likely that CD14-dependent activation of NF-κB is dependent on TLR4-signalling. 
This would suggest that TLR4 is recruited to the cell surface following LPS binding to 
mCD14 or LPS ligation resulted in uptake which activated intracellular TLR4. 
6.5.2.2 CD14-dependent response to LPS or apoptotic cells 
Given the previous data, that demonstrated CD14-dependent activation of NF-κB 
following LPS stimulation, here we assessed if the point at which response pathways to 
LPS and apoptotic cells diverge , is prior to, or following NF-κB activation (figure 68). 
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Figure 68: Apoptotic cells binding to mCD14 does not activate NF-κB response 
A. HeLa was transfected with an NF-κB reporter using LT-mediated transfection along 
with mCD14 (red) or pcDNA3 (empty plasmid) (grey). Following transfection cells were 
seeded at a density of 1.5x10
4
/well in 96-well plates and incubated overnight to allow for 
attachment.Cell surface expression of CD14 was analysed using indirect-
immunofluorescence staining with mAb 63D3 and the data is representative of three 
independent experiments B. Mutu were induced to undergo apoptosis by UV-treatment 
then incubated overnight and apoptosis was assessed by flow cytometry C. Cells were 
washed and then stimulated with 100µl of medium alone, 100µg/ml of LPS in the presence 
of 10% (v/v) NHS or 1.5x10
6
/well apoptotic cells alone for 5 h.  Following incubation, 
100µl of One-Glo was added to each well and the plate incubated for 3min prior to 
measuring luminescence. The data shown is the mean ± SEM of three independent 
experiments. Statistical analysis was conducted using AVONA with Bonferroni post test. 
(*** P<0.001) 
 
The results in figure 68 suggest that incubation of apoptotic cells in the presence or 
absence of mCD14 expression did not result in NF-κB activation.  This suggests that that 
unlike the binding of LPS to mCD14, apoptotic cells do not induce NF-κB activation. The 
data also illustrates that incubation of HeLa with apoptotic cells in the absence of mCD14 
expression, reduced basal levels of NF-kB activation. This data suggest that apoptotic cell 
interaction produces an immunosuppressive and anti-inflammatory effect and is supported 
by Voll et al. (1997) and Fadok et al. (1998). Overall this data suggest that the 
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immunosuppressive and anti-inflammatory effect of apoptotic cell interaction can be 
uncoupled from CD14 expression. This may suggest that CD14 is not required for the anti-
inflammatory response of apoptotic cells therefore suggesting mCD14 function simply for 
tethering apoptotic cells to phagocytes. Alternatively phagocytes may express a variety of 
receptors capable of mediating the anti-inflammatory response of apoptotic cells in the 
absence of CD14. 
6.5.2.3 Is TLR4 recruited following apoptotic cell ligation with CD14? 
Given previous findings that residue 11 of CD14 is required for both apoptotic cell and 
LPS binding the differences in signalling following ligation of CD14 may be a result of 
interaction with signalling partners. Therefore the requirement for TLR4 in the phagocytic 
synapse following LPS stimulation or incubation with apoptotic cells was assessed. 
Double-stimulated THP-1 were previously found to express mCD14 (section 3.2.2) and 
TLR4 (section 3.3.3) therefore following stimulation with LPS or apoptotic cells for 1 hour 
indirect immunofluorescence staining for CD14 (FITC) and TLR4 (PE) was undertaken 
and slides were analysed by confocal microscopy. Following titration of cell number and 
concentrations of antibodies, problems with the effects of the laser on fixative methods 
used arose. Failure to overcome these issues resulted in the use of fluorescent microscopy. 
However due to time limitations the problems with non-specific binding of the secondary 
antibodies could not be overcome and while overlays of all images were conducted the 
results were inconclusive. As part of the future work of this project, the use of FRET 
would be considered to investigate the recruitment of TLR4 to lipid rafts following CD14 
ligation. If TLR4 is recruited to the cell surface following CD14 ligation with apoptotic 
cells, this would suggest that LPS-like patterns on the surface of apoptotic cells are also 
recognised by TLR4. Therefore this would suggest that inflammatory signalling becomes 
reprogrammed as a result of apoptotic cell ligation with CD14, resulting in a dominant 
anti-inflammatory response.  
6.6 Discussion 
CD14, expressed by monocytes and macrophages is well characterised for binding LPS 
and promoting inflammation (Ulevitch and Tobias, 1999 and Wright et al., 1990). CD14 is 
also known to participate in the clearance of apoptotic cells, a process known to have 
immunosuppressive and anti-inflammatory effects (Voll et al., 1997 and Fadok et al., 
1998b). This led to the suggestion that CD14 was involved in the assembly of two distinct 
ligand-dependent macrophage responses, possibly due to variations in ligand-binding. LPS 
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binding to CD14 has been mapped to four regions within the N-terminal pocket of CD14 
(Stelter et al., 1997, Juan et al., 1995a, Juan et al., 1995b, Cunningham et al., 2000 and 
Kim et al., 2005). Apoptotic cell binding to CD14 has not been finely mapped but previous 
work by Devitt et al.(1998) with CD14-blocking mAbs, MEM18 and 61D3, suggested that 
CD14 uses the same or closely-associated regions to bind both LPS and apoptotic cells. 
This was supported by Gregory et al. (2000) and finding here that apoptotic cells expose 
LPS-like structures at their surface (section 3.3.7). Previous work within this thesis using 
soluble CD14 point mutants has suggested that apoptotic cells bind to residues located 
within the LPS-binding regions of CD14. However limitations with the use of soluble 
CD14 point mutants led to a need for the mutations to be membrane-bound and these were 
expressed within HeLa.  
 
6.6.1 Mapping mAb binding to mCD14 
Having generated the panel of membrane-bound CD14 point mutants, the binding of 
MEM18 and 61D3 were mapped, with flow cytometry, as surrogate markers of apoptotic 
cell binding. The flow cytometric data suggests that residue 11 within the first LPS binding 
region of CD14 is required for 61D3 binding. The first LPS binding region is primarily 
composed of aspartic and glutamic acid residues producing an overall negative charge 
likely required for LPS binding. Consequently, substitution of glutamic acid at position 11 
for aspartic acid had no overall effect on 61D3 binding. However a loss of the negative 
charge caused a reduction in 61D3 binding, suggesting that charge may dictated antibody 
binding.  This is further demonstrated when glutamic acid is substituted for arginine, which 
has an overall positive charge, resulting in a complete loss of 61D3 binding. However 
Cunningham et al.(2000) and Shapiro et al. (1997) also found that charge reversal 
mutations had the greatest effect on LPS binding. Taken together the results suggest that 
the first LPS binding region of CD14 contains part or the whole epitope for 61D3. 
Furthermore the results shown here suggest that the glutamic acid (residue 11) of CD14 
may be a contact residue required for 61D3 binding. Residue 14 is two amino acids outside 
the first LPS binding region and therefore located between a negatively charged region of 
the protein, and a neutral, non-polar region which is involved in disulphide bridge 
formation. These data suggested that due to the close proximity of residue 14, a loss of the 
highly basic amino acid; arginine, affects the three-dimensional shape of the surrounding 
area therefore reducing 61D3 binding. 
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Juan et al. (1995b) and Stelter et al. (1997) suggest that the first LPS-binding region is also 
required for TLR4 signalling, as the ability of sCD14 to mediate LPS response was 
impaired following mutation of residues 7-14. This work was conducted with sCD14 and 
using cells that do not express CD14. Therefore this may suggest that residues 7-14 are 
required for sCD14 to interact with cell-bound receptors, such as TLR4, to induce 
inflammation. However it may also suggest that residues 7-14 of mCD14 are required to 
interact with TLR4 and mediate inflammatory signalling. Given this suggestion, 61D3 may 
directly block interaction of TLR4 with CD14, therefore suggesting that LPS binds to 
CD14 but signalling is blocked. However mutation of residue 11 prevents LPS and 61D3 
binding therefore this would suggest that 61D3 binds CD14 which then block LPS binding. 
Given the involvement of residues 7-14 in TLR4 signalling and findings here, that residue 
11 of CD14 is required for apoptotic cell binding, TLR4 may be involved in the binding of 
apoptotic cells to CD14. Therefore a future experiment to consider would be assess the role 
of TLR4 in the CD14-dependent binding of apoptotic cells and could be conducted using 
FRET analysis. This may establish if TLR4 is associated with CD14 when apoptotic cells 
are bound. 
 
The third LPS binding region of CD14 spans amino acids 35-39 and is predominately 
composed of neutral and non-polar residues. However due to the presence of two glutamic 
acid residues, this region is likely to have an overall negative charge. The data suggests 
that a loss of charge or a slight change in the dimension of residue 37 had no effect on 
61D3 binding. The fourth region of CD14 spans amino acids 57-63 and is located on the 
rim of the NH-terminal pocket (Kim et al., 2005). Overall this region has neutral charge 
but most likely exhibits polarity. The data here suggests that a loss of charge or a reduction 
in the length of the side chain of residue 59 had no effect on 61D3 binding. Due to 
competition for binding to CD14, the epitopes of 61D3 and MEM18 are considered the 
same or closely related, however MEM18 binding had been mapped to the fourth LPS-
binding region (Juan et al., 1995a). The data here supports these findings as a loss of 
charge and or change in dimension of residue 59 reduced MEM18 binding. With respect to 
location, the first LPS-binding region (shown to contain 61D3 epitope), is located close to 
the wall of the N-terminal pocket of CD14, while the fourth LPS binding region (to which 
MEM18 binds), is at the rim of the pocket (Kim et al., 2005). The pocket is described as 
relatively large with dimensions of 8Å wide, 13Å long and 10Å deep (Kim et al., 2005). 
However compared to an antibody, the epitopes of MEM18 and 61D3 would probably be 
within close proximity that the binding of MEM18 would sterically hinder the binding of 
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the other 61D3. In comparison, an apoptotic cell is bigger than an antibody therefore the 
mapping studies with MEM18 and 61D3 may suggest that the first and fourth LPS binding 
regions are involved in apoptotic cell binding. Therefore a future experiment to be 
considered would be to map the binding of the Fab-fragments of 61D3 and MEM18 to 
CD14.  
 
6.6.2 Mapping apoptotic cell binding to mCD14 
Membrane CD14 point-mutants were then used to map apoptotic cell binding to HeLa as 
they were previously shown to function as amateur phagocytes (figure 38). HeLa were 
very efficient at clearing apoptotic cells, however the results suggest that CD14 accelerates 
the initial binding of apoptotic cells to these amateur phagocytes.  In order to focus on the 
initial binding events, the temperature and incubation time of the assay was reduced and 
apoptotic cell binding to CD14 was mapped. The data supported previous findings, 
suggesting that residue 11 was important for apoptotic cells binding. This data present here 
supports the suggestion that both charge and the three dimensional conformation in relation 
to residue 11 are important for apoptotic cell binding to CD14. Comparison of the binding 
of apoptotic cells with 61D3 binding, found that alanine replacement or a charge reversal 
reduced 61D3 binding. Residue 14 is two amino acids outside the first LPS binding but 
within the first suggested TLR4 binding domain (Juan et al., 1995b, Stelter et al., 1999), 
therefore mutation of residue 14 may affect TLR4-mediated responses but not binding. 
However the data suggested that the removal of the side chain on arganine at residue 14 
enhanced apoptotic cell binding to CD14, possibly by reducing steric hindrance. 
Alternatively a loss of charge conferred by arginine, may result in changes to the three 
dimensional conformation of the surrounding area which includes the first LPS binding 
region, thereby favouring apoptotic cell binding. Comparison of apoptotic cell binding to 
residue 14 with 61D3 binding, found that alanine replacement also reduced 61D3 binding 
suggests that a loss of charge alters the three-dimensional shape of the surrounding regions. 
Although, considering that 61D3 binding to residue 11 was also reduced upon loss of 
charge, this may simply suggest that 61D3 binding is dictated by charge rather than three-
dimensional changes.  
 
Mutations at residue 37 had no effect on apoptotic cell binding or 61D3 binding compared 
to wtCD14, suggesting apoptotic cells did not bind to the third LPS binding region of 
CD14. Further work is required to confirm this for example by investigation of the effect 
of charge reversal as previously these mutations were found to have the greatest effect on 
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LPS binding (Shapiro et al., 1997).  Residue 59, within the fourth LPS binding region of 
CD14 is located on the same side the N-terminal pocket at the first and third LPS binding 
regions. Replacement of aspartic acid (residue 59) with asparagine and alanine, both 
containing neutrally charged side chains, had no effect on apoptotic cell binding to CD14. 
However to rule out the possibility that apoptotic cells interact with the fourth LPS binding 
region, a charge reversal mutation should be considered. It seems feasible, considering the 
positioning at the edge of the pocket and close proximity to the first LPS binding site that 
apoptotic cells may interact with this region of CD14. This region is important for MEM18 
binding, previously shown to block LPS response (Juan et al., 1995a) and apoptotic cell 
binding to CD14 (Devitt et al., 1998).  Comparison of apoptotic cell and MEM18 mapping 
data found that while MEM18 binding to CD14 was reduced following loss of the negative 
charge apoptotic cell binding was unaffected. This again suggests that mAb binding is 
predominantly dictated by charge of the epitope rather than small changes in the three-
dimensional shape of the epitopes. Taken together, mAbs and apoptotic cell mapping data, 
suggest that apoptotic cells interact with the first LPS binding region of CD14. This may 
suggest that CD14 presents negatively charged hydrophilic residues on one surface of the 
protein to interact with the lipid back bone of LPS and apoptotic cells. However a question 
raised is how the LPS-like patterns at the surface of apoptotic cells are recognised by 
CD14 to result in different downstream signalling events? One possible suggestion is that 
apoptotic cells may interact with the first LPS binding domain, as this region may also be 
responsible for TLR4 signalling (Juan et al., 1995b, Stelter et al., 1999) and block 
interaction with CD14 when apoptotic cells are bound. Alternatively TLR4 also recognises 
the LPS-like pattern presented by apoptotic cells, (like CD14) however another phagocytic 
receptor within the phagocytic synapse induces an inhibitory signal that interferes with the 
inflammatory response. 
 
6.6.3 Mechanistic differences underlying the ligand-dependent responses 
of CD14 
To determine the mechanistic differences underlying the ligand-dependent responses of 
CD14, the ability of apoptotic cells and LPS to activate inflammatory signalling was 
assessed. As an indicator of inflammatory signalling, the production of IL-8 following LPS 
stimulation was examined in HeLa. However HeLa in the absence and presence of mCD14 
expression LPS treatment did not produce a significant IL-8 response. This contrasts with 
previous finding by Sharma et al.(2011) that found upon LPS-induced stimulation, HeLa 
increased NF-κB levels and produced proinflammatory cytokines (IL-6 and IL-1α) and 
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chemokines (IL-8 and MCP-1). Sharma et al.(2011) also found that LPS-induced cell 
activation was mediated though TLR4 but did not comment on CD14 expression or 
involvement in cellular activation. One possible explanation is the type of LPS used to 
stimulate cells, Sharma et al.(2011) used LPS isolated from vaginal strains of E. coli 
therefore HeLa may be more sensitive to these stains. However this seems unlikely as the 
lipid A region is responsible for the biological activity of LPS and its structure is highly 
conserved with only slight variations between bacterial strains. CD14 is known to 
recognise the lipid A portion of LPS and induce inflammation in a TLR4-dependent 
manner (Rietschel et al., 1994 and Wright et al., 1990). Previously Werner et al.(2011) 
found that a range of cervical epithelial cells including HeLa were unresponsive to LPS 
and findings suggests it was due to low RNA production and lack of cell surface TLR4 
expression. Fichorova et al.(2002) found that cervical epithelial cells failed to express 
TLR4 or MD2 mRNA but were able to respond to gram negative infections in the absence 
of MD2/TLR4.  
 
Prior to an IL-8 response the transcription factor, NF-κB is activated leading to 
transcription of proinflammatory mediators. Therefore using an NF-κB reporter assay to 
assess the ability of CD14 to induce inflammatory signalling following ligation with LPS 
or apoptotic cells was established. The data suggests that the point of divergence between 
these two signaling pathways may occur upstream of NF-κB activation, as incubation of 
apoptotic cells for 5 hours with HeLa expressing CD14 did not lead to NF-κB activation. 
These findings are supported by Tassiulas et al.(2007) that reported macrophages 
incubated with apoptotic cells alone did not induce degradation of IκBα and therefore 
prevented NF-κB activation. Following TLR4 activation, MyD88-independent pathway is 
activated resulting in STAT 1 activation; however Tassiulas et al.(2007) also found that 
following incubation with apoptotic cells alone, macrophages did not phosphorylate 
STAT1. Interpretation of these findings, along with data presented here, may suggest that 
apoptotic cells binding residue 11 of CD14 and block TLR4 interaction therefore resulting 
in the exclusion of TLR4 from the phagocytic synapse. This is supported by Shiratsuchi et 
al.(2004), that investigated the ability of LPS and apoptotic cells, following uptake by 
mouse peritoneal macrophages, to induce translocation of NF-κB to the nucleus. The 
findings suggested that incubation of macrophages with apoptotic thymocytes for an hour 
did not induce NF-κB translocation. Taken together with results shown here, these data 
suggest that apoptotic cell binding to CD14 does not induce inflammatory signalling.   
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However the inhibitory signal induced by apoptotic cell uptake may occur upstream of IκB 
kinase complex responsive for NF-κB activation and subsequent translocation. One such 
inhibitor of the innate immune system are the TAM receptor tyrosine kinases (Rothlin et 
al., 2007), also involved the phagocytic clearance of apoptotic cells though association 
with PS-binding protein GAS6 or protein S (Lemke and Rothlin, 2008 & Lemke and 
Burstyn-Cohen, 2010). TAMs are considered to inhibit TLR-dependent inflammation by 
inducing the expression of silencer of cytokine signalling proteins (SOCS) (Rothlin et al., 
2007). Following expression, SOCS1 and SOCS3 are considered to inhibit the JAK/STAT 
pathway, intercepting and therefore inhibiting TLR-mediated cytokine response (Rothlin et 
al., 2007). Therefore ligation of CD14 with LPS or apoptotic cells may induce TLR4 
signalling, however subsequent association of the Mer-tyrosine receptor with a bound 
apoptotic cell may inhibit proinflammatory signalling. This is supported by Scott et 
al.(2001) that reported a direct link between failed clearance due to truncated Mer tyrosine 
kinase receptor and increased auto-antibodies. TAMs are also considered to recruit crk-
DOCK180-ELMO complex to the membrane resulting in Rac1 activation and 
consequently actin-dependent engulfment (Wu et al., 2006).  
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Discussion 
The innate immune system discriminates ‘self’ from ‘infectious non-self’ using a series of 
PRRs that recognise evolutionary conserved PAMPs (Janeway, 1992, Janeway, 2001). 
Research within the field had highlighted the involvement of many PRRs, including, CD14 
in the clearance of apoptotic cells. This has led to the suggestion that apoptotic cells 
present surface patterns that share structural similarities with PAMPs, termed ACAMPs 
(Franc et al., 1999 & Gregory et al., 2000). However while LPS-binding to CD14 
promotes inflammation (Wright et al., 1990, Ziegler-Heitbrock and Ulevitch, 1993, Martin 
et al., 1994), the clearance of apoptotic cells is considered an immunomodulatory and anti-
inflammatory process (Stern et al., 1996, Fadok et al., 1998b, Voll et al., 1997). Devitt et 
al.(1998) first implicated CD14 in the clearance of apoptotic cells by HMDM and further 
work suggests that CD14 functions as a tethering receptor (Devitt et al., 2004). The CD14-
dependent clearance of apoptotic cells has been supported here, by the development of 
several THP-1-derived macrophages models. While this data supports a role for CD14 in 
interaction between apoptotic cells and phagocytes, the potential involvement of CD14 in 
the anti-inflammatory effects which follows these interactions is currently unknown. 
Overall data here suggests that the immunosuppressive effects of apoptotic cells are 
independent of CD14 and expression of its signalling partner, TLR4. These findings are 
supported by Devitt et al.(2004) that reported that CD14-deficient mice had persistent 
apoptotic cells at specific sites without inflammation, suggesting that the anti-
inflammatory consequences of apoptotic cell clearance can be uncoupled from CD14-
dependent binding events. This points to a scenario, in which CD14 functions simply, as a 
tethering receptor which may enhance apoptotic cell interaction with other phagocyte-
receptors that mediate uptake and the anti-inflammatory response. Alternatively, it may 
suggest receptor redundancy with several receptors capable of mediating the anti-
inflammatory response to apoptotic cells in the absence of CD14. 
7.1 The role of non-myeloid CD14 
The macrophage is the professional scavenger of apoptotic cells that efficiently and rapidly 
phagocytoses apoptotic cells when amateur phagocytes are overwhelmed (Gregory and 
Devitt, 2004). The clearance of apoptotic cells is mediated by both professional and 
amateur phagocytes, with clearance in both cases resulting in this characteristic anti-
inflammatory response (Patel et al., 2010). Data presented here using a series of non-
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professional oral, pulmonary, mammary, cervical epithelial cells and pulmonary fibroblasts 
supports the role of amateur phagocytes in the clearance of apoptotic cells. The receptors 
used by amateur phagocytes to clear apoptotic cells are largely unknown, however Monks 
et al. (2005) found that mammary epithelial cells utilised a series of PRR also used by 
macrophages to clear apoptotic cells. Therefore the role of CD14 in the clearance of 
apoptotic cells by a series of amateur phagocytes was examined. Originally, CD14 
expression was considered to be limited to myeloid cells and B cells (Ziegler-Heitbrock 
and Ulevitch, 1993). Fearns et al.(1995), using a mouse model found that epithelial cells in 
certain tissues, including the lung expressed CD14. Furthermore, Devitt et al.(2004) 
observed that CD14-deficient mice had persistent apoptotic cells in the thymus, spleen, 
lung, liver and gut, which implies CD14-mediated clearance is crucial at these sites. 
However due to the repertoire of receptors expressed by macrophages that interact with 
apoptotic cells it is likely that molecular redundancy would facilitate clearance. Therefore 
the persistence of apoptotic cells at these sites, within CD14-deficient mice, may suggest 
that it is the absence of CD14 from amateur phagocytes that results in persistent apoptotic 
cells. This has been supported by the findings here that pulmonary epithelial cells, Beas-2B 
and Calu-3 expressed cell surface CD14, were LPS responsive and participated in the 
CD14-dependent clearance of apoptotic cells. However, in direct comparison, cell surface 
expression of CD14 was undetectable in the cervical epithelial cell line, HeLa which were 
unresponsive to LPS stimulation and interaction with apoptotic cells was not inhibited by 
CD14-blockade. Taken together the data along with findings by Devitt et al.(2004) may 
suggest that the expression and consequently, involvement of CD14 in the innate immune 
responses is tissue specific.  
 
With respect to the lungs, failed clearance of neutrophils would be massively detrimental 
with proinflammatory consequences. While innate immune components provide defence 
against invading pathogens, many have been implicated in the clearance of apoptotic cells, 
including, the mucocilliary escalator, immunoglobulins, complement factors, surfactant 
proteins A and D along and alveolar macrophages.  However, pulmonary epithelial cells 
maintain mucosal integrity by modulating the immune responses and therefore express a 
variety of innate immune receptors to mediate responses to infectious agents (Diamond et 
al., 2000). With several innate immune receptors suggested to be involved in the clearance 
of apoptotic cells, it is likely that pulmonary epithelial cells utilise multiple receptors to 
interact and mediate uptake of apoptotic cells. In terms of CD14, interpretation of the data 
here suggests that expression of CD14 on pulmonary epithelial cells facilitates efficient 
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and rapid removal of apoptotic cells compared to other amateur phagocytes analysed. The 
theoretical mechanism proposed, is that apoptotic cells are rapidly tethered to mCD14, 
which enhances the interaction between apoptotic cell-associated ligands and engulfment 
receptors, such as, Mer or TIM-4 (Hoffmann et al., 2001). Therefore could the expression 
of CD14 on phagocytes dictate their professional status? Data here illustrates that the 
expression of mCD14 in HeLa enhances the initial binding of apoptotic cells. This would 
suggest that the delay in the uptake of apoptotic cells by amateur phagocytes observed by 
Parnaik et al.(2000) may be PS-dependent. However Hoffmann et al. (2001) found that 
PS-exposure alone was insufficient to induce binding or uptake of apoptotic cells, but 
combined with any tethering receptor, PS triggers engulfment. This may suggest tethering 
receptors expressed by amateur phagocytes are limited or low. In turn this would suggest 
that amateur phagocytes, depending on site and location, express certain PRRs, such as 
CD14 in an attempt to modulate local immune responses and improve their professional 
status. 
7.2 Mechanistic differences underlying the responses of CD14 to PAMPs 
Vs ACAMPs  
Data here suggests that specific tissues require CD14 to modulate local immune responses. 
The role of CD14 in the anti-inflammatory consequences of apoptotic cell clearance is 
unknown. While the divergence in ligand-dependent responses of CD14 is currently 
unknown, findings by Hoffmann et al.(2001) and Devitt et al.(2004) suggest that CD14 
functions as a tethering receptor. However Gregory(2000) suggested that CD14 may 
induce an immunosuppressive signal; following apoptotic cell binding, in a manner similar 
to LPS stimulation. This suggests that the divergence in ligand-dependent responses of 
CD14 is a result of the mechanistic difference of PAMPs and ACAMPs recognition (figure 
69).  
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Figure 69 : Possible scenarios involved in CD14-dependent responses 
CD14 dependent response to LPS: 1. LPS binds CD14 (purple domains) and induces a pro-
inflammatory signal (red arrows) though association with TLR4, resulting in NF-κB 
translocation and an inflammatory response. Possible CD14-dependent responses to 
apoptotic cells: 2 ACAMP on apoptotic cells bind to CD14 in an identical manner to LPS 
(purple domains) and induce a pro-inflammatory signal as seen in scenario one. However 
pro-inflammatory signalling is suppressed following further phagocyte receptor ligation 
(e.g. PS-PS receptor) which produces a dominant anti-inflammatory signal (blue arrows). 3 
ACAMP binding to CD14 differs from LPS binding (grey domains), thereby dictating the 
recruitment of an alternative signalling partner to CD14 resulting in anti-inflmmatory 
signalling 4. CD14 here functions very simply just to tether the apoptotic cell to the 
phagocyte. The tethering effects of CD14 may be mediated thought ACAMP interaction 
with LPS-binding regions of CD14 (purple domains) or another region of CD14 (grey 
domains), but interaction does not result in signalling. Therefore interaction of the 
apoptotic cell with another phagocyte receptor independently mediates corpse uptake and 
the anti-inflmmatory response. Adapted from Gregory and Devitt, 2004 
7.2.1 Scenario 1 
Data present here along with mutagenesis studies identified the importance of the amino 
terminal region of CD14 for LPS binding and responses (Viriyakosol and Kirkland, 1995 
& Juan et al., 1995c). Further, separate mAb mapping and point mutations have been used 
to identify four hydrophilic regions, within the amino-terminal that were independently 
required for LPS binding (Juan et al., 1995a, Stelter et al., 1997, Shapiro et al., 1997, 
Cunningham et al., 2000). Cunningham et al.(2000) found that residues located within 
these regions of CD14 contribute to LPS binding.  This is supported by the LPS data 
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shown here, that found that mutations within one significantly reduced LPS binding. The 
protein sequence of mouse CD14 shares 67% homology with human CD14, with all LPS 
binding regions conserved. Furthermore mouse models have previously been used to assess 
the function of CD14 and findings have suggest mouse CD14 functions the same manner 
as human CD14, in terms of LPS responses (Haziot et al., 1996) and apoptotic cell 
clearance (Devitt et al., 2004). Therefore while there is currently no crystal structure for 
human CD14, the crystal structure of mouse CD14 suggests that the LPS-binding regions 
identified, are located within a pocket. LPS-binding regions one and two are located at the 
wall, region three located at the base and region four located on the rim of the pocket (Kim 
et al., 2005). Previous findings by Cunningham et al., (2000) and Kim et al.(2005) along 
with data presented here, suggests that the LPS-binding site of CD14 is dependent on the 
tertiary structure of several residues which are within close proximity. As demonstrated by 
61D3 binding to region one which hinders MEM18 binding to region four.  Prior to the 
mouse crystal structure, Cunningham et al.(2000) suggested that the first, third and fourth 
LPS binding regions of CD14 are located on one side of the protein and proposed that 
CD14 presents several charged residues to interact with LPS and possibly other microbial 
ligands. This theory was supported by the findings that serine or alanine replacement of 
residues throughout the amino terminal of CD14 had little effect on LPS binding 
(Cunningham et al., 2000). As supported by LPS-binding data here, charge reversal had 
the greatest effect on LPS-binding probably by reversing local surrounding charges 
preventing LPS from docking. Another PRR, the scavenger receptor, has broad ligand 
binding specificity and is also considered to interact with ligands by presenting several 
charged residues which act as a “molecular fly paper” (Krieger et al.1992, 1993).  
7.2.2 Scenario 2 Vs 3 
Whilst LPS-binding to CD14 is well characterised, the nature of apoptotic cell interaction 
with this receptor is relatively unclear. Consequently characterisation of this interaction has 
formed a key element of this work. Previously Devitt et al.(1998) found that CD14-
blocking mAbs, MEM18 and 61D3 inhibited both the binding and phagocytosis of 
apoptotic cells, along with LPS-induced production of TNF-α by HMDM. This led to the 
suggestion that MEM18 and 61D3 binding defined both LPS and apoptotic cell binding to 
CD14. Therefore MEM18 and 61D3 binding was mapped to CD14 as a surrogate marker 
of apoptotic cell binding. The data here suggested that both apoptotic cells and LPS 
interact amino acids E11 (within region one) and D59 (within region four). However 
unlike LPS binding, results suggested mAb binding were more susceptible to changes in 
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charge. Alanine replacement of E11 reduced 61D3 binding to background levels but had 
no effect on LPS binding. Furthermore, aspartic acid replacement of E11 reduced LPS 
binding but had no effect on 61D3 binding. This suggested that mAb binding was dictated 
by charge and could therefore be considered the limiting factor in this case. Taken together 
these findings suggest that the ligand binding site of CD14 is a conformational epitope 
composed of several critical hydrophilic residues throughout the N-terminal pocket that 
capture both LPS and possibly apoptotic cells. This was further supported by data here that 
suggests apoptotic cells present ACAMPs that share structural similarities with LPS. 
Interpretation of this data would suggest that due to a resemblance in their binding 
patterns, both LPS and CD14 interact with several charged residues presented by CD14. 
 
Using a panel of membrane-bound CD14 point mutants, apoptotic cell binding was 
mapped. The data suggested that residue E11 (i.e. LPS binding region one) was important 
for apoptotic cell binding while alanine replacement or asparagine replacement of residue 
D59 (LPS binding region four) has no effect on apoptotic cell binding. This suggests that 
both charge and the three dimensional conformation in relation to residue E11 was 
important for apoptotic cell and LPS binding to CD14. However this data also suggests 
that 61D3 binding defines the apoptotic cell binding site of CD14. Therefore the ability of 
MEM18 to inhibit apoptotic cell binding is likely to be a result of the size of the antibody 
and close proximity to residue 11. 
 
Findings by Juan et al., (1995b) and Stelter et al.(1999) using a series of sCD14 point 
mutants identified that amino acids 9-14 were required for cellular responses to LPS in 
cells that do not express mCD14. Mutations within amino acids 9-14 had the most 
detrimental effects on LPS responses. However this region is located within the first LPS 
binding region of CD14, therefore any mutation that affected LPS-binding would be 
expected to impact on cellular responses. Stelter et al.(1999) reported that the inability of 
mutations to induce a response is not due to an impaired capacity to bind to CD14, 
suggesting that LPS binding and cellular response are separate functions of CD14. This 
would suggested that an apoptotic cell may bind to the first LPS binding region of CD14 
and results in no inflammation as proinflammatory signalling partner, TLR4 is excluded. 
One possible way of assessing the association of TLR4 with CD14 when LPS or apoptotic 
cells are bound may be to use FRET analysis. 
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7.2.3 Scenario 2 
Previous data within this study has suggest that apoptotic cells bind to the first LPS-
binding site of CD14 also required for pro-inflammatory signalling (Juan et al., 1995b & 
Stelter et al., 1999). TLR4 is also a PRR therefore if apoptotic cells present LPS-like 
patterns recognised by CD14 it seems likely that binding would induce TLR4 signalling 
resulting in activation of an inflammatory response. Again, this would suggest that LPS 
and apoptotic cells have similar binding patterns, but that the downstream responses are 
reprogrammed to be immunosuppressive or anti-inflammatory. To determine the 
mechanistic differences underlying the ligand-dependent responses of CD14, the ability of 
apoptotic cells and LPS to activate inflammatory signalling was assessed with an NF-kB 
reporter assay. However, the data here suggested that if apoptotic cells do induce an 
inflammatory signal then the point of divergence between these two signaling pathways 
may occur upstream of NF-κB activation. This data is supported by Tassiulas et al.(2007) 
that reported macrophages incubated with apoptotic cells alone did not induce NF-κB 
activation. Tassiulas et al.(2007) also found that following incubation with apoptotic cells 
alone macrophages did not phosphorylate STAT1. This is supported by Shiratsuchi et 
al.(2004), that investigated the ability of LPS and apoptotic cells, following uptake by 
mouse peritoneal macrophages to induce translocation of NF-κB to the nucleus. The 
findings illustrated that co-incubation of macrophages with apoptotic thymocytes for an 
hour, did not induce NF-κB translocation therefore upon ligation with CD14, regardless of 
the LPS-like structures displayed, apoptotic cells do not induce inflammatory signalling.  
 
Alternatively the inhibitory signal induced by apoptotic cell uptake may occur upstream of 
the IκB kinase complex responsive for NF-κB activation and subsequent translocation. A 
family of inhibitors of the innate immune system are the TAM receptor tyrosine kinases 
(Rothlin et al., 2007) which are also implicated in the phagocytic clearance of apoptotic 
cells though their association with PS-binding protein GAS6 or protein S (Lemke and 
Rothlin, 2008 & Lemke and Burstyn-Cohen, 2010). TAMs are considered to inhibit TLR-
dependent inflammation in dendritic cells by inducing the expression of SOCS (Rothlin et 
al., 2007). Following expression, SOCS1 and SOCS3 are considered to inhibit the 
JAK/STAT pathway, intercepting and therefore inhibiting TLR-mediated cytokine 
response (Rothlin et al., 2007). Therefore given the role of TAMs in apoptotic cell 
clearance in macrophages SOCS may also have a role in inhibiting TLR-dependent 
signalling following apoptotic cell ligation with CD14. The role of SOCS in the 
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immunosuppressive and anti-inflammatory effects of apoptotic cell clearance could be 
assessed using siRNA-mediated SOCS knockdown or SOCS-deficient macrophages. If 
apoptotic cell interaction with CD14 then results in inflammation it would suggest scenario 
2 (figure 69). ACAMPs on surface of apoptotic cells bind to CD14 in an identical manner 
to and induce a pro-inflammatory signal. However pro-inflammatory signalling is 
suppressed following further phagocyte receptor ligation which produces a dominant anti-
inflammatory signal. 
7.2.4 Scenario 4 
Alternatively apoptotic cell bound by CD14 may interact with TLR4 in a manner that does 
not induce pro-inflammatory signalling or responses. This was suggested following 
findings by Coats et al. (2011) that the phosphate position of lipid A determined TLR4 
response to LPS. This may suggest that a specific part of the LPS molecule, such as a 
phosphate group of lipid A, is required for TLR4 activation. This would therefore suggest 
that CD14 may function simply to tether apoptotic cells to the phagocyte. Therefore 
apoptotic cell ligation of CD14 does not result in a signalling event. This would suggest 
that engulfment receptors, for example, Mer tyrosine kinase or TIM-4 are required to 
mediate the uptake of apoptotic cells and anti-inflammatory signalling. This is supported 
by Hoffmann et al.(2001) following findings that PS exposure alone was insufficient to 
mediate the phagocytic uptake of apoptotic cells. Following these findings Hoffmann et 
al.(2001)suggested that apoptotic cells engulfment by phagocytes occurs in two distinct 
phases, tethering and uptake  therefore addition phagocyte receptors were required to tether 
the apoptotic cell to the phagocyte prior to PS-dependent uptake. Fadok et al. (1992) 
illustrated the important of PS exposure following activation of apoptotic programme and 
how failure to expose PS resulted in defective clearance.  Mer tyrosine kinase is a member 
of TAMs family which are reported to recruit crk-DOCK180-ELMO complex to the 
membrane resulting in Rac1 activation and consequently actin-dependent engulfment (Wu 
et al., 2006). The association of apoptotic cells with TAMs is considered to involve the 
bridging molecule GAS 6 and protein S which binds to PS. Therefore suggesting that the 
inhibitory effects of apoptotic cells is PS-dependent as considered by Fadok et al.(1998), 
Hoffmann et al.(2001) and Huynh et al.(2002). 
7.3 Conclusions 
The data within this study collectively suggest that the expression of CD14 on professional 
and amateur phagocytes facilitates the clearance of apoptotic cells. Findings shown here 
172 
 
suggest that CD14 functions as a true PRR that presents several charged regions at one 
surface of the protein which are responsible for ligand-binding may be unable to 
discriminate between LPS and LPS-like patterns presented by apoptotic cells. However 
ligand-binding to CD14 may enhance interaction with other phagocyte receptors (PS 
receptor, Mer tyrosine kinase or TLR4) that recognise critical features in the patterns 
bound by CD14 and mediate cellular responses. In an inflammatory capacity, CD14 binds 
LPS and the signalling partner, TLR4 is recruited with respect to apoptotic cells, CD14 
tethers apoptotic cells to the phagocyte and enhances interaction with engulfment receptors 
which mediate clearance and an anti-inflammatory response. The findings in this study 
support previous data that suggest apoptotic cell interaction with phagocytes expressing 
CD14, does not induce inflammatory signalling. Therefore, this would suggest that 
although CD14 recognises and may bind the LPS-like patterns on the surface of apoptotic 
cells, a critical component of this interaction may be unrecognisable to TLR4. Therefore 
suggesting that CD14 enhances apoptotic cell interaction with other phagocyte (both 
professional and amateur) receptors that are responsible for engulfment and the anti-
inflammatory responses. 
 
7.4 Future work 
This study supports previous findings that apoptotic cells and LPS interact with similar 
regions of CD14. Here a panel of CD14 point mutations were used to map the crucial 
regions of CD14 required for LPS and apoptotic cell binding. The data found that a charge 
reversal mutation of residue E11 reduced apoptotic cell binding to background level, 
demonstrating the requirement of this residue for apoptotic cell binding. Charge reversal 
mutations were previously found to have the greatest effect on LPS binding. Therefore 
further characterisation of the binding patterns of apoptotic cells in comparison with LPS 
may be facilitated by using a series of charge reversal mutations. The discovery that LPS 
and apoptotic cells have the same binding patterns would suggest that the downstream 
responses are reprogrammed to be immunosuppressive or anti-inflammatory. However 
CD14 is a GPI anchored glycoprotein that requires a signalling partner to induce cellular 
responses. Ligation of PAMPs, including LPS with CD14 is known to recruit TLRs to the 
signalling complex resulting in an inflammatory response.  Previous work and data shown 
here has suggested that TLR4 expression can be uncoupled from the anti-inflammatory 
response of apoptotic cells. Furthermore work with NF-κB reporter construct has suggested 
that apoptotic cells do not activate proinflammatory signalling pathways. Therefore in 
order to characterise the signalling molecules recruited to CD14 following ligation, 
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immuno-precipitation of the lipid raft following ligation with LPS and apoptotic cells 
would be carried out.  Identification of co-precipitated molecules would be analysed or 
identified by mass spectrometry and western blot analysis. Successful identification of 
partners considered to be involved in the anti-inflammatory responses of apoptotic cells, 
could be expressed with mCD14 and association assessed using FRET analysis following 
apoptotic cell binding.  
 
Should such findings suggest that both apoptotic cells and LPS recruit the same signalling 
partners to CD14, a divergence from the inflammatory signalling pathway activated must 
occur to produce the contrasting ligand-dependent macrophage response. However work 
within this study, may suggest that the inhibitory signal induced by apoptotic cell uptake 
occurs upstream of NF-κB activation. Therefore activation of signalling events prior to IκB 
phosphorylation, including, the initial receptor-mediated events that induce signalling 
could be investigated. Alternatively as mention previously, a known inhibitor of the innate 
immune, inflammatory signalling pathway, are the TAM receptor tyrosine kinases (Rothlin 
et al., 2007). TAMs are considered to inhibit TLR-dependent inflammation by inducing the 
expression of SOCS proteins that are considered to inhibit the JAK/STAT pathway, 
intercepting and therefore inhibiting TLR-mediated cytokine response (Rothlin et al., 
2007). The role of SOCS in the anti-inflammatory signalling could be assessed using RT-
PCR to measure an upregulation of SOC following apoptotic cell uptake. Additionally 
macrophages could be transfected with shNA for SOCS and the effects of down-regulation 
on the anti-inflammatory effect of apoptotic cell clearance observed. 
 
Apoptotic cells are considered to present cell surface molecules, termed ACAMPs that are 
considered to share structural similarities with PAMPs. Results within this study using 
anti-LPS antibodies found that apoptotic cells and LPS have common conformational 
epitopes, suggesting that the ACAMPs recognised by CD14 are LPS-like. Immuno-
precipitation of apoptotic–associated ligands with anti-LPS antibodies and sCD14-Fc 
followed my mass spectrometry may lead to the identification of the ACAMPS recognised 
by CD14.  
 
CD14 also exists in a soluble form present in serum and is elevated following LPS 
stimulation (Fearns et al., 1995). Previous studies have shown that sCD14 binds LPS and 
confers LPS responsiveness to cells that do not express mCD14 (Frey et al., 1992, Pugin et 
al., 1993). While the role of sCD14 in the clearance of apoptotic cells is unknown, a 
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previous study by Devitt et al.(2004) along with data supported here has shown that 
sCD14-Fc binds to apoptotic cells but not viable cells. This may suggest that sCD14 binds 
to apoptotic cells and acts as a soluble bridging molecule that facilitates apoptotic cells 
clearance. Having established a HeLa-based system to assess the role of mCD14 in the 
clearance of apoptotic cells, the same system could be utilised to assess the role of sCD14 
in the clearance of apoptotic cells by amateur phagocytes. 
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